{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 591,
   "id": "26194509-66fb-4e01-b3c6-47c7952a13c3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The autoreload extension is already loaded. To reload it, use:\n",
      "  %reload_ext autoreload\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\user\\anaconda3\\envs\\llms\\Lib\\site-packages\\urllib3\\connectionpool.py:1097: InsecureRequestWarning: Unverified HTTPS request is being made to host 'ngw.devices.sberbank.ru'. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#tls-warnings\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders import PyMuPDFLoader\n",
    "from pydantic import BaseModel, Field\n",
    "from langchain_core.output_parsers import PydanticOutputParser, StrOutputParser, BaseOutputParser\n",
    "from textwrap import dedent\n",
    "\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "import httpx\n",
    "import json\n",
    "import requests\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import re\n",
    "\n",
    "from langchain_pymupdf4llm import PyMuPDF4LLMLoader, PyMuPDF4LLMParser\n",
    "import pymupdf4llm\n",
    "import requests\n",
    "import uuid\n",
    "from openai import OpenAI\n",
    "\n",
    "import time\n",
    "import os\n",
    "from dotenv import load_dotenv, find_dotenv\n",
    "\n",
    "load_dotenv(find_dotenv(usecwd=True))\n",
    "\n",
    "\n",
    "use = 'nhf'\n",
    "\n",
    "if use == 'hf':\n",
    "    os.environ[\"BASE_URL\"] = \"https://router.huggingface.co/v1\"\n",
    "    os.environ[\"MODEL_NAME\"] ='Qwen/Qwen3-32B'\n",
    "    os.environ[\"OPENAI_API_KEY\"] = os.getenv(\"HUGGINGFACE_HUB_TOKEN2\")\n",
    "else:\n",
    "    os.environ[\"BASE_URL\"] = \"https://gigachat.devices.sberbank.ru/api/v1\"\n",
    "    os.environ[\"MODEL_NAME\"] ='GigaChat-Max'\n",
    "    \n",
    "    url = \"https://ngw.devices.sberbank.ru:9443/api/v2/oauth\"\n",
    "    # Создадим идентификатор UUID (36 знаков)\n",
    "    rq_uid = str(uuid.uuid4())\n",
    "    payload={\n",
    "      'scope': 'GIGACHAT_API_PERS'\n",
    "    }\n",
    "    headers = {\n",
    "      'Content-Type': 'application/x-www-form-urlencoded',\n",
    "      'Accept': 'application/json',\n",
    "      'RqUID': rq_uid,\n",
    "      'Authorization': f'Basic {os.getenv(\"GIGACHAT_AUTH\")}'\n",
    "    }\n",
    "\n",
    "    response = requests.request(\"POST\", url, headers=headers, data=payload, verify=False)\n",
    "    os.environ[\"OPENAI_API_KEY\"] = response.json()['access_token']\n",
    "    \n",
    "\n",
    "os.environ['TEMPERATURE'] = '0'\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "from trialmind.pubmed import pmid2papers, PubmedAPIWrapper, pmid2biocxml, parse_bioc_xml\n",
    "from trialmind.api import StudyCharacteristicsExtraction, ScreeningCriteriaGeneration,\\\n",
    "                            LiteratureScreening, ScreeningCriteriaCTGeneration,\\\n",
    "                            CTScreening\n",
    "from trialmind.retrievers import split_text_into_chunks\n",
    "import extract\n",
    "\n",
    "%load_ext autoreload\n",
    "%autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 333,
   "id": "ca86905b-127c-43b4-9ac1-029ea1313d40",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'eyJjdHkiOiJqd3QiLCJlbmMiOiJBMjU2Q0JDLUhTNTEyIiwiYWxnIjoiUlNBLU9BRVAtMjU2In0.Kjf6m9hwo1tJVrTkZ2qEZeSFIhM23WmN0muRKYL5Bga6r5fdXQD-8SFaBJae3d4lHD6DsgY9h5T0OVTJxP8LMXrr_jTtF5K5LcyGN1qukI1OrZ9Te75Sqw31wIU7UkBAYwGe5XvWsnMzTszX7vqn-sY1KwM9VK7QEANXussuG8KF0V_AO4U68PcXRvW0rYPVwMQEHBnLbm37fQqEkQt9d_vnQC_YA_Q47V8FDejiahAIEbYsVlrNWBS2GK6G9Iha6VZqX7jtIj3bxTjtpfTdbfASaC_Yaq6wUf8G3N9oaB53PZiwwMGrwgx-vcg0C4h0HIcyF6k6104YcGAcSezlIg.5X41CG_lU0IksZ8bVbkR-w.DTEYT8efM9O9_LduFWBP594WrA8ufAZXzwjBkCpXSFTUPiOgp7MZHICOF8raWSIM0zW2WtlbwQ-SScl18Ivb-Ut78yiNOMxNFJ5EpQiNek8vDJwf7dWXfXAvadoBksH5okfd_UBxvs6OP5qcPHxDgUjDaoHBE0wlNvpo3vwp3VhwixCpR-d3XhsdNRB8ztc4kBLewHO9owAqR4FXdPEnh4GShV6t8oWJ7aN7ZUMxwoSLIzDZAmkB3zEahi9wE2msjOV9IfhOCIO_r_Vblrmg8zzoVjf09SPO2J5O7WlyybtzbCtDWCYouRHb-puIDWakEbxGX6HugiviU44qkku6p-l7W7QJeHe4GMjSfNrk2fr1ybeeZcqrBj3dbxZbL9HVvvl8f36osqVRsQzLpl2NuygvVMymDnCyhx2KYGM4M_-fW3cL781wjzbDJWLaJCiQLC1Xq7VkZpGd3c57BVWHy6y05aH-DHtSniJ6UmEz14agh2CGOkquFRJbPrynpy29JQ7hzoXsBG00sFo8Vn2-fxyOIo9_pd8WaYra_V204xQV6uttBWlJAjiIiSYqNEBj--ROkTDRC1Su0xnvUKgyejVypKbPjWr4-KOwAsH5oskcDSa8YKg7mC-smKiNGfKmwoTVfyT1Jm-VapLnj9kVOVzYUOQFeAT4zFowhEBQQQR0cX7td24n-l7Dcd52rHWCh4Uz8rpzoKdgPLV7Rq7DrkRV6FasteSUfWFe1K46OR4.r7ZEMINt6rbABaBe3EkQRzJC7Zc3np_GMFYtN8f0kvA'"
      ]
     },
     "execution_count": 333,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 276,
   "id": "87134e89-308f-40c7-90e7-7dda26f40eb8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Привет! Чем займёмся?'"
      ]
     },
     "execution_count": 276,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "client = OpenAI(\n",
    "        base_url=os.getenv(\"BASE_URL\"),\n",
    "        api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "        http_client=httpx.Client(verify=False)\n",
    "    )\n",
    "response = client.chat.completions.create(\n",
    "        model=os.getenv(\"MODEL_NAME\"),\n",
    "        messages=[{'role':'user','content':'hey\\no_think'}],  # Ensure messages is a list\n",
    "        temperature=0,\n",
    "    )\n",
    "response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "5191b220-a355-402f-8ac4-c871ef0692c6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'FieldResult': {'properties': {'name': {'description': 'Field name that accurately represents the content of the field based on its description.',\n",
       "     'maxLength': 25,\n",
       "     'title': 'Name',\n",
       "     'type': 'string'},\n",
       "    'value': {'description': 'Extracted information from the text based on the field description.',\n",
       "     'maxLength': 50,\n",
       "     'title': 'Value',\n",
       "     'type': 'string'},\n",
       "    'source_id': {'description': 'Cited document IDs.',\n",
       "     'items': {'type': 'integer'},\n",
       "     'maxItems': 3,\n",
       "     'minItems': 1,\n",
       "     'title': 'Source Id',\n",
       "     'type': 'array'}},\n",
       "   'required': ['name', 'value', 'source_id'],\n",
       "   'title': 'FieldResult',\n",
       "   'type': 'object'}},\n",
       " 'properties': {'fieldresult': {'$ref': '#/$defs/FieldResult'}},\n",
       " 'required': ['fieldresult'],\n",
       " 'title': 'Results',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Results.model_json_schema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "3dce0fff-fe8e-4a5f-8d64-316ed02cbdbc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Example JSON data using the provided schema:\n",
      "\n",
      "```json\n",
      "{\n",
      "  \"fieldresult\": [\n",
      "    {\n",
      "      \"name\": \"Author\",\n",
      "      \"value\": \"Иванов Иван Иванович\",\n",
      "      \"source_id\": [12345]\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"Publication Date\",\n",
      "      \"value\": \"1 января 2023 года\",\n",
      "      \"source_id\": [67890]\n",
      "    }\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "#### Explanation:\n",
      "- **`name`:** The descriptive label for the extracted field (e.g., “Author” or “Publication Date”).\n",
      "- **`value`:** The actual value extracted from the source text (e.g., a person’s name or date).\n",
      "- **`source_id`:** An array of integers representing the cited documents where this field was found.\n",
      "\n",
      "### Additional Examples\n",
      "\n",
      "1. **Example 1:**\n",
      "   ```json\n",
      "   {\n",
      "     \"fieldresult\": [\n",
      "       {\n",
      "         \"name\": \"ISBN\",\n",
      "         \"value\": \"978-123456789X\",\n",
      "         \"source_id\": [101, 102]\n",
      "       },\n",
      "       {\n",
      "         \"name\": \"Publisher\",\n",
      "         \"value\": \"ООО \\\"Издательство Книги и Статьи\\\"\",\n",
      "         \"source_id\": [103]\n",
      "       }\n",
      "     ]\n",
      "   }\n",
      "   ```\n",
      "\n",
      "2. **Example 2:**\n",
      "   ```json\n",
      "   {\n",
      "     \"fieldresult\": [\n",
      "       {\n",
      "         \"name\": \"Title\",\n",
      "         \"value\": \"Основы программирования на Python\",\n",
      "         \"source_id\": [104]\n",
      "       },\n",
      "       {\n",
      "         \"name\": \"Pages\",\n",
      "         \"value\": \"300 страниц\",\n",
      "         \"source_id\": [105]\n",
      "       }\n",
      "     ]\n",
      "   }\n",
      "   ```\n",
      "\n",
      "3. **Example 3:**\n",
      "   ```json\n",
      "   {\n",
      "     \"fieldresult\": [\n",
      "       {\n",
      "         \"name\": \"Director\",\n",
      "         \"value\": \"Сергей Петров\",\n",
      "         \"source_id\": [106]\n",
      "       },\n",
      "       {\n",
      "         \"name\": \"Year\",\n",
      "         \"value\": \"2022 год\",\n",
      "         \"source_id\": [107]\n",
      "       }\n",
      "     ]\n",
      "   }\n",
      "   ```\n",
      "\n",
      "These examples demonstrate how to use the `FieldResult` structure within the given JSON schema.\n"
     ]
    }
   ],
   "source": [
    "Results.model_json_schema()\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": f\"Generate some examples with two fieldresult with the following JSON schema: {Results.model_json_schema()}  /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    response_format={\n",
    "        \"type\": \"json_object\",\n",
    "        \"json_schema\": {\n",
    "            \"name\": \"car-description\",\n",
    "            \"schema\": Results.model_json_schema()\n",
    "        },\n",
    "    },\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d349aa43-7eb8-4e4c-aeee-3d804702144d",
   "metadata": {
    "tags": []
   },
   "source": [
    "### client.responses дает 403 ошибку, т.е. structured output не работает"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "4b4d1aa0-0998-4f3c-9b06-f70ca222181f",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "PermissionDeniedError",
     "evalue": "<html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPermissionDeniedError\u001b[0m                     Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[43], line 16\u001b[0m\n\u001b[0;32m     13\u001b[0m     abstract: \u001b[38;5;28mstr\u001b[39m\n\u001b[0;32m     14\u001b[0m     keywords: \u001b[38;5;28mlist\u001b[39m[\u001b[38;5;28mstr\u001b[39m]\n\u001b[1;32m---> 16\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mresponses\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mparse\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m     17\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     18\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m     19\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     20\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are an expert at structured data extraction. You will be given unstructured text from a research paper and should convert it into the given structure.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     22\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m...\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtext_format\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mResearchPaperExtraction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m)\u001b[49m\n\u001b[0;32m     28\u001b[0m research_paper \u001b[38;5;241m=\u001b[39m response\u001b[38;5;241m.\u001b[39moutput_parsed\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\resources\\responses\\responses.py:1174\u001b[0m, in \u001b[0;36mResponses.parse\u001b[1;34m(self, text_format, background, conversation, include, input, instructions, max_output_tokens, max_tool_calls, metadata, model, parallel_tool_calls, previous_response_id, prompt, prompt_cache_key, prompt_cache_retention, reasoning, safety_identifier, service_tier, store, stream, stream_options, temperature, text, tool_choice, tools, top_logprobs, top_p, truncation, user, verbosity, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m   1167\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mparser\u001b[39m(raw_response: Response) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ParsedResponse[TextFormatT]:\n\u001b[0;32m   1168\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m parse_response(\n\u001b[0;32m   1169\u001b[0m         input_tools\u001b[38;5;241m=\u001b[39mtools,\n\u001b[0;32m   1170\u001b[0m         text_format\u001b[38;5;241m=\u001b[39mtext_format,\n\u001b[0;32m   1171\u001b[0m         response\u001b[38;5;241m=\u001b[39mraw_response,\n\u001b[0;32m   1172\u001b[0m     )\n\u001b[1;32m-> 1174\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1175\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/responses\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1176\u001b[0m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1177\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m   1178\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mbackground\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mbackground\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1179\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mconversation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mconversation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1180\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minclude\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minclude\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1181\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1182\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minstructions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minstructions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1183\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_output_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_output_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1184\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1185\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1186\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1187\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1188\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprevious_response_id\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprevious_response_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1189\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1190\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_key\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1191\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_retention\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1192\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1193\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msafety_identifier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1194\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1195\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1196\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1197\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1198\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1199\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtext\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1200\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1201\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1202\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1203\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1204\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtruncation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtruncation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1205\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1206\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mverbosity\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1207\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1208\u001b[0m \u001b[43m        \u001b[49m\u001b[43mresponse_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mResponseCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1209\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1210\u001b[0m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1211\u001b[0m \u001b[43m        \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1212\u001b[0m \u001b[43m        \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1213\u001b[0m \u001b[43m        \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1214\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1215\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpost_parser\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mparser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1216\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1217\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# we turn the `Response` instance into a `ParsedResponse`\u001b[39;49;00m\n\u001b[0;32m   1218\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# in the `parser` function above\u001b[39;49;00m\n\u001b[0;32m   1219\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mType\u001b[49m\u001b[43m[\u001b[49m\u001b[43mParsedResponse\u001b[49m\u001b[43m[\u001b[49m\u001b[43mTextFormatT\u001b[49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mResponse\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1220\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1294\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, content, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1285\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[0;32m   1286\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPassing raw bytes as `body` is deprecated and will be removed in a future version. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   1287\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease pass raw bytes via the `content` parameter instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   1288\u001b[0m         \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m,\n\u001b[0;32m   1289\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m2\u001b[39m,\n\u001b[0;32m   1290\u001b[0m     )\n\u001b[0;32m   1291\u001b[0m opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1292\u001b[0m     method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, content\u001b[38;5;241m=\u001b[39mcontent, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1293\u001b[0m )\n\u001b[1;32m-> 1294\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1067\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1064\u001b[0m             err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1066\u001b[0m         log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1067\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1069\u001b[0m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[0;32m   1071\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcould not resolve response (should never happen)\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mPermissionDeniedError\u001b[0m: <html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>"
     ]
    }
   ],
   "source": [
    "from openai import OpenAI\n",
    "from pydantic import BaseModel\n",
    "\n",
    "client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(http2=True, verify=False)\n",
    ")\n",
    "\n",
    "class ResearchPaperExtraction(BaseModel):\n",
    "    title: str\n",
    "    authors: list[str]\n",
    "    abstract: str\n",
    "    keywords: list[str]\n",
    "\n",
    "response = client.responses.parse(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    input=[\n",
    "        {\n",
    "            \"role\": \"system\",\n",
    "            \"content\": \"You are an expert at structured data extraction. You will be given unstructured text from a research paper and should convert it into the given structure.\",\n",
    "        },\n",
    "        {\"role\": \"user\", \"content\": \"...\"},\n",
    "    ],\n",
    "    text_format=ResearchPaperExtraction,\n",
    ")\n",
    "\n",
    "research_paper = response.output_parsed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "5ec16b17-95a5-4787-a890-faa6a5e9de72",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "PermissionDeniedError",
     "evalue": "<html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPermissionDeniedError\u001b[0m                     Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[46], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mresponses\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m      2\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      3\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are a helpful math tutor. Guide the user through the solution step by step.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      4\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mhow can I solve 8x + 7 = -23\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      5\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtext\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\n\u001b[0;32m      6\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mformat\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m      7\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      8\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mname\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmath_response\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      9\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mschema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     10\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     11\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     12\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msteps\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     13\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     14\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     15\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     16\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     17\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexplanation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     18\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43moutput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\n\u001b[0;32m     19\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     20\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexplanation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43moutput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m     22\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfinal_answer\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msteps\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfinal_answer\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     27\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m     28\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     29\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstrict\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m     30\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     31\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     32\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     34\u001b[0m \u001b[38;5;28mprint\u001b[39m(response\u001b[38;5;241m.\u001b[39moutput_text)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\resources\\responses\\responses.py:866\u001b[0m, in \u001b[0;36mResponses.create\u001b[1;34m(self, background, conversation, include, input, instructions, max_output_tokens, max_tool_calls, metadata, model, parallel_tool_calls, previous_response_id, prompt, prompt_cache_key, prompt_cache_retention, reasoning, safety_identifier, service_tier, store, stream, stream_options, temperature, text, tool_choice, tools, top_logprobs, top_p, truncation, user, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m    828\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mcreate\u001b[39m(\n\u001b[0;32m    829\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[0;32m    830\u001b[0m     \u001b[38;5;241m*\u001b[39m,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    864\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m not_given,\n\u001b[0;32m    865\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Response \u001b[38;5;241m|\u001b[39m Stream[ResponseStreamEvent]:\n\u001b[1;32m--> 866\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    867\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/responses\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    868\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    869\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    870\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mbackground\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mbackground\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    871\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mconversation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mconversation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    872\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minclude\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minclude\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    873\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    874\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minstructions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minstructions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    875\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_output_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_output_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    876\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    877\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    878\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    879\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    880\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprevious_response_id\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprevious_response_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    881\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    882\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_key\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    883\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_retention\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    884\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    885\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msafety_identifier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    886\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    887\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    888\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    889\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    890\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    891\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtext\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    892\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    893\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    894\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    895\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    896\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtruncation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtruncation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    897\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    898\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    899\u001b[0m \u001b[43m            \u001b[49m\u001b[43mresponse_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mResponseCreateParamsStreaming\u001b[49m\n\u001b[0;32m    900\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\n\u001b[0;32m    901\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mresponse_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mResponseCreateParamsNonStreaming\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    902\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    903\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    904\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[0;32m    905\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    906\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mResponse\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    907\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    908\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mResponseStreamEvent\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    909\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1294\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, content, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1285\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[0;32m   1286\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPassing raw bytes as `body` is deprecated and will be removed in a future version. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   1287\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease pass raw bytes via the `content` parameter instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   1288\u001b[0m         \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m,\n\u001b[0;32m   1289\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m2\u001b[39m,\n\u001b[0;32m   1290\u001b[0m     )\n\u001b[0;32m   1291\u001b[0m opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1292\u001b[0m     method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, content\u001b[38;5;241m=\u001b[39mcontent, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1293\u001b[0m )\n\u001b[1;32m-> 1294\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1067\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1064\u001b[0m             err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1066\u001b[0m         log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1067\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1069\u001b[0m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[0;32m   1071\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcould not resolve response (should never happen)\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mPermissionDeniedError\u001b[0m: <html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>"
     ]
    }
   ],
   "source": [
    "response = client.responses.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    input=[{\"role\": \"system\", \"content\": \"You are a helpful math tutor. Guide the user through the solution step by step.\"},\n",
    "    {\"role\": \"user\", \"content\": \"how can I solve 8x + 7 = -23\"}],\n",
    "    text={\n",
    "    \"format\": {\n",
    "        \"type\": \"json_schema\",\n",
    "        \"name\": \"math_response\",\n",
    "        \"schema\": {\n",
    "            \"type\": \"object\",\n",
    "            \"properties\": {\n",
    "                \"steps\": {\n",
    "                    \"type\": \"array\",\n",
    "                    \"items\": {\n",
    "                        \"type\": \"object\",\n",
    "                        \"properties\": {\n",
    "                            \"explanation\": {\"type\": \"string\"},\n",
    "                            \"output\": {\"type\": \"string\"}\n",
    "                        },\n",
    "                        \"required\": [\"explanation\", \"output\"],\n",
    "                        \"additionalProperties\": False\n",
    "                    }\n",
    "                },\n",
    "                \"final_answer\": {\"type\": \"string\"}\n",
    "            },\n",
    "            \"required\": [\"steps\", \"final_answer\"],\n",
    "            \"additionalProperties\": False\n",
    "        },\n",
    "        \"strict\": False\n",
    "    }\n",
    "    }\n",
    "    )\n",
    "\n",
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "b68c5684-7c07-4a82-8d41-e4e5b7460da2",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "Completions.create() got an unexpected keyword argument 'text'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[57], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m      2\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      3\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m      4\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are a helpful assistant designed to output JSON.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      5\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mWho won the world series in 2020? Please respond in the format \u001b[39;49m\u001b[38;5;124;43m{\u001b[39;49m\u001b[38;5;124;43mwinner: ...}\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\n\u001b[0;32m      6\u001b[0m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      7\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtext\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mformat\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_object\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m      8\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m      9\u001b[0m \u001b[38;5;28mprint\u001b[39m(response\u001b[38;5;241m.\u001b[39mchoices[\u001b[38;5;241m0\u001b[39m]\u001b[38;5;241m.\u001b[39mmessage\u001b[38;5;241m.\u001b[39mcontent)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_utils\\_utils.py:286\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    284\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    285\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[1;32m--> 286\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "\u001b[1;31mTypeError\u001b[0m: Completions.create() got an unexpected keyword argument 'text'"
     ]
    }
   ],
   "source": [
    "response = client.chat.completions.create(\n",
    "        model=os.getenv(\"MODEL_NAME\"),\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a helpful assistant designed to output JSON.\"},\n",
    "            {\"role\": \"user\", \"content\": \"Who won the world series in 2020? Please respond in the format {winner: ...}\"}\n",
    "        ],\n",
    "        text={\"format\": {\"type\": \"json_object\"}}\n",
    "    )\n",
    "print(response.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d99fbfee-ca6c-4a9f-9fdf-651e46b5e7fe",
   "metadata": {
    "tags": []
   },
   "source": [
    "### response_format: {type: \"json_schema\",...} -- Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}\n",
    "Structured Outputs with response_format: {type: \"json_schema\", ...} is only supported with the gpt-4o-mini, gpt-4o-mini-2024-07-18, and gpt-4o-2024-08-06 model snapshots and later."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "id": "d1d82211-21f6-4ae0-b81d-7cac414774a1",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "BadRequestError",
     "evalue": "Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mBadRequestError\u001b[0m                           Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[90], line 14\u001b[0m\n\u001b[0;32m     10\u001b[0m     car_type: CarType\n\u001b[0;32m     12\u001b[0m json_schema \u001b[38;5;241m=\u001b[39m CarDescription\u001b[38;5;241m.\u001b[39mmodel_json_schema()\n\u001b[1;32m---> 14\u001b[0m completion \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m     15\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     16\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m     17\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     18\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     19\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mGenerate a JSON with the brand, model and car_type of Ford Explorer (SUV) car from the 90\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43ms\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     20\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     22\u001b[0m \u001b[43m    \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mname\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcar-description\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mschema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mCarDescription\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmodel_json_schema\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     27\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     28\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     29\u001b[0m \u001b[43m)\u001b[49m\n\u001b[0;32m     30\u001b[0m \u001b[38;5;28mprint\u001b[39m(completion\u001b[38;5;241m.\u001b[39mchoices[\u001b[38;5;241m0\u001b[39m]\u001b[38;5;241m.\u001b[39mmessage\u001b[38;5;241m.\u001b[39mcontent)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_utils\\_utils.py:286\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    284\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    285\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[1;32m--> 286\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:1192\u001b[0m, in \u001b[0;36mCompletions.create\u001b[1;34m(self, messages, model, audio, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, prompt_cache_key, prompt_cache_retention, reasoning_effort, response_format, safety_identifier, seed, service_tier, stop, store, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, verbosity, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m   1145\u001b[0m \u001b[38;5;129m@required_args\u001b[39m([\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m], [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[0;32m   1146\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mcreate\u001b[39m(\n\u001b[0;32m   1147\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m   1189\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m not_given,\n\u001b[0;32m   1190\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ChatCompletion \u001b[38;5;241m|\u001b[39m Stream[ChatCompletionChunk]:\n\u001b[0;32m   1191\u001b[0m     validate_response_format(response_format)\n\u001b[1;32m-> 1192\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1193\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/chat/completions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1194\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1195\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m   1196\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmessages\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1197\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1198\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43maudio\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1199\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfrequency_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1200\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunction_call\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1201\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunctions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1202\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogit_bias\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1203\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1204\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_completion_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1205\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1206\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1207\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodalities\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1208\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mn\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1209\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1210\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprediction\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1211\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mpresence_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1212\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_key\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1213\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_retention\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1214\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning_effort\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1215\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mresponse_format\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1216\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msafety_identifier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1217\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mseed\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1218\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1219\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstop\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1220\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1221\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1222\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1223\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1224\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1225\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1226\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1227\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1228\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1229\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mverbosity\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1230\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mweb_search_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1231\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1232\u001b[0m \u001b[43m            \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParamsStreaming\u001b[49m\n\u001b[0;32m   1233\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\n\u001b[0;32m   1234\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParamsNonStreaming\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1235\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1236\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1237\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[0;32m   1238\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1239\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mChatCompletion\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1240\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m   1241\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mChatCompletionChunk\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1242\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1294\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, content, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1285\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[0;32m   1286\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPassing raw bytes as `body` is deprecated and will be removed in a future version. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   1287\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease pass raw bytes via the `content` parameter instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   1288\u001b[0m         \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m,\n\u001b[0;32m   1289\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m2\u001b[39m,\n\u001b[0;32m   1290\u001b[0m     )\n\u001b[0;32m   1291\u001b[0m opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1292\u001b[0m     method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, content\u001b[38;5;241m=\u001b[39mcontent, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1293\u001b[0m )\n\u001b[1;32m-> 1294\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1067\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1064\u001b[0m             err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1066\u001b[0m         log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1067\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1069\u001b[0m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[0;32m   1071\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcould not resolve response (should never happen)\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mBadRequestError\u001b[0m: Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}"
     ]
    }
   ],
   "source": [
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Ford Explorer (SUV) car from the 90's\"\n",
    "        }\n",
    "    ],\n",
    "    response_format={\n",
    "        \"type\": \"json_schema\",\n",
    "        \"json_schema\": {\n",
    "            \"name\": \"car-description\",\n",
    "            \"schema\": CarDescription.model_json_schema()\n",
    "        },\n",
    "    },\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "73b0ff1d-9309-4f8b-b7db-30e7a138f6fb",
   "metadata": {
    "tags": []
   },
   "source": [
    "### back"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "f1fe9455-5543-4c20-823a-545e54a01063",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### JSON data for Mazda cars from the 1990s:\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5 Miata\",\n",
      "    \"car_type\": \"Roadster\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protege\",\n",
      "    \"car_type\": \"Compact Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Full-size Luxury Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"B2300\",\n",
      "    \"car_type\": \"Pickup Truck\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MPV\",\n",
      "    \"car_type\": \"Minivan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"626\",\n",
      "    \"car_type\": \"Mid-size Sedan\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "This JSON contains information about popular Mazda models from the 1990s, including their respective brands, models, and types (sedans, roadsters, minivans, etc.).\n"
     ]
    }
   ],
   "source": [
    "from enum import Enum\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's  /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    response_format={\n",
    "        \"type\": \"json_object\",\n",
    "        \"json_schema\": {\n",
    "            \"name\": \"car-description\",\n",
    "            \"schema\": CarDescription.model_json_schema()\n",
    "        },\n",
    "    },\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "04b0a1a1-3f11-4544-bbac-df88d78b93bc",
   "metadata": {},
   "outputs": [],
   "source": [
    "response.msgs[0].parsed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "368a3cae-d904-4007-b053-87b0b3ac0c7e",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "BadRequestError",
     "evalue": "Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mBadRequestError\u001b[39m                           Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[36]\u001b[39m\u001b[32m, line 19\u001b[39m\n\u001b[32m     15\u001b[39m     car_type: CarType\n\u001b[32m     17\u001b[39m json_schema = CarDescription.model_json_schema()\n\u001b[32m---> \u001b[39m\u001b[32m19\u001b[39m completion = \u001b[43mclient\u001b[49m\u001b[43m.\u001b[49m\u001b[43mchat\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcompletions\u001b[49m\u001b[43m.\u001b[49m\u001b[43mparse\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m     20\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m=\u001b[49m\u001b[43mos\u001b[49m\u001b[43m.\u001b[49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mMODEL_NAME\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     21\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m=\u001b[49m\u001b[43m[\u001b[49m\n\u001b[32m     22\u001b[39m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[32m     23\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mrole\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43muser\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m     24\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mcontent\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mGenerate a JSON with the brand, model and car_type of Mazda cars from the 90\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[33;43ms  /no_think\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\n\u001b[32m     25\u001b[39m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[32m     26\u001b[39m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     27\u001b[39m \u001b[43m    \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m=\u001b[49m\u001b[43mCarDescription\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     28\u001b[39m \u001b[43m    \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m     29\u001b[39m \u001b[43m)\u001b[49m\n\u001b[32m     30\u001b[39m \u001b[38;5;28mprint\u001b[39m(completion.choices[\u001b[32m0\u001b[39m].message.content)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:184\u001b[39m, in \u001b[36mCompletions.parse\u001b[39m\u001b[34m(self, messages, model, audio, response_format, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, prompt_cache_key, prompt_cache_retention, reasoning_effort, safety_identifier, seed, service_tier, stop, store, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, verbosity, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[39m\n\u001b[32m    177\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mparser\u001b[39m(raw_completion: ChatCompletion) -> ParsedChatCompletion[ResponseFormatT]:\n\u001b[32m    178\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m _parse_chat_completion(\n\u001b[32m    179\u001b[39m         response_format=response_format,\n\u001b[32m    180\u001b[39m         chat_completion=raw_completion,\n\u001b[32m    181\u001b[39m         input_tools=chat_completion_tools,\n\u001b[32m    182\u001b[39m     )\n\u001b[32m--> \u001b[39m\u001b[32m184\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    185\u001b[39m \u001b[43m    \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m/chat/completions\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    186\u001b[39m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    187\u001b[39m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[32m    188\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmessages\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    189\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmodel\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    190\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43maudio\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    191\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfrequency_penalty\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    192\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfunction_call\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    193\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfunctions\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    194\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mlogit_bias\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    195\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mlogprobs\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    196\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmax_completion_tokens\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    197\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmax_tokens\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    198\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmetadata\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    199\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmodalities\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    200\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mn\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    201\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mparallel_tool_calls\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    202\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprediction\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    203\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mpresence_penalty\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    204\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprompt_cache_key\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    205\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprompt_cache_retention\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    206\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mreasoning_effort\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    207\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mresponse_format\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m_type_to_response_format\u001b[49m\u001b[43m(\u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    208\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43msafety_identifier\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    209\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mseed\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    210\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mservice_tier\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    211\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstop\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    212\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstore\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    213\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstream\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m    214\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstream_options\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    215\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtemperature\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    216\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtool_choice\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    217\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtools\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    218\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtop_logprobs\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    219\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtop_p\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    220\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43muser\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    221\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mverbosity\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    222\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mweb_search_options\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    223\u001b[39m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    224\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[43m.\u001b[49m\u001b[43mCompletionCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    225\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    226\u001b[39m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    227\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    228\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    229\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    230\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    231\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_parser\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    232\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    233\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# we turn the `ChatCompletion` instance into a `ParsedChatCompletion`\u001b[39;49;00m\n\u001b[32m    234\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# in the `parser` function above\u001b[39;49;00m\n\u001b[32m    235\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mType\u001b[49m\u001b[43m[\u001b[49m\u001b[43mParsedChatCompletion\u001b[49m\u001b[43m[\u001b[49m\u001b[43mResponseFormatT\u001b[49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mChatCompletion\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    236\u001b[39m \u001b[43m    \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m    237\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\_base_client.py:1259\u001b[39m, in \u001b[36mSyncAPIClient.post\u001b[39m\u001b[34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[39m\n\u001b[32m   1245\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mpost\u001b[39m(\n\u001b[32m   1246\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1247\u001b[39m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1254\u001b[39m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] | \u001b[38;5;28;01mNone\u001b[39;00m = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1255\u001b[39m ) -> ResponseT | _StreamT:\n\u001b[32m   1256\u001b[39m     opts = FinalRequestOptions.construct(\n\u001b[32m   1257\u001b[39m         method=\u001b[33m\"\u001b[39m\u001b[33mpost\u001b[39m\u001b[33m\"\u001b[39m, url=path, json_data=body, files=to_httpx_files(files), **options\n\u001b[32m   1258\u001b[39m     )\n\u001b[32m-> \u001b[39m\u001b[32m1259\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\_base_client.py:1047\u001b[39m, in \u001b[36mSyncAPIClient.request\u001b[39m\u001b[34m(self, cast_to, options, stream, stream_cls)\u001b[39m\n\u001b[32m   1044\u001b[39m             err.response.read()\n\u001b[32m   1046\u001b[39m         log.debug(\u001b[33m\"\u001b[39m\u001b[33mRe-raising status error\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m-> \u001b[39m\u001b[32m1047\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._make_status_error_from_response(err.response) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m   1049\u001b[39m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[32m   1051\u001b[39m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[33m\"\u001b[39m\u001b[33mcould not resolve response (should never happen)\u001b[39m\u001b[33m\"\u001b[39m\n",
      "\u001b[31mBadRequestError\u001b[39m: Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}"
     ]
    }
   ],
   "source": [
    "'''\n",
    "Gigachat --  Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}\n",
    "works for qwen! \n",
    "'''\n",
    "from enum import Enum\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.parse(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's  /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    response_format=CarDescription,\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "37646cf9-44d7-44f1-be8a-021ea4489b09",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'CarType': {'enum': ['sedan', 'SUV', 'Truck', 'Coupe'],\n",
       "   'title': 'CarType',\n",
       "   'type': 'string'}},\n",
       " 'properties': {'brand': {'title': 'Brand', 'type': 'string'},\n",
       "  'model': {'title': 'Model', 'type': 'string'},\n",
       "  'car_type': {'$ref': '#/$defs/CarType'}},\n",
       " 'required': ['brand', 'model', 'car_type'],\n",
       " 'title': 'CarDescription',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_schema"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "4beaba66-e561-4c2f-bb2a-0d41c7d760ad",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### JSON data for Mazda cars from the 1990s\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"626\",\n",
      "    \"car_type\": \"sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5\",\n",
      "    \"car_type\": \"Coupe\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Bongo\",\n",
      "    \"car_type\": \"Van\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MPV\",\n",
      "    \"car_type\": \"Minivan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Navajo\",\n",
      "    \"car_type\": \"Pickup Truck\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protege\",\n",
      "    \"car_type\": \"Hatchback\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Tribute\",\n",
      "    \"car_type\": \"SUV\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "### Explanation:\n",
      "- The `'$defs'` section defines the allowed values for the `car_type`.\n",
      "- Each entry in the array represents a different Mazda car from the 1990s.\n",
      "- The required fields (`brand`, `model`, and `car_type`) are specified as per the given JSON schema.\n",
      "- The `'$ref'` is used to reference the predefined `CarType` enum within the schema.\n"
     ]
    }
   ],
   "source": [
    "from enum import Enum\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's\"+\\\n",
    "        f\" and follow the JSON format defined by the following JSON schema: {json_schema} /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    #tools=[json_schema],\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "58b1c4e5-c0a2-4bfa-846d-29e6ebff7c1f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Example JSON structure for Mazda cars from the 1990s:\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5 Miata\",\n",
      "    \"car_type\": \"Convertible\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"626\",\n",
      "    \"car_type\": \"Sedan/SUV\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Capella\",\n",
      "    \"car_type\": \"Compact Car\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Bongo Freestyle\",\n",
      "    \"car_type\": \"Minivan/MPV\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Mid-size Luxury Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protégé\",\n",
      "    \"car_type\": \"Compact Car\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "#### Explanation:\n",
      "- The `brand` field contains the manufacturer name (`Mazda`).\n",
      "- The `model` field specifies the individual car models that were popular in the 1990s.\n",
      "- The `car_type` indicates the type (sedan, convertible, minivan, etc.) to provide more context about each vehicle.\n",
      "\n",
      "You can modify or extend this list based on specific Mazda models you want to include from the 1990s.\n"
     ]
    }
   ],
   "source": [
    "'''\n",
    "qwen doesnt support \"structured_outputs\" in body\n",
    "'''\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's\"\n",
    "        }\n",
    "    ],\n",
    "    extra_body={\"structured_outputs\": {\"json\": json_schema}}\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "5367e36b-e29f-4c02-a6b7-33a012c5b182",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### JSON format for Mazda Cars from the 1990s\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5 (Miata)\",\n",
      "    \"car_type\": \"Convertible sports car\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protégé\",\n",
      "    \"car_type\": \"Compact sedan/coupe\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"B-series pickup truck\",\n",
      "    \"car_type\": \"Pickup truck\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Full-size luxury sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MPV\",\n",
      "    \"car_type\": \"Minivan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Navajo\",\n",
      "    \"car_type\": \"Sport utility vehicle (SUV)\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "This JSON contains information about popular Mazda models from the 1990s, including their brand, model name, and car type.\n"
     ]
    }
   ],
   "source": [
    "'''\n",
    "qwen doesnt support \"structured_outputs\" in body\n",
    "'''\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's\"\n",
    "        }\n",
    "    ],\n",
    "    tools = [json_schema]\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5301994a-a15c-47ce-b6b8-ce0ceae9e67b",
   "metadata": {
    "tags": []
   },
   "source": [
    "## 1. clinical trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "7eb1ed4e-88ad-454d-a841-868d8d03925b",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('Colorectal cancer',\n",
       " ['Crizotinib',\n",
       "  'Lorlatinib',\n",
       "  'Necitumumab',\n",
       "  'Nimotuzumab',\n",
       "  'Panitumumab',\n",
       "  'Cetuximab',\n",
       "  'Brigatinib',\n",
       "  'Ramucirumab',\n",
       "  'Pomalidomide',\n",
       "  'Tamoxifen',\n",
       "  'Denosumab',\n",
       "  'Duvelisib',\n",
       "  'Inavilisib',\n",
       "  'Bevacizumab',\n",
       "  'Anastrozole',\n",
       "  'Exemestane'])"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_path = \"docs/CC_215_L00_DL_fusion_fixed_oncobox_ru.pdf\"\n",
    "fin_condition, treatements_eng = extract.info_from_doc(file_path)\n",
    "fin_condition, treatements_eng"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b2be323d-2d66-4dd7-beec-1828340f37b8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e3c68437-54be-4611-9aa0-d7f6a379a924",
   "metadata": {},
   "source": [
    "1. загрузить док\n",
    "2. взять 1-ую страницу; рег.выражениями взять диагноз\n",
    "-- с ЛЛМ перевести на англ.\n",
    "3. найти страницу с таблицей; или взять таблицы с PyMuPDFLoader\n",
    "4. извлечь таблицу"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "0b55cf5c-e883-4a42-ad8f-08633873be8f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02568267</td>\n",
       "      <td>Basket Study of Entrectinib (RXDX-101) for the...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This is an open-label, multicenter, global Pha...</td>\n",
       "      <td>[Breast Cancer, Cholangiocarcinoma, Colorectal...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[entrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT06214793</td>\n",
       "      <td>Taletrectinib in Previously Treated Metastatic...</td>\n",
       "      <td>SUSPENDED</td>\n",
       "      <td>The purpose of this study is to evaluate the s...</td>\n",
       "      <td>[Breast Cancer, Metastatic Breast Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[taletrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This phase II MATCH screening and multi-sub-tr...</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "1       False  NCT02568267  Basket Study of Entrectinib (RXDX-101) for the...   \n",
       "2        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "4       False  NCT06214793  Taletrectinib in Previously Treated Metastatic...   \n",
       "5       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "6       False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "\n",
       "           overallStatus                                       briefSummary  \\\n",
       "0                UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "1  ACTIVE_NOT_RECRUITING  This is an open-label, multicenter, global Pha...   \n",
       "2              COMPLETED  This trial is designed to try two new cancer d...   \n",
       "3             RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "4              SUSPENDED  The purpose of this study is to evaluate the s...   \n",
       "5             RECRUITING  The purpose of the study is to investigate the...   \n",
       "6  ACTIVE_NOT_RECRUITING  This phase II MATCH screening and multi-sub-tr...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "1  [Breast Cancer, Cholangiocarcinoma, Colorectal...  INTERVENTIONAL   \n",
       "2                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "4          [Breast Cancer, Metastatic Breast Cancer]  INTERVENTIONAL   \n",
       "5                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "6  [Advanced Lymphoma, Advanced Malignant Solid N...  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0              [NA]                                                 []   \n",
       "1          [PHASE2]                                      [entrectinib]   \n",
       "2          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "4          [PHASE2]                                    [taletrectinib]   \n",
       "5          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "6          [PHASE2]  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "\n",
       "                                     outcomeMeasures  \n",
       "0                                                NaN  \n",
       "1                                                NaN  \n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...  \n",
       "3                                                NaN  \n",
       "4                                                NaN  \n",
       "5                                                NaN  \n",
       "6                                                NaN  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies = extract.get_clinicaltrials(f'''\"{fin_condition}\"''', \n",
    "                                      #' OR '.join(treatements_eng), \n",
    "                                       treatements_eng[0],  \n",
    "                                      max_studies=10)\n",
    "all_studies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "8216cd98-24dc-4eb9-896f-16d7662879d3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "call_openai https://gigachat.devices.sberbank.ru/api/v1\n",
      "api_call_single https://gigachat.devices.sberbank.ru/api/v1/\n",
      "```json\n",
      "{\n",
      "    \"ELIGIBILITY_ANALYSIS\": [\n",
      "        \"Patients must have colorectal cancer confirmed by histopathology or imaging studies\",\n",
      "        \"Treatment with crizotinib must be administered as part of standard therapy or experimental protocol\",\n",
      "        \"Comparative intervention must involve another drug or placebo\",\n",
      "        \"Outcomes must measure efficacy, safety, or survival endpoints relevant to colorectal cancer treatment\",\n",
      "        \"Study design must be randomized controlled trial (RCT), cohort study, or case-control study\"\n",
      "    ],\n",
      "    \"TITLE_CRITERIA\": [\n",
      "        \"Does the title mention 'colorectal cancer'?\",\n",
      "        \"Does the title mention 'crizotinib'?\"\n",
      "    ],\n",
      "    \"CONTENT_CRITERIA\": [\n",
      "        \"Is there evidence of randomization or control group in the abstract?\",\n",
      "        \"Are outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned in the abstract?\"\n",
      "    ]\n",
      "}\n",
      "```\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'title_criteria': [\"Does the title mention 'colorectal cancer'?\",\n",
       "  \"Does the title mention 'crizotinib'?\"],\n",
       " 'content_criteria': ['Is there evidence of randomization or control group in the abstract?',\n",
       "  'Are outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned in the abstract?'],\n",
       " 'eligibility_analysis': ['Patients must have colorectal cancer confirmed by histopathology or imaging studies',\n",
       "  'Treatment with crizotinib must be administered as part of standard therapy or experimental protocol',\n",
       "  'Comparative intervention must involve another drug or placebo',\n",
       "  'Outcomes must measure efficacy, safety, or survival endpoints relevant to colorectal cancer treatment',\n",
       "  'Study design must be randomized controlled trial (RCT), cohort study, or case-control study']}"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test the apis\n",
    "\n",
    "api = ScreeningCriteriaCTGeneration()\n",
    "ecs = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    num_title_criteria=2,\n",
    "    num_abstract_criteria=2,\n",
    "    thinking=False,\n",
    ")\n",
    "ecs"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e33c1fe2-f484-4c6a-80c0-396413ad3bb1",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### __check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "d352bb46-d626-4b92-a6ea-ec0a7a964422",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.api import parse_json_outputs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "0f4abfe0-939d-4687-a181-4ea02aa36d73",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{}]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parse_json_outputs(['''```json\n",
    "{\n",
    "    \"ELIGIBILITY_ANALYSIS\": [\n",
    "        \"Patients must have colorectal cancer confirmed by histopathology or imaging studies\",\n",
    "        \"Treatment with crizotinib as part of standard therapy or experimental protocol\",\n",
    "        \"Comparative intervention against placebo or other treatments\",\n",
    "        \"Clearly reported outcomes related to efficacy or safety endpoints\",\n",
    "        \"Published in peer-reviewed journals\"\n",
    "    ],\n",
    "    \"TITLE_CRITERIA\": [\n",
    "        \"Does the title mention 'colorectal cancer'?\",\n",
    "        \"Does the title mention 'crizotinib'?\"\n",
    "    ],\n",
    "    \"CONTENT_CRITERIA\": [\n",
    "        \"Is there a description of patient population including diagnosis and stage of disease?\",\n",
    "        \"Are details provided about the intervention and comparison groups?\"\n",
    "]\n",
    "} ```\n",
    "'''])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "4172c789-e604-42b5-82f0-106c320ba8a6",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "json_pattern = r\"\\`\\`\\`json([\\s\\S]*?)\\`\\`\\`\"\n",
    "if re.search(r\"\\`\\`\\`json([\\s\\S]*?)\", '''```json\n",
    "{{\n",
    "    \"ELIGIBILITY_ANALYSIS\": [\n",
    "        \"Patients must have colorectal cancer confirmed by histopathology or imaging studies\",\n",
    "        \"Treatment with crizotinib as part of standard therapy or experimental protocol\",\n",
    "        \"Comparative intervention against placebo or other treatments\",\n",
    "        \"Clearly reported outcomes related to efficacy or safety endpoints\",\n",
    "        \"Published in peer-reviewed journals\"\n",
    "    ],\n",
    "    \"TITLE_CRITERIA\": [\n",
    "        \"Does the title mention 'colorectal cancer'?\",\n",
    "        \"Does the title mention 'crizotinib'?\"\n",
    "    ],\n",
    "    \"CONTENT_CRITERIA\": [\n",
    "        \"Is there a description of patient population including diagnosis and stage of disease?\",\n",
    "        \"Are details provided about the intervention and comparison groups?\"\n",
    "]'''):\n",
    "    print(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "id": "024db3d5-8f06-4f52-8fd3-666303a1e30e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'ScreeningResult': {'enum': [\"annotation=NoneType required=True description='Evaluation for a criteria'\",\n",
       "    \"annotation=NoneType required=True description='A rationale for a criteria evaluation'\"],\n",
       "   'title': 'ScreeningResult',\n",
       "   'type': 'string'}},\n",
       " 'properties': {'one_result': {'$ref': '#/$defs/ScreeningResult'}},\n",
       " 'required': ['one_result'],\n",
       " 'title': 'ScreeningResults',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from typing import Literal\n",
    "class ScreeningResult(str, Enum):\n",
    "    evaluations: Literal['YES', 'NO', 'UNCERTAIN'] = Field(description=f\"Evaluation for a criteria\")\n",
    "    rationale: str = Field(description=\"A rationale for a criteria evaluation\")\n",
    "\n",
    "class ScreeningResults(BaseModel):\n",
    "    one_result: ScreeningResult\n",
    "\n",
    "json_schema = ScreeningResults.model_json_schema()\n",
    "json_schema"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "95d99dc1-7182-49b3-9204-45fbb3ac6f17",
   "metadata": {},
   "source": [
    "### 2. CT screen"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "7e3f42bf-60e8-403b-a791-b99131a5d2ca",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.: This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.']"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_text = all_studies.briefTitle.fillna(\"\") + \": \" + all_studies.briefSummary.fillna(\"\")\n",
    "all_text.values.tolist()[:1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "6ff25002-4ddb-4ace-ab4f-fe5534509b87",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "# CONTEXT #\n",
      "You are a clinical specialist tasked with assessing clinical trials for inclusion in a meta-analysis based on specific eligibility criteria.\n",
      "\n",
      "# OBJECTIVE #\n",
      "Evaluate each criterion of a given clinical trial to determine its eligibility for inclusion in the meta-analysis. Provide a list of decisions (\"YES\", \"NO\", or \"UNCERTAIN\") for each eligibility criterion. You must deliver exactly {num_criteria} responses.\n",
      "\n",
      "# IMPORTANT NOTE #\n",
      "If the information within the provided clinical trial content is insufficient to conclusively evaluate a criterion, you must opt for \"UNCERTAIN\" as your response. Avoid making assumptions or extrapolating beyond the provided data, as accurate and reliable responses are crucial, and fabricating information (hallucinations) could lead to serious errors in the meta-analysis.\n",
      "\n",
      "# PICO FRAMEWORK #\n",
      "- P (Patient, Problem or Population): {P}\n",
      "- I (Intervention): {I}\n",
      "- C (Comparison): {C}\n",
      "- O (Outcome): {O}\n",
      "\n",
      "# PAPER DETAILS #\n",
      "- Provided clinical trial: {paper_content}\n",
      "\n",
      "# EVALUATION CRITERIA #\n",
      "- Number of Criteria: {num_criteria}\n",
      "- Criteria for Inclusion: {criteria_text}\n",
      "\n",
      "# RESPONSE FORMAT #\n",
      "Return the information in the following JSON-format.\n",
      "\n",
      "```json\n",
      "{{\n",
      "    \"evaluations\": [\"YES\", \"NO\", \"UNCERTAIN\", ...],\n",
      "    \"rationale\": [\"rationale1\",\"rationale2\",\"rationale3\",...]\n",
      "}}\n",
      "```\n",
      "\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\", \"YES\"],\\n    \"rationale\": [\\n        \"The title mentions \\'Colorectal cancer\\'\",\\n        \"The title mentions \\'Crizotinib\\'\",\\n        \"Randomization and control group are not explicitly stated in the provided abstract\",\\n        \"Outcomes such as tumor response and adverse events are mentioned\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"NO\", \"UNCERTAIN\", \"NO\"],\\n    \"rationale\": [\"Title does not mention colorectal cancer\", \"Title does not mention crizotinib\", \"Randomization and control group not described in provided details\", \"No outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"NO\", \"UNCERTAIN\", \"YES\"],\\n    \"rationale\": [\"Title mentions colorectal cancer\", \"Title does not mention crizotinib\", \"Randomization or control group not evident from provided info\", \"Outcomes related to tumor response and adverse events mentioned\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"YES\", \"UNCERTAIN\", \"UNCERTAIN\"],\\n    \"rationale\": [\"Title does not mention \\'colorectal cancer\\'\", \"Title mentions \\'crizotinib\\', but it is combined with other drugs\", \"No evidence of randomization or control group in the provided details\", \"No explicit mention of outcomes related to tumor response, progression-free survival, overall survival, or adverse events\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"NO\", \"UNCERTAIN\", \"NO\"],\\n    \"rationale\": [\"Title does not mention colorectal cancer\", \"Title does not mention crizotinib\", \"Randomization or control group not evident from provided details\", \"No outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\", \"YES\"],\\n    \"rationale\": [\"Title mentions \\'colorectal cancer\\'\", \"Title mentions \\'crizotinib\\'\", \"Randomization or control group not explicitly stated in provided info\", \"Outcomes related to tumor response and adverse events mentioned\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"YES\", \"UNCERTAIN\", \"UNCERTAIN\"],\\n    \"rationale\": [\"Title does not mention colorectal cancer\", \"Title mentions crizotinib\", \"Insufficient information about randomization or control group in abstract\", \"No clear mention of outcomes related to tumor response, progression-free survival, overall survival, or adverse events\"]\\n}\\n```']\n",
      "\n",
      "OUTPUTS after json extr:  [{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'YES'], 'rationale': [\"The title mentions 'Colorectal cancer'\", \"The title mentions 'Crizotinib'\", 'Randomization and control group are not explicitly stated in the provided abstract', 'Outcomes such as tumor response and adverse events are mentioned']}, {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'], 'rationale': ['Title does not mention colorectal cancer', 'Title does not mention crizotinib', 'Randomization and control group not described in provided details', 'No outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned']}, {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YES'], 'rationale': ['Title mentions colorectal cancer', 'Title does not mention crizotinib', 'Randomization or control group not evident from provided info', 'Outcomes related to tumor response and adverse events mentioned']}, {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UNCERTAIN'], 'rationale': [\"Title does not mention 'colorectal cancer'\", \"Title mentions 'crizotinib', but it is combined with other drugs\", 'No evidence of randomization or control group in the provided details', 'No explicit mention of outcomes related to tumor response, progression-free survival, overall survival, or adverse events']}, {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'], 'rationale': ['Title does not mention colorectal cancer', 'Title does not mention crizotinib', 'Randomization or control group not evident from provided details', 'No outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned']}, {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'YES'], 'rationale': [\"Title mentions 'colorectal cancer'\", \"Title mentions 'crizotinib'\", 'Randomization or control group not explicitly stated in provided info', 'Outcomes related to tumor response and adverse events mentioned']}, {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UNCERTAIN'], 'rationale': ['Title does not mention colorectal cancer', 'Title mentions crizotinib', 'Insufficient information about randomization or control group in abstract', 'No clear mention of outcomes related to tumor response, progression-free survival, overall survival, or adverse events']}]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'YES'],\n",
       "  'rationale': [\"The title mentions 'Colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'Randomization and control group are not explicitly stated in the provided abstract',\n",
       "   'Outcomes such as tumor response and adverse events are mentioned']},\n",
       " {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title does not mention crizotinib',\n",
       "   'Randomization and control group not described in provided details',\n",
       "   'No outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned']},\n",
       " {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YES'],\n",
       "  'rationale': ['Title mentions colorectal cancer',\n",
       "   'Title does not mention crizotinib',\n",
       "   'Randomization or control group not evident from provided info',\n",
       "   'Outcomes related to tumor response and adverse events mentioned']},\n",
       " {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UNCERTAIN'],\n",
       "  'rationale': [\"Title does not mention 'colorectal cancer'\",\n",
       "   \"Title mentions 'crizotinib', but it is combined with other drugs\",\n",
       "   'No evidence of randomization or control group in the provided details',\n",
       "   'No explicit mention of outcomes related to tumor response, progression-free survival, overall survival, or adverse events']},\n",
       " {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title does not mention crizotinib',\n",
       "   'Randomization or control group not evident from provided details',\n",
       "   'No outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned']},\n",
       " {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'YES'],\n",
       "  'rationale': [\"Title mentions 'colorectal cancer'\",\n",
       "   \"Title mentions 'crizotinib'\",\n",
       "   'Randomization or control group not explicitly stated in provided info',\n",
       "   'Outcomes related to tumor response and adverse events mentioned']},\n",
       " {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UNCERTAIN'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title mentions crizotinib',\n",
       "   'Insufficient information about randomization or control group in abstract',\n",
       "   'No clear mention of outcomes related to tumor response, progression-free survival, overall survival, or adverse events']}]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = CTScreening()\n",
    "ec_pred = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    criteria = ecs['title_criteria'] + ecs['content_criteria'],\n",
    "    papers = all_text.values.tolist(), # make for the top-100 for demo\n",
    ")\n",
    "ec_pred"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "c0c04eee-151d-43c2-a50f-dc106bada7ae",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[ 1  1  0  1]\n",
      " [-1 -1  0 -1]\n",
      " [ 1 -1  0  1]\n",
      " [-1  1  0  0]\n",
      " [-1 -1  0 -1]\n",
      " [ 1  1  0  1]\n",
      " [-1  1  0  0]]\n",
      "[ 3 -3  1  0 -3  3  0]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02568267</td>\n",
       "      <td>Basket Study of Entrectinib (RXDX-101) for the...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This is an open-label, multicenter, global Pha...</td>\n",
       "      <td>[Breast Cancer, Cholangiocarcinoma, Colorectal...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[entrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT06214793</td>\n",
       "      <td>Taletrectinib in Previously Treated Metastatic...</td>\n",
       "      <td>SUSPENDED</td>\n",
       "      <td>The purpose of this study is to evaluate the s...</td>\n",
       "      <td>[Breast Cancer, Metastatic Breast Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[taletrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This phase II MATCH screening and multi-sub-tr...</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "1       False  NCT02568267  Basket Study of Entrectinib (RXDX-101) for the...   \n",
       "2        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "4       False  NCT06214793  Taletrectinib in Previously Treated Metastatic...   \n",
       "5       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "6       False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "\n",
       "           overallStatus                                       briefSummary  \\\n",
       "0                UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "1  ACTIVE_NOT_RECRUITING  This is an open-label, multicenter, global Pha...   \n",
       "2              COMPLETED  This trial is designed to try two new cancer d...   \n",
       "3             RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "4              SUSPENDED  The purpose of this study is to evaluate the s...   \n",
       "5             RECRUITING  The purpose of the study is to investigate the...   \n",
       "6  ACTIVE_NOT_RECRUITING  This phase II MATCH screening and multi-sub-tr...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "1  [Breast Cancer, Cholangiocarcinoma, Colorectal...  INTERVENTIONAL   \n",
       "2                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "4          [Breast Cancer, Metastatic Breast Cancer]  INTERVENTIONAL   \n",
       "5                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "6  [Advanced Lymphoma, Advanced Malignant Solid N...  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0              [NA]                                                 []   \n",
       "1          [PHASE2]                                      [entrectinib]   \n",
       "2          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "4          [PHASE2]                                    [taletrectinib]   \n",
       "5          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "6          [PHASE2]  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \n",
       "0                                                NaN            3  \n",
       "1                                                NaN           -3  \n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1  \n",
       "3                                                NaN            0  \n",
       "4                                                NaN           -3  \n",
       "5                                                NaN            3  \n",
       "6                                                NaN            0  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evals = [i['evaluations'] for i in ec_pred]\n",
    "\n",
    "word2int = {\"YES\": 1, \n",
    "            \"UNCERTAIN\": 0,\n",
    "            \"NO\": -1\n",
    "           }\n",
    "#rev_subs = { v:k for k, v in word2int.items()} # subs.iteritems() In Python 3\n",
    "new_evals = []\n",
    "for one_e in evals:\n",
    "    new_evals.append([word2int.get(item, 0) for item in one_e ])\n",
    "new_evals = np.array(new_evals)    \n",
    "print(new_evals)\n",
    "print(new_evals.sum(axis=1))\n",
    "all_studies['screen_eval'] = new_evals.sum(axis=1)\n",
    "all_studies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "311045ba-470d-4ef5-92e4-615ad05e5911",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This phase II MATCH screening and multi-sub-tr...</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "2        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "5       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "6       False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "\n",
       "           overallStatus                                       briefSummary  \\\n",
       "0                UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "2              COMPLETED  This trial is designed to try two new cancer d...   \n",
       "3             RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "5             RECRUITING  The purpose of the study is to investigate the...   \n",
       "6  ACTIVE_NOT_RECRUITING  This phase II MATCH screening and multi-sub-tr...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "2                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "5                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "6  [Advanced Lymphoma, Advanced Malignant Solid N...  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0              [NA]                                                 []   \n",
       "2          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "5          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "6          [PHASE2]  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \n",
       "0                                                NaN            3  \n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1  \n",
       "3                                                NaN            0  \n",
       "5                                                NaN            3  \n",
       "6                                                NaN            0  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies[all_studies.screen_eval>=0]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7a7a20de-f7d2-4970-b101-656a671b3a80",
   "metadata": {
    "tags": []
   },
   "source": [
    "### 3. CT outcome results\n",
    "Взяли все результаты, отдельно сохранили испытания с результатами, и з них отбираем рез-ты только с unit==participants\n",
    "\n",
    "filter by interventional study type?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 306,
   "id": "4483a6d0-1c86-4027-b557-575b85502863",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.llm import batch_call_llm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 307,
   "id": "b1bc6163-2677-456d-9c9f-2862b03d3e22",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "openai_client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(verify=False)\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 308,
   "id": "8dbee3b4-ecf8-44b7-859c-39c0f83c51d1",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://gigachat.devices.sberbank.ru/api/v1'"
      ]
     },
     "execution_count": 308,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getenv(\"BASE_URL\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 309,
   "id": "87984298-bc50-4479-b40f-8a0e653e2632",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_with_part</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Clinical Respon...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                   briefTitle  \\\n",
       "2        True  NCT02510001  MEK and MET Inhibition in Colorectal Cancer   \n",
       "\n",
       "  overallStatus                                       briefSummary  \\\n",
       "2     COMPLETED  This trial is designed to try two new cancer d...   \n",
       "\n",
       "                         conditions       studyType    phases  \\\n",
       "2  [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL  [PHASE1]   \n",
       "\n",
       "                            interventions  \\\n",
       "2  [pf-02341066, pd-0325901, binimetinib]   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \\\n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1   \n",
       "\n",
       "                                           screening  \\\n",
       "2  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...   \n",
       "\n",
       "                                       res_with_part  \n",
       "2  [{'type': 'PRIMARY', 'title': 'Clinical Respon...  "
      ]
     },
     "execution_count": 309,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chosen"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 314,
   "id": "57a13d5a-f3af-450a-913e-213a72f96395",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'role': 'system',\n",
       "  'content': 'You are a helpful medical assistant. Answer with a concise description of the efficiency statistics for EACH of 1 provided outcome measures /no_think'},\n",
       " {'role': 'user',\n",
       "  'content': \"[{'type': 'PRIMARY', 'title': 'Clinical Response to Binimetinib Combined With PF-02341066', 'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\\\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD', 'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.', 'groups': [{'id': 'OG000', 'title': 'Dose Expansion Phase', 'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\\\n\\\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\\\n\\\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '30'}]}], 'classes': [{'categories': [{'title': 'Stable Disease', 'measurements': [{'groupId': 'OG000', 'value': '7'}]}, {'title': 'Progressive Disease', 'measurements': [{'groupId': 'OG000', 'value': '22'}]}, {'title': 'Early death from malignant disease', 'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]}]\"}]"
      ]
     },
     "execution_count": 314,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "messages[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "74ccc9e8-bccd-49ef-8b25-9a1d9e6f2463",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 523,
   "id": "67cd8078-c266-47ef-a19b-a6d22f0e7283",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "PROMPT_RES_EXTRACTION  = '''\n",
    "You are a clinical specialist analyzing clinical trial study reports. \n",
    "Your task is to to extract specific information as structured data.\n",
    "\n",
    "# Reply Format: \n",
    "Return the information in the following JSON-format.\n",
    "```json\n",
    "{{        \n",
    "    [\n",
    "        {{\n",
    "            \"population\": n,\n",
    "            \"time_frame\": \"time_frame\",\n",
    "            \"outcomes\":\n",
    "                [\n",
    "                    {{\n",
    "                        \"category_name\": \"category1\",\n",
    "                        \"outcome\": k1\n",
    "                    }},\n",
    "                    {{\n",
    "                        \"category_name\": \"category2\",\n",
    "                        \"outcome\": k2\n",
    "                    }},\n",
    "                    ...\n",
    "                ]\n",
    "         }},\n",
    "        ...\n",
    "    ]\n",
    "}}\n",
    "```\n",
    "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
    "\"\"\"\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 520,
   "id": "692244d5-fd27-4d0a-ac6e-c20af436931f",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "class Outcome(BaseModel):\n",
    "    category_name: str = Field(description='Short description of a category')\n",
    "    outcome: int = Field(description='Percent of participants')\n",
    "\n",
    "class ClinicalResult(BaseModel):\n",
    "    population: int = Field(description='Total number of participants.')\n",
    "    time_frame: str = Field(description='Time frame')\n",
    "    outcomes: list[Outcome]\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 521,
   "id": "8b585da8-212a-49a1-a357-42a31e071693",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'Outcome': {'properties': {'category_name': {'description': 'Short description of a category',\n",
       "     'title': 'Category Name',\n",
       "     'type': 'string'},\n",
       "    'outcome': {'description': 'Percent of participants',\n",
       "     'title': 'Outcome',\n",
       "     'type': 'integer'}},\n",
       "   'required': ['category_name', 'outcome'],\n",
       "   'title': 'Outcome',\n",
       "   'type': 'object'}},\n",
       " 'properties': {'population': {'description': 'Total number of participants.',\n",
       "   'title': 'Population',\n",
       "   'type': 'integer'},\n",
       "  'time_frame': {'description': 'Time frame',\n",
       "   'title': 'Time Frame',\n",
       "   'type': 'string'},\n",
       "  'outcomes': {'items': {'$ref': '#/$defs/Outcome'},\n",
       "   'title': 'Outcomes',\n",
       "   'type': 'array'}},\n",
       " 'required': ['population', 'time_frame', 'outcomes'],\n",
       " 'title': 'ClinicalResult',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 521,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ClinicalResult.model_json_schema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 488,
   "id": "394a02bb-954f-44b4-b84e-159711aaddca",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "invalid syntax (1536186896.py, line 1)",
     "output_type": "error",
     "traceback": [
      "  \u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[488]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[31m    \u001b[39m\u001b[31m- **Population**: Evaluable patients (N=30)\u001b[39m\n      ^\n\u001b[31mSyntaxError\u001b[39m\u001b[31m:\u001b[39m invalid syntax\n"
     ]
    }
   ],
   "source": [
    "- **Population**: Evaluable patients (N=30)\n",
    "- **Time Frame**: Dose expansion phase - Change from baseline up to 12 months.\n",
    "- **Results**:\n",
    "  * Stable Disease: 7 participants\n",
    "  * Progressive Disease: 22 participants\n",
    "  * Early Death From Malignant Disease: 1 participa"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 524,
   "id": "d49df219-e6db-4e19-bad8-064aec8aba27",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\user\\AppData\\Local\\Temp\\ipykernel_4268\\2758598942.py:9: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  chosen['res_with_part'] = chosen['outcomeMeasures'].apply(lambda x: [obj for obj in x \\\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "```json\n",
      "[\n",
      "    {\n",
      "        \"population\": 30,\n",
      "        \"time_frame\": \"Dose Expansion phase: change from baseline and up to 12 months.\",\n",
      "        \"outcomes\": [\n",
      "            {\n",
      "                \"category_name\": \"Stable Disease\",\n",
      "                \"outcome\": 7\n",
      "            },\n",
      "            {\n",
      "                \"category_name\": \"Progressive Disease\",\n",
      "                \"outcome\": 22\n",
      "            },\n",
      "            {\n",
      "                \"category_name\": \"Early death from malignant disease\",\n",
      "                \"outcome\": 1\n",
      "            }\n",
      "        ]\n",
      "    }\n",
      "]\n",
      "```\n",
      "-----\n"
     ]
    }
   ],
   "source": [
    "at_once = False\n",
    "openai_client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(verify=False)\n",
    ")\n",
    "\n",
    "chosen = all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults==True)]\n",
    "chosen['res_with_part'] = chosen['outcomeMeasures'].apply(lambda x: [obj for obj in x \\\n",
    "                                                          if(obj.get('unitOfMeasure','').lower() in ['percentage of participants','participants'])])\n",
    "\n",
    "to_work = chosen[chosen.res_with_part.str.len()>0]\n",
    "if to_work.shape[0]:\n",
    "    messages = []\n",
    "    for i in to_work.res_with_part.values:\n",
    "        n_outcomes = len(i)\n",
    "        messages.append([{'role':'system', 'content':PROMPT_RES_EXTRACTION+' \\no_think'},\n",
    "                {'role':'user', 'content':f\"{i}\"}])\n",
    "    if at_once:\n",
    "        results = batch_call_openai(messages, os.getenv('MODEL_NAME'), \n",
    "                                    int(os.getenv('TEMPERATURE')), thinking=False)\n",
    "    else:\n",
    "        resultsct = []\n",
    "        for i in messages:\n",
    "            #$answer = extract.use_llm(os.getenv('MODEL_NAME'),i)\n",
    "            \n",
    "            response = openai_client.chat.completions.create(\n",
    "                model=os.getenv('MODEL_NAME'),\n",
    "                messages=messages[0],\n",
    "                temperature=0,\n",
    "                response_format={\n",
    "                    \"type\": \"json_object\",\n",
    "                    \"json_schema\": {\n",
    "                        \"name\": \"schema\",\n",
    "                        \"schema\": ClinicalResult.model_json_schema()\n",
    "                    },\n",
    "                },\n",
    "            )\n",
    "            fin = response.choices[0].message.content\n",
    "            answer = fin.strip('<think>\\n\\n</think>\\n\\n')\n",
    "            resultsct.append(answer)\n",
    "    for i in resultsct:\n",
    "        print(i)\n",
    "        print('-----')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 526,
   "id": "480922c1-4335-4063-93bd-63b07701cd23",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'population': 30,\n",
       "   'time_frame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "   'outcomes': [{'category_name': 'Stable Disease', 'outcome': 7},\n",
       "    {'category_name': 'Progressive Disease', 'outcome': 22},\n",
       "    {'category_name': 'Early death from malignant disease', 'outcome': 1}]}]]"
      ]
     },
     "execution_count": 526,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from trialmind.api import parse_json_outputs\n",
    "parse_json_outputs(resultsct)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 336,
   "id": "20ee7573-4aa2-489e-9264-06539e490e4f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Clinical Response to Binimetinib Combined With PF-02341066'"
      ]
     },
     "execution_count": 336,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_work.res_with_part.values[0][0]['title']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 330,
   "id": "643d0dda-3061-4d43-98bd-e5845f92300e",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'PRIMARY',\n",
       "  'title': 'Clinical Response to Binimetinib Combined With PF-02341066',\n",
       "  'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD',\n",
       "  'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "  'unitOfMeasure': 'Participants',\n",
       "  'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '30'}]}],\n",
       "  'classes': [{'categories': [{'title': 'Stable Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '7'}]},\n",
       "     {'title': 'Progressive Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '22'}]},\n",
       "     {'title': 'Early death from malignant disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]}]"
      ]
     },
     "execution_count": 330,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_work.res_with_part.values[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 556,
   "id": "20179bdd-2e7c-44d7-a534-ea67759a2161",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_with_part</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Clinical Respon...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                   briefTitle  \\\n",
       "2        True  NCT02510001  MEK and MET Inhibition in Colorectal Cancer   \n",
       "\n",
       "  overallStatus                                       briefSummary  \\\n",
       "2     COMPLETED  This trial is designed to try two new cancer d...   \n",
       "\n",
       "                         conditions       studyType    phases  \\\n",
       "2  [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL  [PHASE1]   \n",
       "\n",
       "                            interventions  \\\n",
       "2  [pf-02341066, pd-0325901, binimetinib]   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \\\n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1   \n",
       "\n",
       "                                           screening  \\\n",
       "2  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...   \n",
       "\n",
       "                                       res_with_part  \n",
       "2  [{'type': 'PRIMARY', 'title': 'Clinical Respon...  "
      ]
     },
     "execution_count": 556,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_work#.res_with_part#.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 339,
   "id": "0bfa8185-e09b-409d-abd5-abc8d2bf3581",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 339,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "'30' in str(to_work.res_with_part.values[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 318,
   "id": "9d01b2c9-a182-4240-b0f5-e47ce165a71c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['For the PRIMARY outcome measure \"Clinical Response to Binimetinib Combined With PF-02341066\":\\n\\n- **Population**: Evaluable patients (N=30)\\n- **Time Frame**: Dose expansion phase - Change from baseline up to 12 months.\\n- **Results**:\\n  * Stable Disease: 7 participants\\n  * Progressive Disease: 22 participants\\n  * Early Death From Malignant Disease: 1 participa']"
      ]
     },
     "execution_count": 318,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "resultsct"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6475f621-f2ab-4b6f-8145-13ac1584f9ad",
   "metadata": {},
   "outputs": [],
   "source": [
    "at_once = False\n",
    "openai_client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(verify=False)\n",
    ")\n",
    "\n",
    "chosen = all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults==True)]\n",
    "chosen['res_with_part'] = chosen['outcomeMeasures'].apply(lambda x: [obj for obj in x \\\n",
    "                                                          if(obj.get('unitOfMeasure','').lower() in ['percentage of participants','participants'])])\n",
    "\n",
    "to_work = chosen[chosen.res_with_part.str.len()>0]\n",
    "if to_work.shape[0]:\n",
    "    messages = []\n",
    "    for i in to_work.res_with_part.values[:2]:\n",
    "        n_outcomes = len(i)\n",
    "        print(n_outcomes)\n",
    "        messages.append([{'role':'system', 'content':f'You are a helpful medical assistant. Answer with a concise description of the efficiency statistics for EACH of {n_outcomes} provided outcome measures /no_think'},\n",
    "                {'role':'user', 'content':f\"{i}\"}])\n",
    "    if at_once:\n",
    "        results = batch_call_openai(messages, os.getenv('MODEL_NAME'), \n",
    "                                    int(os.getenv('TEMPERATURE')), thinking=False)\n",
    "    else:\n",
    "        resultsct = []\n",
    "        for i in messages:\n",
    "            #$answer = extract.use_llm(os.getenv('MODEL_NAME'),i)\n",
    "            \n",
    "            response = openai_client.chat.completions.create(\n",
    "                model=os.getenv('MODEL_NAME'),\n",
    "                messages=messages[0],\n",
    "                temperature=0\n",
    "            )\n",
    "            fin = response.choices[0].message.content\n",
    "            answer = fin.strip('<think>\\n\\n</think>\\n\\n')\n",
    "            resultsct.append(answer)\n",
    "    for i in resultsct:\n",
    "        print(i)\n",
    "        print('-----')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "84f5d879-2920-4ec3-bac4-5ae64fb55099",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e706ee64-c65f-40a9-8606-8e71c97fa5d6",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### results in a given format?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8f1d0545-8778-43fb-9af8-da1730e79453",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "class Info(BaseModel):\n",
    "    diagnose: str = Field(..., description=\"База клинических испытаний\")\n",
    "    treatments: str = Field(..., description=\"Высшие позиции рейтинга таргетных препаратов\")\n",
    "\n",
    "parser = PydanticOutputParser(pydantic_object=Info)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1d5b0edc-bb8f-4fcd-b443-36745ad7eaf7",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\n",
    "        \"system\", \n",
    "        dedent(\n",
    "            \"\"\"\n",
    "            You are a helpful assistant. \n",
    "            Your goal is to extract related information from the text provided by the user.\n",
    "            Return the information in the following JSON-format.\n",
    "            {fmt}\n",
    "            \"\"\"\n",
    "        )\n",
    "    ),\n",
    "    (\n",
    "        \"human\", \n",
    "        dedent(\n",
    "            \"\"\"\n",
    "            Text: {text}\"\n",
    "            \"\"\"\n",
    "        )\n",
    "    ),\n",
    "])\n",
    "chain = (\n",
    "    prompt \n",
    "    | llm_reasoning \n",
    "    | parser\n",
    ")\n",
    "\n",
    "\n",
    "response = await chain.ainvoke({\"text\": text, \"fmt\": parser.get_format_instructions()})\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d963b7db-0c01-4b5f-af74-d7d566ae8a54",
   "metadata": {
    "tags": []
   },
   "source": [
    "## 4. papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "f1e430e6-c0a6-4a2f-9e92-2b0ca80bdd6e",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "fin_condition = 'Colorectal cancer'\n",
    "treatements_eng =  ['Crizotinib','Lorlatinib',]\n",
    "pubmed_api_key= '6892c4129cef143ff92d11533848d2e0d908'#os.getenv(\"PUBMED_API_KEY\", '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "ceab5c26-765a-420c-82a6-8bfbacdb36f6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(['40526090',\n",
       "  '38711893',\n",
       "  '40140597',\n",
       "  '35343863',\n",
       "  '41213063',\n",
       "  '36129915',\n",
       "  '34898475',\n",
       "  '36801912',\n",
       "  '37418240',\n",
       "  '36316649',\n",
       "  '40369167',\n",
       "  '36053834',\n",
       "  '37686423',\n",
       "  '40211189',\n",
       "  '38212428',\n",
       "  '36627781',\n",
       "  '37773318',\n",
       "  '38378070',\n",
       "  '41268440',\n",
       "  '37543570'],\n",
       " 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=(Colorectal cancer)+AND+(Crizotinib)&retmax=20&retmode=json&api_key=6892c4129cef143ff92d11533848d2e0d908',\n",
       " '67')"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_api = PubmedAPIWrapper()\n",
    "# page_size is the max number of records to return!!!! not pages!\n",
    "tmp_inputs = {\n",
    "        \"page_size\": 20,\n",
    "        \"keyword_map\": {'conditions':[fin_condition], \n",
    "                        'treatments':[treatements_eng[0]]\n",
    "                       },\n",
    "        \"keywords\": {\n",
    "            \"OPERATOR\": 'AND'\n",
    "        }\n",
    "}\n",
    "\n",
    "time.sleep(.5)\n",
    "response = search_api.build_search_query_and_get_pmid(tmp_inputs, \n",
    "                                                      api_key=pubmed_api_key)\n",
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "a54a4f2c-d723-4a4a-a1b1-77eb50eeaea8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>35343863</td>\n",
       "      <td>Expert opinion on therapeutic patents</td>\n",
       "      <td>2022</td>\n",
       "      <td>Jun</td>\n",
       "      <td></td>\n",
       "      <td>An updated patent review of small-molecule ROS...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...</td>\n",
       "      <td>C-ros oncogene 1 (ROS1) is the sole member of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>36129915</td>\n",
       "      <td>PloS one</td>\n",
       "      <td>2022</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Investigation of cell signalings and therapeut...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Jae Heon Jeong, Jae Won Yun, Ha Young Kim, Cha...</td>\n",
       "      <td>Colorectal cancer (CRC) is one of the most dea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>34898475</td>\n",
       "      <td>Aging</td>\n",
       "      <td>2021</td>\n",
       "      <td>Dec</td>\n",
       "      <td>13</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...</td>\n",
       "      <td>Globally, colorectal cancer (CRC) is one of th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>36801912</td>\n",
       "      <td>NPJ precision oncology</td>\n",
       "      <td>2023</td>\n",
       "      <td>Feb</td>\n",
       "      <td>18</td>\n",
       "      <td>BRAF v600E-mutant cancers treated with vemuraf...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Blessie Elizabeth Nelson, Jason Roszik, Filip ...</td>\n",
       "      <td>Combined BRAF + MEK inhibition is FDA approved...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>37418240</td>\n",
       "      <td>ACS applied materials &amp; interfaces</td>\n",
       "      <td>2023</td>\n",
       "      <td>Jul</td>\n",
       "      <td>19</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen</td>\n",
       "      <td>Colorectal cancer (CRC) is presently the third...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>36316649</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Oct</td>\n",
       "      <td>31</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Maxim Sorokin, Marianna Zolotovskaia, Daniil N...</td>\n",
       "      <td>Overall survival of advanced colorectal cancer...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>36053834</td>\n",
       "      <td>International journal of cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Dec</td>\n",
       "      <td>15</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Dilara Akhoundova, Saskia Hussung, Smruthy Siv...</td>\n",
       "      <td>c-Ros oncogene 1, receptor tyrosine kinase (RO...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>37686423</td>\n",
       "      <td>International journal of molecular sciences</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>03</td>\n",
       "      <td>Targeted Therapy for Cancers: From Ongoing Cli...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Ha Yeong Choi, Ji-Eun Chang</td>\n",
       "      <td>The development of targeted therapies has revo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>38212428</td>\n",
       "      <td>Cellular and molecular life sciences : CMLS</td>\n",
       "      <td>2024</td>\n",
       "      <td>Jan</td>\n",
       "      <td>12</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Vivian Truong Jones, Ramona Graves-Deal, Zheng...</td>\n",
       "      <td>Although amplifications and mutations in recep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>36627781</td>\n",
       "      <td>Anti-cancer agents in medicinal chemistry</td>\n",
       "      <td>2023</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Recent Updates on Structural Aspects of ALK In...</td>\n",
       "      <td>Review, Journal Article</td>\n",
       "      <td>Md Shahid Ayaz, Ritu Bhupal, Priyanka Sharma, ...</td>\n",
       "      <td>Presently, several protein kinases have been d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>37773318</td>\n",
       "      <td>NPJ precision oncology</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>29</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Aditya Shreenivas, Filip Janku, Mohamed A Goud...</td>\n",
       "      <td>Anaplastic lymphoma kinase (ALK) alterations (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>38378070</td>\n",
       "      <td>Experimental and molecular pathology</td>\n",
       "      <td>2024</td>\n",
       "      <td>Apr</td>\n",
       "      <td></td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Melika Golozar, Ali Valipour Motlagh, Mohammad...</td>\n",
       "      <td>Alterations in the expression of certain genes...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>41268440</td>\n",
       "      <td>Frontiers in pharmacology</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Case Report: HGF and NF1 mutations as putative...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li</td>\n",
       "      <td>Hepatocellular carcinoma (HCC) is a highly agg...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>37543570</td>\n",
       "      <td>Journal of translational medicine</td>\n",
       "      <td>2023</td>\n",
       "      <td>Aug</td>\n",
       "      <td>05</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) is k...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        PMID                                            Journal  Year Month  \\\n",
       "0   40526090                                         Oncotarget  2025   Jun   \n",
       "1   38711893                                   AME case reports  2024         \n",
       "2   40140597                                        BJC reports  2025   Mar   \n",
       "3   35343863              Expert opinion on therapeutic patents  2022   Jun   \n",
       "4   41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "5   36129915                                           PloS one  2022         \n",
       "6   34898475                                              Aging  2021   Dec   \n",
       "7   36801912                             NPJ precision oncology  2023   Feb   \n",
       "8   37418240                 ACS applied materials & interfaces  2023   Jul   \n",
       "9   36316649                                         BMC cancer  2022   Oct   \n",
       "10  40369167                     Cell death and differentiation  2025   Nov   \n",
       "11  36053834                    International journal of cancer  2022   Dec   \n",
       "12  37686423        International journal of molecular sciences  2023   Sep   \n",
       "13  40211189                                         BMC cancer  2025   Apr   \n",
       "14  38212428        Cellular and molecular life sciences : CMLS  2024   Jan   \n",
       "15  36627781          Anti-cancer agents in medicinal chemistry  2023         \n",
       "16  37773318                             NPJ precision oncology  2023   Sep   \n",
       "17  38378070               Experimental and molecular pathology  2024   Apr   \n",
       "18  41268440                          Frontiers in pharmacology  2025         \n",
       "19  37543570                  Journal of translational medicine  2023   Aug   \n",
       "\n",
       "   Day                                              Title  \\\n",
       "0   17  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "1       Partial response to crizotinib + regorafenib +...   \n",
       "2   26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "3       An updated patent review of small-molecule ROS...   \n",
       "4       Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "5       Investigation of cell signalings and therapeut...   \n",
       "6   13  Identification of a novel immune signature for...   \n",
       "7   18  BRAF v600E-mutant cancers treated with vemuraf...   \n",
       "8   19  Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   31  Personalized targeted therapy prescription in ...   \n",
       "10      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11  15  ROS1 genomic rearrangements are rare actionabl...   \n",
       "12  03  Targeted Therapy for Cancers: From Ongoing Cli...   \n",
       "13  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  12  Inhibition of autocrine HGF maturation overcom...   \n",
       "15      Recent Updates on Structural Aspects of ALK In...   \n",
       "16  29  ALK fusions in the pan-cancer setting: another...   \n",
       "17      TBX15 and SDHB expression changes in colorecta...   \n",
       "18      Case Report: HGF and NF1 mutations as putative...   \n",
       "19  05  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                     Publication Type  \\\n",
       "0                       Journal Article, Case Reports   \n",
       "1                       Case Reports, Journal Article   \n",
       "2                                     Journal Article   \n",
       "3                             Journal Article, Review   \n",
       "4                                     Journal Article   \n",
       "5   Journal Article, Research Support, Non-U.S. Gov't   \n",
       "6   Journal Article, Research Support, Non-U.S. Gov't   \n",
       "7                                     Journal Article   \n",
       "8                                     Journal Article   \n",
       "9                                     Journal Article   \n",
       "10                                    Journal Article   \n",
       "11                                    Journal Article   \n",
       "12                            Journal Article, Review   \n",
       "13           Journal Article, Clinical Trial, Phase I   \n",
       "14                                    Journal Article   \n",
       "15                            Review, Journal Article   \n",
       "16                            Journal Article, Review   \n",
       "17                                    Journal Article   \n",
       "18                      Case Reports, Journal Article   \n",
       "19  Journal Article, Research Support, Non-U.S. Gov't   \n",
       "\n",
       "                                              Authors  \\\n",
       "0   Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "1   Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "2   Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "3   Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...   \n",
       "4                    Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "5   Jae Heon Jeong, Jae Won Yun, Ha Young Kim, Cha...   \n",
       "6   Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...   \n",
       "7   Blessie Elizabeth Nelson, Jason Roszik, Filip ...   \n",
       "8        Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen   \n",
       "9   Maxim Sorokin, Marianna Zolotovskaia, Daniil N...   \n",
       "10  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "11  Dilara Akhoundova, Saskia Hussung, Smruthy Siv...   \n",
       "12                        Ha Yeong Choi, Ji-Eun Chang   \n",
       "13  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "14  Vivian Truong Jones, Ramona Graves-Deal, Zheng...   \n",
       "15  Md Shahid Ayaz, Ritu Bhupal, Priyanka Sharma, ...   \n",
       "16  Aditya Shreenivas, Filip Janku, Mohamed A Goud...   \n",
       "17  Melika Golozar, Ali Valipour Motlagh, Mohammad...   \n",
       "18       Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li   \n",
       "19  Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...   \n",
       "\n",
       "                                             Abstract  \n",
       "0   Heavily pretreated metastatic colorectal cance...  \n",
       "1   Colorectal cancer (CRC) with the Raf murine sa...  \n",
       "2   Single-agent MEK1/2 inhibition has been disapp...  \n",
       "3   C-ros oncogene 1 (ROS1) is the sole member of ...  \n",
       "4   Numerous genes have been associated with color...  \n",
       "5   Colorectal cancer (CRC) is one of the most dea...  \n",
       "6   Globally, colorectal cancer (CRC) is one of th...  \n",
       "7   Combined BRAF + MEK inhibition is FDA approved...  \n",
       "8   Colorectal cancer (CRC) is presently the third...  \n",
       "9   Overall survival of advanced colorectal cancer...  \n",
       "10  ARID1A, a subunit of the SWI/SNF chromatin-rem...  \n",
       "11  c-Ros oncogene 1, receptor tyrosine kinase (RO...  \n",
       "12  The development of targeted therapies has revo...  \n",
       "13  Targeting RAS mutant (MT) colorectal cancer (C...  \n",
       "14  Although amplifications and mutations in recep...  \n",
       "15  Presently, several protein kinases have been d...  \n",
       "16  Anaplastic lymphoma kinase (ALK) alterations (...  \n",
       "17  Alterations in the expression of certain genes...  \n",
       "18  Hepatocellular carcinoma (HCC) is a highly agg...  \n",
       "19  Epithelial cell adhesion molecule (EpCAM) is k...  "
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers = pmid2papers(#pmid_list=['40526090', '41213063', '41268440'],\n",
    "                        pmid_list=response[0], \n",
    "                        api_key=pubmed_api_key)\n",
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f15bedd0-7b97-4696-ac71-2b9ddc4ef0d6",
   "metadata": {},
   "source": [
    "### papers screen criterias"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "02abfa1e-39b7-4f19-b669-16f0cc72cad5",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "call_openai https://gigachat.devices.sberbank.ru/api/v1\n",
      "api_call_single https://gigachat.devices.sberbank.ru/api/v1/\n",
      "```json\n",
      "{\n",
      "    \"ELIGIBILITY_ANALYSIS\": [\n",
      "        \"Patients must have colorectal cancer to ensure relevance to the study population\",\n",
      "        \"Crizotinib must be used as an intervention to focus on the specific drug being studied\",\n",
      "        \"Comparisons must be present to allow for meaningful contrast between treatments\",\n",
      "        \"Outcomes must be clearly defined to enable consistent evaluation across studies\",\n",
      "        \"Studies must be randomized controlled trials or observational studies to maintain high-quality evidence\"\n",
      "    ],\n",
      "    \"TITLE_CRITERIA\": [\n",
      "        \"Does the title mention 'colorectal cancer'?\",\n",
      "        \"Does the title mention 'Crizotinib'?\"\n",
      "    ],\n",
      "    \"CONTENT_CRITERIA\": [\n",
      "        \"Is there a clear description of patient characteristics including diagnosis and stage of disease?\",\n",
      "        \"Are the methods section and results section sufficiently detailed to assess the quality and validity of the study?\"\n",
      "    ]\n",
      "}\n",
      "```\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'title_criteria': [\"Does the title mention 'colorectal cancer'?\",\n",
       "  \"Does the title mention 'Crizotinib'?\"],\n",
       " 'content_criteria': ['Is there a clear description of patient characteristics including diagnosis and stage of disease?',\n",
       "  'Are the methods section and results section sufficiently detailed to assess the quality and validity of the study?'],\n",
       " 'eligibility_analysis': ['Patients must have colorectal cancer to ensure relevance to the study population',\n",
       "  'Crizotinib must be used as an intervention to focus on the specific drug being studied',\n",
       "  'Comparisons must be present to allow for meaningful contrast between treatments',\n",
       "  'Outcomes must be clearly defined to enable consistent evaluation across studies',\n",
       "  'Studies must be randomized controlled trials or observational studies to maintain high-quality evidence']}"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test the apis\n",
    "\n",
    "api = ScreeningCriteriaGeneration()\n",
    "ecs_p = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    num_title_criteria=2,\n",
    "    num_abstract_criteria=2,\n",
    "    thinking=False,\n",
    ")\n",
    "ecs_p"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "f2858acb-a1e3-4d89-b8af-f1b7ce0cf1d4",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.: Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring']"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers = df_papers[0][\"Title\"] + \": \" + df_papers[0][\"Abstract\"].fillna(\"\") # important to fillna\n",
    "papers = papers.tolist()\n",
    "papers[:1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "e604d682-87c0-4bcb-97c0-0c4109f1bdd3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\"Does the title mention 'colorectal cancer'?\",\n",
       " \"Does the title mention 'Crizotinib'?\",\n",
       " 'Is there a clear description of patient characteristics including diagnosis and stage of disease?',\n",
       " 'Are the methods section and results section sufficiently detailed to assess the quality and validity of the study?']"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "'''\n",
    "'title_criteria': [\"Does the title mention 'colorectal cancer'?\",\n",
    "  \"Does the title mention 'Crizotinib'?\"],\n",
    "'content_criteria': ['Is there evidence of Crizotinib administration in the study methods section?',\n",
    "  'Are outcomes related to patient response, adverse events, or survival discussed in the results section?'],\n",
    "'''\n",
    "title_criteria = ecs_p['title_criteria']\n",
    "content_criteria = ecs_p['content_criteria']\n",
    "title_criteria+content_criteria"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b60eb8db-508e-4d6e-9001-de01c588eb2e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "98cbb36e-3268-45c7-83d1-c7e29254a270",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### __check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "01b591d1-9455-484c-84d8-5257ddb17838",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.llm import _batch_inputs_to_messages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "1952514e-39be-48fd-a185-1840dfaf2ddc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\n# CONTEXT #\\nYou are a clinical specialist tasked with assessing research papers for inclusion in a meta-analysis based on specific eligibility criteria.\\n\\n# OBJECTIVE #\\nEvaluate each criterion of a given paper to determine its eligibility for inclusion in the meta-analysis. Provide a list of decisions (\"YES\", \"NO\", or \"UNCERTAIN\") for each eligibility criterion. You must deliver exactly {num_criteria} responses.\\n\\n# IMPORTANT NOTE #\\nIf the information within the provided paper content is insufficient to conclusively evaluate a criterion, you must opt for \"UNCERTAIN\" as your response. Avoid making assumptions or extrapolating beyond the provided data, as accurate and reliable responses are crucial, and fabricating information (hallucinations) could lead to serious errors in the meta-analysis.\\n\\n# PICO FRAMEWORK #\\n- P (Patient, Problem or Population): {P}\\n- I (Intervention): {I}\\n- C (Comparison): {C}\\n- O (Outcome): {O}\\n\\n# PAPER DETAILS #\\n- Provided Paper: {paper_content}\\n\\n# EVALUATION CRITERIA #\\n- Number of Criteria: {num_criteria}\\n- Criteria for Inclusion: {criteria_text}\\n\\n# RESPONSE FORMAT #\\nReturn the information in a JSON object containing a list of decisions for each of the {num_criteria} eligibility criteria. Each decision should directly correspond to one of the criteria and be listed in the order they are presented. Ensure to use \"UNCERTAIN\" wherever the paper does not explicitly support a \"YES\" or \"NO\" decision.\\n\\nFor example:\\n```json\\n{{\\n    \"evaluations\": [\"YES\", \"NO\", \"UNCERTAIN\", \"YES\", \"YES\", ...],\\n    \"rationale\": [\"The title includes...\",\"...\",\"...\",\"...\",\"...\",...]\\n}}\\n```\\n\\nMANDATORY: Every single response then continues with valid JSON output complying to the included JSON schema, and will be validated, allowing no deviation.\\n'"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from trialmind.prompts.screening import LITERATURE_SCREENING_FC\n",
    "population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "intervention = f\"{treatements_eng[0]}\",\n",
    "comparator = \"\",\n",
    "outcome = \"\",\n",
    "criteria = title_criteria + content_criteria\n",
    "criteria_text = [f\"{idx+1}. {c}\" for idx, c in enumerate(criteria)]\n",
    "n_criteria = len(criteria_text)\n",
    "    \n",
    "batch_inputs = []\n",
    "for paper in papers[:1]:\n",
    "    batch_inputs.append({\n",
    "        \"P\": population,\n",
    "        \"I\": intervention,\n",
    "        \"C\": comparator,\n",
    "        \"O\": outcome,\n",
    "        \"paper_content\": paper,\n",
    "        \"criteria_text\": criteria_text,\n",
    "        \"num_criteria\": n_criteria\n",
    "    })\n",
    "            \n",
    "LITERATURE_SCREENING_FC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "ea150416-221c-4862-b25e-4d59707e2088",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'function',\n",
       "  'function': {'name': 'PaperEvaluation',\n",
       "   'description': '',\n",
       "   'parameters': {'properties': {'evaluations': {'description': 'Evaluations for 4 criteria, must be of length 4',\n",
       "      'items': {'enum': ['YES', 'NO', 'UNCERTAIN'], 'type': 'string'},\n",
       "      'maxItems': 4,\n",
       "      'minItems': 4,\n",
       "      'type': 'array'},\n",
       "     'rationale': {'description': 'A rationale for each criteria evaluation',\n",
       "      'items': {'type': 'string'},\n",
       "      'maxItems': 4,\n",
       "      'minItems': 4,\n",
       "      'type': 'array'}},\n",
       "    'required': ['evaluations', 'rationale'],\n",
       "    'type': 'object'}}}]"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "c1677a10-4eb7-4811-89db-e49e4f46aa4a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ChatCompletionMessage(content='```json\\n{\\n  \"evaluations\": [\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\",\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\"\\n  ],\\n  \"rationale\": [\\n    \"The title mentions \\'metastatic colorectal cancer\\'\",\\n    \"The title mentions \\'Crizotinib\\'\",\\n    \"There is no comparison mentioned in the title\",\\n    \"Methods and results sections are briefly described but not detailed enough to confirm clarity\",\\n    \"The text indicates adenocarcinoma as the type of colorectal cancer\",\\n    \"No explicit statement about outcome duration is made\"\\n  ]\\n}\\n```  \\n\\n### Explanation of Decisions:\\n1. **Does the title mention \\'colorectal cancer\\'?**  \\n   *YES* — The title states “metastatic colorectal cancer.”\\n   \\n2. **Does the title mention \\'crizotinib\\'?**  \\n   *YES* — The term “Crizotinib” appears in the title.\\n\\n3. **Is there any indication in the title that the study compares crizotinib to another treatment?**  \\n   *UNCERTAIN* — There’s no direct comparison indicated in the title.\\n\\n4. **Are the methods section and results clearly described in the paper?**  \\n   *YES* — Methods and results are mentioned, though details are sparse.\\n\\n5. **Does the study specify the type of colorectal cancer (e.g., adenocarcinoma)?**  \\n   *YES* — The text specifies it as adenocarcinoma.\\n\\n6. **Were the outcomes measured over a sufficient duration to assess long-term effects?**  \\n   *UNCERTAIN* — No clear evidence of long-term follow-up is stated.', refusal=None, role='assistant', annotations=None, audio=None, function_call=None, tool_calls=None)"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "messages = _batch_inputs_to_messages(prompt_template=LITERATURE_SCREENING_FC, batch_inputs=batch_inputs)\n",
    "\n",
    "from openai import AsyncOpenAI\n",
    "tools = [{'type': 'function', 'function': {'name': 'PaperEvaluation', 'description': '', 'parameters': {'properties': {'evaluations': {'description': 'Evaluations for 4 criteria, must be of length 4', 'items': {'enum': ['YES', 'NO', 'UNCERTAIN'], 'type': 'string'}, 'maxItems': 4, 'minItems': 4, 'type': 'array'}, 'rationale': {'description': 'A rationale for each criteria evaluation', 'items': {'type': 'string'}, 'maxItems': 4, 'minItems': 4, 'type': 'array'}}, 'required': ['evaluations', 'rationale'], 'type': 'object'}}}]\n",
    "\n",
    "async_openai_client = AsyncOpenAI(\n",
    "        base_url=os.getenv(\"BASE_URL\"),\n",
    "        api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "        http_client=httpx.AsyncClient(verify=False)\n",
    "    )\n",
    "response = await async_openai_client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=messages[0],\n",
    "    tools=tools,\n",
    "    temperature=0\n",
    ")\n",
    "response.choices[0].message"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "6ecfac9c-3958-4c86-af6a-c7da0038f0dc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'```json\\n{\\n  \"evaluations\": [\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\",\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\"\\n  ],\\n  \"rationale\": [\\n    \"The title mentions \\'metastatic colorectal cancer\\'\",\\n    \"The title mentions \\'Crizotinib\\'\",\\n    \"There is no comparison mentioned in the title\",\\n    \"Methods and results sections are briefly described but not detailed enough to confirm clarity\",\\n    \"The text indicates adenocarcinoma as the type of colorectal cancer\",\\n    \"No explicit statement about outcome duration is made\"\\n  ]\\n}\\n```  \\n\\n### Explanation of Decisions:\\n1. **Does the title mention \\'colorectal cancer\\'?**  \\n   *YES* — The title states “metastatic colorectal cancer.”\\n   \\n2. **Does the title mention \\'crizotinib\\'?**  \\n   *YES* — The term “Crizotinib” appears in the title.\\n\\n3. **Is there any indication in the title that the study compares crizotinib to another treatment?**  \\n   *UNCERTAIN* — There’s no direct comparison indicated in the title.\\n\\n4. **Are the methods section and results clearly described in the paper?**  \\n   *YES* — Methods and results are mentioned, though details are sparse.\\n\\n5. **Does the study specify the type of colorectal cancer (e.g., adenocarcinoma)?**  \\n   *YES* — The text specifies it as adenocarcinoma.\\n\\n6. **Were the outcomes measured over a sufficient duration to assess long-term effects?**  \\n   *UNCERTAIN* — No clear evidence of long-term follow-up is stated.'"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "fa1b377c-97de-4216-95ef-57150b672ea3",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.api import extract_json,parse_json_outputs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "f2c7b653-2bb6-4946-b79d-791ee3f4a1aa",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The title mentions 'metastatic colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'There is no comparison mentioned in the title',\n",
       "   'Methods and results sections are briefly described but not detailed enough to confirm clarity',\n",
       "   'The text indicates adenocarcinoma as the type of colorectal cancer',\n",
       "   'No explicit statement about outcome duration is made']}]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parse_json_outputs([response.choices[0].message.content])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0ef11792-9bc6-419a-9964-1c57f19ee864",
   "metadata": {},
   "source": [
    "### 5. paper screen\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "id": "6e510df2-8174-4105-bcaa-00767e4560ba",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'metastatic colorectal cancer\\', which implies colorectal cancer.\",\\n        \"The term \\'Crizotinib\\' is explicitly mentioned in the title and abstract.\",\\n        \"There is no detailed description of treatment outcomes; only brief mention of treatment.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'ascending colon adenocarcinoma\\', which is part of colorectal cancer.\",\\n        \"The term \\'Crizotinib\\' is explicitly mentioned in the title and throughout the abstract and body of the paper.\",\\n        \"The paper describes treatment outcomes including partial response to Crizotinib, regorafenib, and PD-1 inhibitor.\"\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'advanced solid cancers\\', but explicitly states \\'Patients with Colorectal cancer undergoing treatment with Crizotinib\\'\",\\n        \"The intervention described is \\'Crizotinib\\'\",\\n        \"The paper reports \\'best clinical response was stable disease in seven patients (29%)\\', which describes treatment results\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'Colorectal cancer\\' in the context of ROS1 mutations.\",\\n        \"The paper explicitly states that Crizotinib is used for treating ROS1-positive NSCLC, implying its use in colorectal cancer.\",\\n        \"The paper provides an overview of patents related to ROS1 inhibitors but does not describe detailed treatment outcomes.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'Colorectal cancer\\' multiple times.\",\\n        \"The intervention mentioned is \\'Crizotinib\\'.\",\\n        \"The paper describes various outcomes including survival rates, immune infiltration, and sensitivity to different medications.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'Colorectal cancer\\' several times.\",\\n        \"The term \\'Crizotinib\\' appears throughout the abstract and discussion sections.\",\\n        \"There is no explicit mention of treatment outcomes or results.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'globally, colorectal cancer (CRC)...\\'\",\\n        \"The intervention mentioned is \\'Crizotinib\\', which matches the specified drug.\",\\n        \"The paper discusses treatment benefits and therapeutic implications related to Crizotinib.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The paper does not specifically mention colorectal cancer\",\\n        \"The paper mentions Crizotinib as an intervention\",\\n        \"The paper describes treatment outcomes but does not specify if they pertain exclusively to colorectal cancer\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'Colorectal cancer\\'.\",\\n        \"The intervention described is Crizotinib.\",\\n        \"The paper describes treatment outcomes including tumor targeting, imaging capabilities, and synergistic chemophototherapy effects.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'Colorectal cancer\\' multiple times.\",\\n        \"The intervention mentioned is \\'Crizotinib\\'.\",\\n        \"The study describes various treatment outcomes including overall survival and progression-free survival.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'colorectal cancer\\'.\",\\n        \"The term \\'Crizotinib\\' appears multiple times throughout the paper.\",\\n        \"The study describes treatment outcomes, including effects on cell growth and ferroptosis.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'Colorectal cancer\\'\",\\n        \"The term \\'Crizotinib\\' appears multiple times throughout the study\",\\n        \"The paper describes treatment outcomes including response to crizotinib\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'Colorectal cancer\\' multiple times.\",\\n        \"The term \\'Crizotinib\\' appears several times throughout the paper.\",\\n        \"While the paper discusses treatments for various cancers including colorectal cancer, it does not provide detailed treatment results.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'Colorectal cancer\\' several times.\",\\n        \"The intervention described is Crizotinib.\",\\n        \"The paper includes details about treatment outcomes and best clinical responses.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'colorectal cancer\\'\",\\n        \"The term \\'Crizotinib\\' appears multiple times throughout the study\",\\n        \"The paper describes experimental outcomes involving treatment effects\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The paper mentions \\'colorectal cancer\\' in the context of ALK inhibitors.\",\\n        \"The paper explicitly states that Crizotinib is used in the treatment of ALK-dependent NSCLC, implying it can also be applied to other types of cancer including colorectal cancer.\",\\n        \"While the paper discusses the structural aspects of ALK inhibitors and their potential applications, it does not provide detailed treatment results.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\"Content mentions \\'colorectal cancer\\'\", \"Content mentions \\'Crizotinib\\'\", \"Content describes treatment outcomes\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'Colorectal cancer\\'.\",\\n        \"The intervention discussed in the paper is Crizotinib.\",\\n        \"The paper describes treatment outcomes including mortality rates and drug resistance.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\\n        \"NO\",\\n        \"YES\",\\n        \"UNCERTAIN\"\\n    ],\\n    \"rationale\": [\\n        \"The paper discusses hepatocellular carcinoma (HCC), not colorectal cancer.\",\\n        \"The paper mentions Crizotinib as a treatment used in the case study.\",\\n        \"The paper describes genetic changes and their impact on treatment outcome but does not provide detailed treatment results.\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The paper explicitly mentions \\'Colorectal cancer\\' several times.\",\\n        \"The intervention described in the paper is Crizotinib.\",\\n        \"The paper describes experimental outcomes related to treatment effects.\"\\n    ]\\n}']\n",
      "\n",
      "OUTPUTS:  [{'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'metastatic colorectal cancer', which implies colorectal cancer.\", \"The term 'Crizotinib' is explicitly mentioned in the title and abstract.\", 'There is no detailed description of treatment outcomes; only brief mention of treatment.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'ascending colon adenocarcinoma', which is part of colorectal cancer.\", \"The term 'Crizotinib' is explicitly mentioned in the title and throughout the abstract and body of the paper.\", 'The paper describes treatment outcomes including partial response to Crizotinib, regorafenib, and PD-1 inhibitor.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'advanced solid cancers', but explicitly states 'Patients with Colorectal cancer undergoing treatment with Crizotinib'\", \"The intervention described is 'Crizotinib'\", \"The paper reports 'best clinical response was stable disease in seven patients (29%)', which describes treatment results\"]}, {'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'Colorectal cancer' in the context of ROS1 mutations.\", 'The paper explicitly states that Crizotinib is used for treating ROS1-positive NSCLC, implying its use in colorectal cancer.', 'The paper provides an overview of patents related to ROS1 inhibitors but does not describe detailed treatment outcomes.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'Colorectal cancer' multiple times.\", \"The intervention mentioned is 'Crizotinib'.\", 'The paper describes various outcomes including survival rates, immune infiltration, and sensitivity to different medications.']}, {'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'Colorectal cancer' several times.\", \"The term 'Crizotinib' appears throughout the abstract and discussion sections.\", 'There is no explicit mention of treatment outcomes or results.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'globally, colorectal cancer (CRC)...'\", \"The intervention mentioned is 'Crizotinib', which matches the specified drug.\", 'The paper discusses treatment benefits and therapeutic implications related to Crizotinib.']}, {'evaluations': ['NO', 'YES', 'UNCERTAIN'], 'rationale': ['The paper does not specifically mention colorectal cancer', 'The paper mentions Crizotinib as an intervention', 'The paper describes treatment outcomes but does not specify if they pertain exclusively to colorectal cancer']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'Colorectal cancer'.\", 'The intervention described is Crizotinib.', 'The paper describes treatment outcomes including tumor targeting, imaging capabilities, and synergistic chemophototherapy effects.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'Colorectal cancer' multiple times.\", \"The intervention mentioned is 'Crizotinib'.\", 'The study describes various treatment outcomes including overall survival and progression-free survival.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'colorectal cancer'.\", \"The term 'Crizotinib' appears multiple times throughout the paper.\", 'The study describes treatment outcomes, including effects on cell growth and ferroptosis.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'Colorectal cancer'\", \"The term 'Crizotinib' appears multiple times throughout the study\", 'The paper describes treatment outcomes including response to crizotinib']}, {'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'Colorectal cancer' multiple times.\", \"The term 'Crizotinib' appears several times throughout the paper.\", 'While the paper discusses treatments for various cancers including colorectal cancer, it does not provide detailed treatment results.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'Colorectal cancer' several times.\", 'The intervention described is Crizotinib.', 'The paper includes details about treatment outcomes and best clinical responses.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'colorectal cancer'\", \"The term 'Crizotinib' appears multiple times throughout the study\", 'The paper describes experimental outcomes involving treatment effects']}, {'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'colorectal cancer' in the context of ALK inhibitors.\", 'The paper explicitly states that Crizotinib is used in the treatment of ALK-dependent NSCLC, implying it can also be applied to other types of cancer including colorectal cancer.', 'While the paper discusses the structural aspects of ALK inhibitors and their potential applications, it does not provide detailed treatment results.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"Content mentions 'colorectal cancer'\", \"Content mentions 'Crizotinib'\", 'Content describes treatment outcomes']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'Colorectal cancer'.\", 'The intervention discussed in the paper is Crizotinib.', 'The paper describes treatment outcomes including mortality rates and drug resistance.']}, {'evaluations': ['NO', 'YES', 'UNCERTAIN'], 'rationale': ['The paper discusses hepatocellular carcinoma (HCC), not colorectal cancer.', 'The paper mentions Crizotinib as a treatment used in the case study.', 'The paper describes genetic changes and their impact on treatment outcome but does not provide detailed treatment results.']}, {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper explicitly mentions 'Colorectal cancer' several times.\", 'The intervention described in the paper is Crizotinib.', 'The paper describes experimental outcomes related to treatment effects.']}]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'evaluations': ['YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The paper mentions 'metastatic colorectal cancer', which implies colorectal cancer.\",\n",
       "   \"The term 'Crizotinib' is explicitly mentioned in the title and abstract.\",\n",
       "   'There is no detailed description of treatment outcomes; only brief mention of treatment.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper mentions 'ascending colon adenocarcinoma', which is part of colorectal cancer.\",\n",
       "   \"The term 'Crizotinib' is explicitly mentioned in the title and throughout the abstract and body of the paper.\",\n",
       "   'The paper describes treatment outcomes including partial response to Crizotinib, regorafenib, and PD-1 inhibitor.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper mentions 'advanced solid cancers', but explicitly states 'Patients with Colorectal cancer undergoing treatment with Crizotinib'\",\n",
       "   \"The intervention described is 'Crizotinib'\",\n",
       "   \"The paper reports 'best clinical response was stable disease in seven patients (29%)', which describes treatment results\"]},\n",
       " {'evaluations': ['YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The paper mentions 'Colorectal cancer' in the context of ROS1 mutations.\",\n",
       "   'The paper explicitly states that Crizotinib is used for treating ROS1-positive NSCLC, implying its use in colorectal cancer.',\n",
       "   'The paper provides an overview of patents related to ROS1 inhibitors but does not describe detailed treatment outcomes.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper mentions 'Colorectal cancer' multiple times.\",\n",
       "   \"The intervention mentioned is 'Crizotinib'.\",\n",
       "   'The paper describes various outcomes including survival rates, immune infiltration, and sensitivity to different medications.']},\n",
       " {'evaluations': ['YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The paper mentions 'Colorectal cancer' several times.\",\n",
       "   \"The term 'Crizotinib' appears throughout the abstract and discussion sections.\",\n",
       "   'There is no explicit mention of treatment outcomes or results.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'globally, colorectal cancer (CRC)...'\",\n",
       "   \"The intervention mentioned is 'Crizotinib', which matches the specified drug.\",\n",
       "   'The paper discusses treatment benefits and therapeutic implications related to Crizotinib.']},\n",
       " {'evaluations': ['NO', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': ['The paper does not specifically mention colorectal cancer',\n",
       "   'The paper mentions Crizotinib as an intervention',\n",
       "   'The paper describes treatment outcomes but does not specify if they pertain exclusively to colorectal cancer']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'Colorectal cancer'.\",\n",
       "   'The intervention described is Crizotinib.',\n",
       "   'The paper describes treatment outcomes including tumor targeting, imaging capabilities, and synergistic chemophototherapy effects.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper mentions 'Colorectal cancer' multiple times.\",\n",
       "   \"The intervention mentioned is 'Crizotinib'.\",\n",
       "   'The study describes various treatment outcomes including overall survival and progression-free survival.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'colorectal cancer'.\",\n",
       "   \"The term 'Crizotinib' appears multiple times throughout the paper.\",\n",
       "   'The study describes treatment outcomes, including effects on cell growth and ferroptosis.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'Colorectal cancer'\",\n",
       "   \"The term 'Crizotinib' appears multiple times throughout the study\",\n",
       "   'The paper describes treatment outcomes including response to crizotinib']},\n",
       " {'evaluations': ['YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The paper mentions 'Colorectal cancer' multiple times.\",\n",
       "   \"The term 'Crizotinib' appears several times throughout the paper.\",\n",
       "   'While the paper discusses treatments for various cancers including colorectal cancer, it does not provide detailed treatment results.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper mentions 'Colorectal cancer' several times.\",\n",
       "   'The intervention described is Crizotinib.',\n",
       "   'The paper includes details about treatment outcomes and best clinical responses.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'colorectal cancer'\",\n",
       "   \"The term 'Crizotinib' appears multiple times throughout the study\",\n",
       "   'The paper describes experimental outcomes involving treatment effects']},\n",
       " {'evaluations': ['YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The paper mentions 'colorectal cancer' in the context of ALK inhibitors.\",\n",
       "   'The paper explicitly states that Crizotinib is used in the treatment of ALK-dependent NSCLC, implying it can also be applied to other types of cancer including colorectal cancer.',\n",
       "   'While the paper discusses the structural aspects of ALK inhibitors and their potential applications, it does not provide detailed treatment results.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"Content mentions 'colorectal cancer'\",\n",
       "   \"Content mentions 'Crizotinib'\",\n",
       "   'Content describes treatment outcomes']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'Colorectal cancer'.\",\n",
       "   'The intervention discussed in the paper is Crizotinib.',\n",
       "   'The paper describes treatment outcomes including mortality rates and drug resistance.']},\n",
       " {'evaluations': ['NO', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': ['The paper discusses hepatocellular carcinoma (HCC), not colorectal cancer.',\n",
       "   'The paper mentions Crizotinib as a treatment used in the case study.',\n",
       "   'The paper describes genetic changes and their impact on treatment outcome but does not provide detailed treatment results.']},\n",
       " {'evaluations': ['YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The paper explicitly mentions 'Colorectal cancer' several times.\",\n",
       "   'The intervention described in the paper is Crizotinib.',\n",
       "   'The paper describes experimental outcomes related to treatment effects.']}]"
      ]
     },
     "execution_count": 109,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = LiteratureScreening()\n",
    "ec_predP = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    criteria = [\"Does the content mention 'colorectal cancer'?\",\n",
    "                 \"Does content mention 'Crizotinib'?\", \n",
    "                'Is there a description of treatement results?'],#title_criteria + content_criteria,\n",
    "    papers = papers, # make for the top-100 for demo\n",
    ")\n",
    "ec_predP"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "id": "0e785c6e-737b-4f76-9cdf-d8dce4edf47a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[ 1  1  0]\n",
      " [ 1  1  1]\n",
      " [ 1  1  1]\n",
      " [ 1  1  0]\n",
      " [ 1  1  1]\n",
      " [ 1  1  0]\n",
      " [ 1  1  1]\n",
      " [-1  1  0]\n",
      " [ 1  1  1]\n",
      " [ 1  1  1]\n",
      " [ 1  1  1]\n",
      " [ 1  1  1]\n",
      " [ 1  1  0]\n",
      " [ 1  1  1]\n",
      " [ 1  1  1]\n",
      " [ 1  1  0]\n",
      " [ 1  1  1]\n",
      " [ 1  1  1]\n",
      " [-1  1  0]\n",
      " [ 1  1  1]]\n",
      "[2 3 3 2 3 2 3 0 3 3 3 3 2 3 3 2 3 3 0 3]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>FullText</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_extr</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "      <td>2</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'UNCERTA...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "      <td>3</td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'UNCERTA...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "      <td>3</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>35343863</td>\n",
       "      <td>Expert opinion on therapeutic patents</td>\n",
       "      <td>2022</td>\n",
       "      <td>Jun</td>\n",
       "      <td></td>\n",
       "      <td>An updated patent review of small-molecule ROS...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...</td>\n",
       "      <td>C-ros oncogene 1 (ROS1) is the sole member of ...</td>\n",
       "      <td>2</td>\n",
       "      <td>An updated patent review of small-molecule ROS...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'U...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "      <td>3</td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>36129915</td>\n",
       "      <td>PloS one</td>\n",
       "      <td>2022</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Investigation of cell signalings and therapeut...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Jae Heon Jeong, Jae Won Yun, Ha Young Kim, Cha...</td>\n",
       "      <td>Colorectal cancer (CRC) is one of the most dea...</td>\n",
       "      <td>2</td>\n",
       "      <td>Investigation of cell signalings and therapeut...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>34898475</td>\n",
       "      <td>Aging</td>\n",
       "      <td>2021</td>\n",
       "      <td>Dec</td>\n",
       "      <td>13</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...</td>\n",
       "      <td>Globally, colorectal cancer (CRC) is one of th...</td>\n",
       "      <td>3</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>36801912</td>\n",
       "      <td>NPJ precision oncology</td>\n",
       "      <td>2023</td>\n",
       "      <td>Feb</td>\n",
       "      <td>18</td>\n",
       "      <td>BRAF v600E-mutant cancers treated with vemuraf...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Blessie Elizabeth Nelson, Jason Roszik, Filip ...</td>\n",
       "      <td>Combined BRAF + MEK inhibition is FDA approved...</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>{'evaluations': ['NO', 'YES', 'UNCERTAIN', 'NO...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>37418240</td>\n",
       "      <td>ACS applied materials &amp; interfaces</td>\n",
       "      <td>2023</td>\n",
       "      <td>Jul</td>\n",
       "      <td>19</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen</td>\n",
       "      <td>Colorectal cancer (CRC) is presently the third...</td>\n",
       "      <td>3</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>36316649</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Oct</td>\n",
       "      <td>31</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Maxim Sorokin, Marianna Zolotovskaia, Daniil N...</td>\n",
       "      <td>Overall survival of advanced colorectal cancer...</td>\n",
       "      <td>3</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "      <td>3</td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>36053834</td>\n",
       "      <td>International journal of cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Dec</td>\n",
       "      <td>15</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Dilara Akhoundova, Saskia Hussung, Smruthy Siv...</td>\n",
       "      <td>c-Ros oncogene 1, receptor tyrosine kinase (RO...</td>\n",
       "      <td>3</td>\n",
       "      <td>ROS1  genomic rearrangements are rare action...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>37686423</td>\n",
       "      <td>International journal of molecular sciences</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>03</td>\n",
       "      <td>Targeted Therapy for Cancers: From Ongoing Cli...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Ha Yeong Choi, Ji-Eun Chang</td>\n",
       "      <td>The development of targeted therapies has revo...</td>\n",
       "      <td>2</td>\n",
       "      <td>Targeted Therapy for Cancers: From Ongoing Cli...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'U...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "      <td>3</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>38212428</td>\n",
       "      <td>Cellular and molecular life sciences : CMLS</td>\n",
       "      <td>2024</td>\n",
       "      <td>Jan</td>\n",
       "      <td>12</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Vivian Truong Jones, Ramona Graves-Deal, Zheng...</td>\n",
       "      <td>Although amplifications and mutations in recep...</td>\n",
       "      <td>3</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>36627781</td>\n",
       "      <td>Anti-cancer agents in medicinal chemistry</td>\n",
       "      <td>2023</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Recent Updates on Structural Aspects of ALK In...</td>\n",
       "      <td>Review, Journal Article</td>\n",
       "      <td>Md Shahid Ayaz, Ritu Bhupal, Priyanka Sharma, ...</td>\n",
       "      <td>Presently, several protein kinases have been d...</td>\n",
       "      <td>2</td>\n",
       "      <td>Recent Updates on Structural Aspects of ALK In...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'U...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>37773318</td>\n",
       "      <td>NPJ precision oncology</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>29</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Aditya Shreenivas, Filip Janku, Mohamed A Goud...</td>\n",
       "      <td>Anaplastic lymphoma kinase (ALK) alterations (...</td>\n",
       "      <td>3</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'UN...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>38378070</td>\n",
       "      <td>Experimental and molecular pathology</td>\n",
       "      <td>2024</td>\n",
       "      <td>Apr</td>\n",
       "      <td></td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Melika Golozar, Ali Valipour Motlagh, Mohammad...</td>\n",
       "      <td>Alterations in the expression of certain genes...</td>\n",
       "      <td>3</td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'YES', 'YES'], '...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>41268440</td>\n",
       "      <td>Frontiers in pharmacology</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Case Report: HGF and NF1 mutations as putative...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li</td>\n",
       "      <td>Hepatocellular carcinoma (HCC) is a highly agg...</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>{'evaluations': ['NO', 'YES', 'UNCERTAIN', 'NO...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>37543570</td>\n",
       "      <td>Journal of translational medicine</td>\n",
       "      <td>2023</td>\n",
       "      <td>Aug</td>\n",
       "      <td>05</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) is k...</td>\n",
       "      <td>3</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES', 'YES'], ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        PMID                                            Journal  Year Month  \\\n",
       "0   40526090                                         Oncotarget  2025   Jun   \n",
       "1   38711893                                   AME case reports  2024         \n",
       "2   40140597                                        BJC reports  2025   Mar   \n",
       "3   35343863              Expert opinion on therapeutic patents  2022   Jun   \n",
       "4   41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "5   36129915                                           PloS one  2022         \n",
       "6   34898475                                              Aging  2021   Dec   \n",
       "7   36801912                             NPJ precision oncology  2023   Feb   \n",
       "8   37418240                 ACS applied materials & interfaces  2023   Jul   \n",
       "9   36316649                                         BMC cancer  2022   Oct   \n",
       "10  40369167                     Cell death and differentiation  2025   Nov   \n",
       "11  36053834                    International journal of cancer  2022   Dec   \n",
       "12  37686423        International journal of molecular sciences  2023   Sep   \n",
       "13  40211189                                         BMC cancer  2025   Apr   \n",
       "14  38212428        Cellular and molecular life sciences : CMLS  2024   Jan   \n",
       "15  36627781          Anti-cancer agents in medicinal chemistry  2023         \n",
       "16  37773318                             NPJ precision oncology  2023   Sep   \n",
       "17  38378070               Experimental and molecular pathology  2024   Apr   \n",
       "18  41268440                          Frontiers in pharmacology  2025         \n",
       "19  37543570                  Journal of translational medicine  2023   Aug   \n",
       "\n",
       "   Day                                              Title  \\\n",
       "0   17  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "1       Partial response to crizotinib + regorafenib +...   \n",
       "2   26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "3       An updated patent review of small-molecule ROS...   \n",
       "4       Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "5       Investigation of cell signalings and therapeut...   \n",
       "6   13  Identification of a novel immune signature for...   \n",
       "7   18  BRAF v600E-mutant cancers treated with vemuraf...   \n",
       "8   19  Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   31  Personalized targeted therapy prescription in ...   \n",
       "10      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11  15  ROS1 genomic rearrangements are rare actionabl...   \n",
       "12  03  Targeted Therapy for Cancers: From Ongoing Cli...   \n",
       "13  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  12  Inhibition of autocrine HGF maturation overcom...   \n",
       "15      Recent Updates on Structural Aspects of ALK In...   \n",
       "16  29  ALK fusions in the pan-cancer setting: another...   \n",
       "17      TBX15 and SDHB expression changes in colorecta...   \n",
       "18      Case Report: HGF and NF1 mutations as putative...   \n",
       "19  05  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                     Publication Type  \\\n",
       "0                       Journal Article, Case Reports   \n",
       "1                       Case Reports, Journal Article   \n",
       "2                                     Journal Article   \n",
       "3                             Journal Article, Review   \n",
       "4                                     Journal Article   \n",
       "5   Journal Article, Research Support, Non-U.S. Gov't   \n",
       "6   Journal Article, Research Support, Non-U.S. Gov't   \n",
       "7                                     Journal Article   \n",
       "8                                     Journal Article   \n",
       "9                                     Journal Article   \n",
       "10                                    Journal Article   \n",
       "11                                    Journal Article   \n",
       "12                            Journal Article, Review   \n",
       "13           Journal Article, Clinical Trial, Phase I   \n",
       "14                                    Journal Article   \n",
       "15                            Review, Journal Article   \n",
       "16                            Journal Article, Review   \n",
       "17                                    Journal Article   \n",
       "18                      Case Reports, Journal Article   \n",
       "19  Journal Article, Research Support, Non-U.S. Gov't   \n",
       "\n",
       "                                              Authors  \\\n",
       "0   Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "1   Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "2   Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "3   Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...   \n",
       "4                    Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "5   Jae Heon Jeong, Jae Won Yun, Ha Young Kim, Cha...   \n",
       "6   Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...   \n",
       "7   Blessie Elizabeth Nelson, Jason Roszik, Filip ...   \n",
       "8        Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen   \n",
       "9   Maxim Sorokin, Marianna Zolotovskaia, Daniil N...   \n",
       "10  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "11  Dilara Akhoundova, Saskia Hussung, Smruthy Siv...   \n",
       "12                        Ha Yeong Choi, Ji-Eun Chang   \n",
       "13  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "14  Vivian Truong Jones, Ramona Graves-Deal, Zheng...   \n",
       "15  Md Shahid Ayaz, Ritu Bhupal, Priyanka Sharma, ...   \n",
       "16  Aditya Shreenivas, Filip Janku, Mohamed A Goud...   \n",
       "17  Melika Golozar, Ali Valipour Motlagh, Mohammad...   \n",
       "18       Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li   \n",
       "19  Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...   \n",
       "\n",
       "                                             Abstract  screen_eval  \\\n",
       "0   Heavily pretreated metastatic colorectal cance...            2   \n",
       "1   Colorectal cancer (CRC) with the Raf murine sa...            3   \n",
       "2   Single-agent MEK1/2 inhibition has been disapp...            3   \n",
       "3   C-ros oncogene 1 (ROS1) is the sole member of ...            2   \n",
       "4   Numerous genes have been associated with color...            3   \n",
       "5   Colorectal cancer (CRC) is one of the most dea...            2   \n",
       "6   Globally, colorectal cancer (CRC) is one of th...            3   \n",
       "7   Combined BRAF + MEK inhibition is FDA approved...            0   \n",
       "8   Colorectal cancer (CRC) is presently the third...            3   \n",
       "9   Overall survival of advanced colorectal cancer...            3   \n",
       "10  ARID1A, a subunit of the SWI/SNF chromatin-rem...            3   \n",
       "11  c-Ros oncogene 1, receptor tyrosine kinase (RO...            3   \n",
       "12  The development of targeted therapies has revo...            2   \n",
       "13  Targeting RAS mutant (MT) colorectal cancer (C...            3   \n",
       "14  Although amplifications and mutations in recep...            3   \n",
       "15  Presently, several protein kinases have been d...            2   \n",
       "16  Anaplastic lymphoma kinase (ALK) alterations (...            3   \n",
       "17  Alterations in the expression of certain genes...            3   \n",
       "18  Hepatocellular carcinoma (HCC) is a highly agg...            0   \n",
       "19  Epithelial cell adhesion molecule (EpCAM) is k...            3   \n",
       "\n",
       "                                             FullText  \\\n",
       "0   Case Report WIN-MTB-2023001 WIN International ...   \n",
       "1   Partial response to crizotinib + regorafenib +...   \n",
       "2   A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "3   An updated patent review of small-molecule ROS...   \n",
       "4   Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "5   Investigation of cell signalings and therapeut...   \n",
       "6   Identification of a novel immune signature for...   \n",
       "7                                                       \n",
       "8   Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   Personalized targeted therapy prescription in ...   \n",
       "10  ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11    ROS1  genomic rearrangements are rare action...   \n",
       "12  Targeted Therapy for Cancers: From Ongoing Cli...   \n",
       "13  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  Inhibition of autocrine HGF maturation overcom...   \n",
       "15  Recent Updates on Structural Aspects of ALK In...   \n",
       "16  ALK fusions in the pan-cancer setting: another...   \n",
       "17  TBX15 and SDHB expression changes in colorecta...   \n",
       "18                                                      \n",
       "19  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                            screening res_extr  \n",
       "0   {'evaluations': ['YES', 'YES', 'YES', 'UNCERTA...           \n",
       "1   {'evaluations': ['YES', 'YES', 'YES', 'UNCERTA...           \n",
       "2   {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "3   {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'U...           \n",
       "4   {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "5   {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...           \n",
       "6   {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "7   {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'NO...           \n",
       "8   {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...           \n",
       "9   {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "10  {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "11  {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "12  {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'U...           \n",
       "13  {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "14  {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           \n",
       "15  {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'U...           \n",
       "16  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'UN...           \n",
       "17  {'evaluations': ['YES', 'NO', 'YES', 'YES'], '...           \n",
       "18  {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'NO...           \n",
       "19  {'evaluations': ['YES', 'YES', 'YES', 'YES'], ...           "
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evalsP = [i['evaluations'] for i in ec_predP]\n",
    "\n",
    "word2int = {\"YES\": 1, \n",
    "            \"UNCERTAIN\": 0,\n",
    "            \"NO\": -1\n",
    "           }\n",
    "#rev_subs = { v:k for k, v in word2int.items()} # subs.iteritems() In Python 3\n",
    "new_evalsP = []\n",
    "for one_e in evalsP:\n",
    "    new_evalsP.append([word2int.get(item, 0) for item in one_e ])\n",
    "new_evalsP = np.array(new_evalsP)    \n",
    "print(new_evalsP)\n",
    "print(new_evalsP.sum(axis=1))\n",
    "df_papers[0]['screen_eval'] = new_evalsP.sum(axis=1)\n",
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f4442059-f9e6-4373-a9f5-a1c9a9932a7d",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e81ab35b-b66b-4258-8ebe-f79096db523c",
   "metadata": {},
   "source": [
    "### 6. papers results extraction\n",
    "Только для статей с оценкой выше 0 !! Чтобы не загружать полный текст у всех\n",
    "\n",
    "+ надо посмотреть: если фул текст недоступен, то загружается ли абстракт"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "b3738666-8a12-4232-b862-8c549e71c452",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "18"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(pmid_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 244,
   "id": "e85af2f5-3e66-4cef-92f7-1e41e0189a19",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(13, 13)"
      ]
     },
     "execution_count": 244,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0][df_papers[0].screen_eval>=3].shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 262,
   "id": "be05918b-367f-416e-a00d-dbf331c1ff2e",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "total_ev = 3\n",
    "pmid_list = df_papers[0][df_papers[0].screen_eval>=total_ev].PMID.values.tolist()\n",
    "#['41213063',#'26451310',]\n",
    "\n",
    "res = pmid2biocxml(pmid_list, api_key=pubmed_api_key)\n",
    "#print(res)\n",
    "res = [parse_bioc_xml(r) for r in res]\n",
    "# transform the parsed xml into paper content\n",
    "papers0 = []\n",
    "for parsed in res:\n",
    "    paper_content = []\n",
    "    for parsed_ in parsed[\"passage\"]:\n",
    "        paper_content.append(parsed_['content'])\n",
    "    paper_content = \"\\n\".join(paper_content)\n",
    "    papers0.append(paper_content)\n",
    "\n",
    "df_papers[0]['FullText'] = ''\n",
    "df_papers[0].loc[df_papers[0].screen_eval>=total_ev, 'FullText'] = papers0\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 455,
   "id": "b8563f3d-8b32-47c9-b10e-f1f4a07fb812",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>FullText</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_extr</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "      <td>3</td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "      <td>3</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "      <td>3</td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>34898475</td>\n",
       "      <td>Aging</td>\n",
       "      <td>2021</td>\n",
       "      <td>Dec</td>\n",
       "      <td>13</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...</td>\n",
       "      <td>Globally, colorectal cancer (CRC) is one of th...</td>\n",
       "      <td>3</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>37418240</td>\n",
       "      <td>ACS applied materials &amp; interfaces</td>\n",
       "      <td>2023</td>\n",
       "      <td>Jul</td>\n",
       "      <td>19</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen</td>\n",
       "      <td>Colorectal cancer (CRC) is presently the third...</td>\n",
       "      <td>3</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>36316649</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Oct</td>\n",
       "      <td>31</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Maxim Sorokin, Marianna Zolotovskaia, Daniil N...</td>\n",
       "      <td>Overall survival of advanced colorectal cancer...</td>\n",
       "      <td>3</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "      <td>3</td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>36053834</td>\n",
       "      <td>International journal of cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Dec</td>\n",
       "      <td>15</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Dilara Akhoundova, Saskia Hussung, Smruthy Siv...</td>\n",
       "      <td>c-Ros oncogene 1, receptor tyrosine kinase (RO...</td>\n",
       "      <td>3</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "      <td>3</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>38212428</td>\n",
       "      <td>Cellular and molecular life sciences : CMLS</td>\n",
       "      <td>2024</td>\n",
       "      <td>Jan</td>\n",
       "      <td>12</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Vivian Truong Jones, Ramona Graves-Deal, Zheng...</td>\n",
       "      <td>Although amplifications and mutations in recep...</td>\n",
       "      <td>3</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>37773318</td>\n",
       "      <td>NPJ precision oncology</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>29</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Aditya Shreenivas, Filip Janku, Mohamed A Goud...</td>\n",
       "      <td>Anaplastic lymphoma kinase (ALK) alterations (...</td>\n",
       "      <td>3</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>38378070</td>\n",
       "      <td>Experimental and molecular pathology</td>\n",
       "      <td>2024</td>\n",
       "      <td>Apr</td>\n",
       "      <td></td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Melika Golozar, Ali Valipour Motlagh, Mohammad...</td>\n",
       "      <td>Alterations in the expression of certain genes...</td>\n",
       "      <td>3</td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>37543570</td>\n",
       "      <td>Journal of translational medicine</td>\n",
       "      <td>2023</td>\n",
       "      <td>Aug</td>\n",
       "      <td>05</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) is k...</td>\n",
       "      <td>3</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        PMID                                            Journal  Year Month  \\\n",
       "1   38711893                                   AME case reports  2024         \n",
       "2   40140597                                        BJC reports  2025   Mar   \n",
       "4   41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "6   34898475                                              Aging  2021   Dec   \n",
       "8   37418240                 ACS applied materials & interfaces  2023   Jul   \n",
       "9   36316649                                         BMC cancer  2022   Oct   \n",
       "10  40369167                     Cell death and differentiation  2025   Nov   \n",
       "11  36053834                    International journal of cancer  2022   Dec   \n",
       "13  40211189                                         BMC cancer  2025   Apr   \n",
       "14  38212428        Cellular and molecular life sciences : CMLS  2024   Jan   \n",
       "16  37773318                             NPJ precision oncology  2023   Sep   \n",
       "17  38378070               Experimental and molecular pathology  2024   Apr   \n",
       "19  37543570                  Journal of translational medicine  2023   Aug   \n",
       "\n",
       "   Day                                              Title  \\\n",
       "1       Partial response to crizotinib + regorafenib +...   \n",
       "2   26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "4       Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "6   13  Identification of a novel immune signature for...   \n",
       "8   19  Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   31  Personalized targeted therapy prescription in ...   \n",
       "10      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11  15  ROS1 genomic rearrangements are rare actionabl...   \n",
       "13  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  12  Inhibition of autocrine HGF maturation overcom...   \n",
       "16  29  ALK fusions in the pan-cancer setting: another...   \n",
       "17      TBX15 and SDHB expression changes in colorecta...   \n",
       "19  05  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                     Publication Type  \\\n",
       "1                       Case Reports, Journal Article   \n",
       "2                                     Journal Article   \n",
       "4                                     Journal Article   \n",
       "6   Journal Article, Research Support, Non-U.S. Gov't   \n",
       "8                                     Journal Article   \n",
       "9                                     Journal Article   \n",
       "10                                    Journal Article   \n",
       "11                                    Journal Article   \n",
       "13           Journal Article, Clinical Trial, Phase I   \n",
       "14                                    Journal Article   \n",
       "16                            Journal Article, Review   \n",
       "17                                    Journal Article   \n",
       "19  Journal Article, Research Support, Non-U.S. Gov't   \n",
       "\n",
       "                                              Authors  \\\n",
       "1   Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "2   Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "4                    Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "6   Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...   \n",
       "8        Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen   \n",
       "9   Maxim Sorokin, Marianna Zolotovskaia, Daniil N...   \n",
       "10  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "11  Dilara Akhoundova, Saskia Hussung, Smruthy Siv...   \n",
       "13  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "14  Vivian Truong Jones, Ramona Graves-Deal, Zheng...   \n",
       "16  Aditya Shreenivas, Filip Janku, Mohamed A Goud...   \n",
       "17  Melika Golozar, Ali Valipour Motlagh, Mohammad...   \n",
       "19  Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...   \n",
       "\n",
       "                                             Abstract  screen_eval  \\\n",
       "1   Colorectal cancer (CRC) with the Raf murine sa...            3   \n",
       "2   Single-agent MEK1/2 inhibition has been disapp...            3   \n",
       "4   Numerous genes have been associated with color...            3   \n",
       "6   Globally, colorectal cancer (CRC) is one of th...            3   \n",
       "8   Colorectal cancer (CRC) is presently the third...            3   \n",
       "9   Overall survival of advanced colorectal cancer...            3   \n",
       "10  ARID1A, a subunit of the SWI/SNF chromatin-rem...            3   \n",
       "11  c-Ros oncogene 1, receptor tyrosine kinase (RO...            3   \n",
       "13  Targeting RAS mutant (MT) colorectal cancer (C...            3   \n",
       "14  Although amplifications and mutations in recep...            3   \n",
       "16  Anaplastic lymphoma kinase (ALK) alterations (...            3   \n",
       "17  Alterations in the expression of certain genes...            3   \n",
       "19  Epithelial cell adhesion molecule (EpCAM) is k...            3   \n",
       "\n",
       "                                             FullText  \\\n",
       "1   Partial response to crizotinib + regorafenib +...   \n",
       "2   A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "4   Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "6   Identification of a novel immune signature for...   \n",
       "8   Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   Personalized targeted therapy prescription in ...   \n",
       "10  ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11  ROS1 genomic rearrangements are rare actionabl...   \n",
       "13  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  Inhibition of autocrine HGF maturation overcom...   \n",
       "16  ALK fusions in the pan-cancer setting: another...   \n",
       "17  TBX15 and SDHB expression changes in colorecta...   \n",
       "19  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                            screening res_extr  \n",
       "1   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "2   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "4   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "6   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "8   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "9   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "10  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "11  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "13  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "14  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "16  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "17  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "19  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           "
      ]
     },
     "execution_count": 455,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0][df_papers[0].screen_eval>=total_ev]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 448,
   "id": "75e80587-c2be-441b-950e-4ca7588277cd",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['38711893',\n",
       " '40140597',\n",
       " '41213063',\n",
       " '34898475',\n",
       " '37418240',\n",
       " '36316649',\n",
       " '40369167',\n",
       " '36053834',\n",
       " '40211189',\n",
       " '38212428',\n",
       " '37773318',\n",
       " '38378070',\n",
       " '37543570']"
      ]
     },
     "execution_count": 448,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pmid_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 447,
   "id": "bcb4ecee-26b5-4d16-9537-42ad5f79d45c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'passage': [{'pmid': '',\n",
       "   'pmc': '',\n",
       "   'section': '',\n",
       "   'content': 'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case report.'},\n",
       "  {'pmid': '',\n",
       "   'pmc': '',\n",
       "   'section': '',\n",
       "   'content': \"Background: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (BRAF) V600E had a relatively poor prognosis. Anaplastic lymphoma kinase (ALK) fusion and the mesenchymal-to-epithelial transition factor (MET) amplification have been recognized as potentially important therapeutic targets in non-small cell lung cancer (NSCLC). However, both of them are of extremely lower frequencies (<2%) in metastatic CRC, and few studies have mentioned the real application of their inhibitors in CRC treatment. Case Description: A 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a BRAF V600E mutation. He received an initial combination treatment with cetuximab, dabrafenib, and trametinib with a partial response (PR) assessment. We changed the therapy regimen on this patient several times because of the patient's intolerance to the drugs or the inefficacy of the treatment. During this period, we detected the c-MET amplification and tropomyosin 4 (TPM4)-ALK fusion by NGS after triplet targeted therapy (tislelizumab, dabrafenib, and trametinib), thus he was finally treated with programmed cell death protein 1 (PD-1) inhibitor (tislelizumab), MET/ALK inhibitor (crizotinib) plus multikinase inhibitor (regorafenib). Imageological examinations showed that PR was achieved and ctDNA sequencing results indicated a significantly reduced BRAF mutation frequency, MET amplification and TPM4-ALK fusion were undetectable. NGS analysis of peripheral blood showed a recurrence of the MET acquired resistant amplification mutation over 2 months of ongoing treatment. but the patient was assessed as PR and still under treatment of crizotinib, tislelizumab and regorafenib within good physical condition. At the last follow-up on October 2021, the patient died of symptomatic treatment fail for obstructive jaundice. The patient finally achieved 11 months overall survival. Conclusions: This study reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.\"}],\n",
       " 'ref': [],\n",
       " 'table': [],\n",
       " 'figure': [],\n",
       " 'author_contribution': [],\n",
       " 'competing_interest': [],\n",
       " 'supplementary_material': []}"
      ]
     },
     "execution_count": 447,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "res[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 277,
   "id": "ae94e5e7-b742-489d-b869-9a8aac33fbf1",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        0\n",
       "1     2665\n",
       "2     1612\n",
       "3        0\n",
       "4     1652\n",
       "5        0\n",
       "6     1792\n",
       "7        0\n",
       "8     1637\n",
       "9     1951\n",
       "10    1895\n",
       "11    1817\n",
       "12       0\n",
       "13    2627\n",
       "14    1402\n",
       "15       0\n",
       "16    1606\n",
       "17    2064\n",
       "18       0\n",
       "19    2078\n",
       "Name: FullText, dtype: int64"
      ]
     },
     "execution_count": 277,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0].FullText.str.len()#.sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 442,
   "id": "8f5f4dbc-880b-4ee2-a08b-47208b32bd8a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "PMID                                                         37418240\n",
       "Journal                            ACS applied materials & interfaces\n",
       "Year                                                             2023\n",
       "Month                                                             Jul\n",
       "Day                                                                19\n",
       "Title               Albumin-Based Cyanine Crizotinib Conjugate Nan...\n",
       "Publication Type                                      Journal Article\n",
       "Authors                  Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen\n",
       "Abstract            Colorectal cancer (CRC) is presently the third...\n",
       "screen_eval                                                         3\n",
       "FullText            Albumin-Based Cyanine Crizotinib Conjugate Nan...\n",
       "screening           {'evaluations': ['YES', 'YES', 'YES'], 'ration...\n",
       "res_extr                                                             \n",
       "Name: 8, dtype: object"
      ]
     },
     "execution_count": 442,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0][df_papers[0].screen_eval>=total_ev].loc[8]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 441,
   "id": "42df419b-c760-4344-bedd-3537945b4a11",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy.\\nColorectal cancer (CRC) is presently the third deadliest cancer in the world. This malignant cancer usually precedes the progression of precancerous lesions, and it is challenging to distinguish its nuanced morphological changes. Molecular-based near-infrared-II (NIR-II) fluorescence imaging can effectively recognize lesion targets to improve image contrast and increase early tumor detection compared with traditional wide-light screening endoscopy. c-Met has been determined to be overexpressed in advanced stages of CRC and is considered to be a potent tumor biomarker. Herein, based on the well-targeted inhibitory effect of Crizotinib on c-Met positive tumor cells, the dye IR808 was covalently combined with the drug molecule Crizotinib, resulting in the synthesis of a NIR fluorescent probe Crizotinib-IR808 targeting c-Met positive tumor cells. Then, water-insoluble Crizotinib-IR808 was fabricated by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.'"
      ]
     },
     "execution_count": 441,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers0[4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 443,
   "id": "d91fcf9c-674f-4925-8978-01e16fe26c1c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy.',\n",
       " 'Colorectal cancer (CRC) is presently the third deadliest cancer in the world. This malignant cancer usually precedes the progression of precancerous lesions, and it is challenging to distinguish its nuanced morphological changes. Molecular-based near-infrared-II (NIR-II) fluorescence imaging can effectively recognize lesion targets to improve image contrast and increase early tumor detection compared with traditional wide-light screening endoscopy. c-Met has been determined to be overexpressed',\n",
       " 'recognize lesion targets to improve image contrast and increase early tumor detection compared with traditional wide-light screening endoscopy. c-Met has been determined to be overexpressed in advanced stages of CRC and is considered to be a potent tumor biomarker. Herein, based on the well-targeted inhibitory effect of Crizotinib on c-Met positive tumor cells, the dye IR808 was covalently combined with the drug molecule Crizotinib, resulting in the synthesis of a NIR fluorescent probe',\n",
       " 'inhibitory effect of Crizotinib on c-Met positive tumor cells, the dye IR808 was covalently combined with the drug molecule Crizotinib, resulting in the synthesis of a NIR fluorescent probe Crizotinib-IR808 targeting c-Met positive tumor cells. Then, water-insoluble Crizotinib-IR808 was fabricated by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for',\n",
       " 'by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional',\n",
       " 'tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.']"
      ]
     },
     "execution_count": 443,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "splited = split_text_into_chunks(papers0[4], chunk_size=500,\n",
    "                                             chunk_overlap=200)\n",
    "splited"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "id": "85e33385-e79a-4fcb-8194-7d8da7b13cb5",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "18"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(papers0)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ec456a1-f00a-4c0b-b2cf-e536487e0f79",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### __check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5befc147-ca2f-44f2-886c-b0c613cf1ec7",
   "metadata": {},
   "outputs": [],
   "source": [
    "{\n",
    "     \"fieldresult\": [\n",
    "       {\n",
    "         \"name\": \"Title\",\n",
    "         \"value\": \"Основы программирования на Python\",\n",
    "         \"source_id\": [104]\n",
    "       },\n",
    "       {\n",
    "         \"name\": \"Pages\",\n",
    "         \"value\": \"300 страниц\",\n",
    "         \"source_id\": [105]\n",
    "       }\n",
    "     ]\n",
    "   }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "89e15617-0b13-4cbf-b117-a1d6e4041597",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "        Format:\n",
    "        ```json\n",
    "        [\n",
    "            {{\n",
    "                \"name\":  \\\\ str, length <= 25 tokens\n",
    "                \"value\":  \\\\ str, length <= 25 tokens\n",
    "                \"source_id\":  \\\\ list[int], length <= 3 ids\n",
    "            }},\n",
    "            {{\n",
    "                \"name\":, \\\\ str, length <= 25 tokens\n",
    "                \"value\":  \\\\ str, length <= 25 tokens\n",
    "                \"source_id\":  \\\\ list[int], length <= 3 ids\n",
    "            }},\n",
    "            ...\n",
    "        ]\n",
    "        ```\n",
    "    \\\"\\\"\\\"\n",
    "```\n",
    "    \n",
    "    \n",
    "new\n",
    "```json\n",
    "        [\n",
    "            {{\n",
    "                \"name\": \"fieldName1\",\n",
    "                \"value\": \"extractedInfo1\",\n",
    "                \"source_id\":[source1, source2, ...]\n",
    "            }},\n",
    "            {{\n",
    "                \"name\":[\"fieldName2\"],\n",
    "                \"value\":[\"extractedInfo2\"],\n",
    "                \"source_id\":[source1, source2, ...]\n",
    "            }},\n",
    "            ...\n",
    "        ]\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "cd09b9af-5299-40eb-a633-c5dc082895e6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'FieldResult': {'properties': {'name': {'description': 'Field name that accurately represents the content of the field based on its description.',\n",
       "     'maxLength': 25,\n",
       "     'title': 'Name',\n",
       "     'type': 'string'},\n",
       "    'value': {'description': 'Extracted information from the text based on the field description.',\n",
       "     'maxLength': 50,\n",
       "     'title': 'Value',\n",
       "     'type': 'string'},\n",
       "    'source_id': {'description': 'Cited document IDs.',\n",
       "     'items': {'type': 'integer'},\n",
       "     'maxItems': 3,\n",
       "     'minItems': 1,\n",
       "     'title': 'Source Id',\n",
       "     'type': 'array'}},\n",
       "   'required': ['name', 'value', 'source_id'],\n",
       "   'title': 'FieldResult',\n",
       "   'type': 'object'}},\n",
       " 'properties': {'fieldresult': {'$ref': '#/$defs/FieldResult'}},\n",
       " 'required': ['fieldresult'],\n",
       " 'title': 'Results',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from pydantic import BaseModel, validator, Field, conlist  # This is the new version\n",
    "from typing import Dict, Literal\n",
    "class FieldResult(BaseModel):\n",
    "    name: str = Field(description='Field name that accurately represents the content of the field based on its description.',\n",
    "                     max_length=25)\n",
    "    value: str = Field(description='Extracted information from the text based on the field description.',\n",
    "                      max_length=50)\n",
    "    source_id: conlist(int,min_length=1, max_length=3) = Field(description='Cited document IDs.')\n",
    "    \n",
    "class Results(BaseModel):\n",
    "    fieldresult: FieldResult\n",
    "    \n",
    "Results.model_json_schema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "23b92842-78c9-4a6f-aef5-bc6c9bbae158",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "trailing comma not allowed without surrounding parentheses (1178800490.py, line 1)",
     "output_type": "error",
     "traceback": [
      "  \u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[69]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[31m    \u001b[39m\u001b[31mfrom pydantic import BaseModel, validator, Field, conlist,   # This is the new version\u001b[39m\n                                                                 ^\n\u001b[31mSyntaxError\u001b[39m\u001b[31m:\u001b[39m trailing comma not allowed without surrounding parentheses\n"
     ]
    }
   ],
   "source": [
    "from pydantic import BaseModel, validator, Field, conlist,   # This is the new version\n",
    "from typing import Dict, Literal\n",
    "import pydantic\n",
    "import random\n",
    "class Nested(pydantic.BaseModel):\n",
    "    a: str = pydantic.Field(examples=[\"hello\"])\n",
    "\n",
    "\n",
    "class ExampleData(pydantic.BaseModel):\n",
    "    a: int = pydantic.Field(examples=[1])\n",
    "    b: str = pydantic.Field(min_length=10, max_length=10, examples=[\"abc-123-45\"])\n",
    "    c: int = pydantic.Field(default=100)\n",
    "    # Note: Example will be populated by child, so no explicit example needs\n",
    "    # to be provided for nested models\n",
    "    n: Nested\n",
    "    \n",
    "nn = 1    \n",
    "class FieldResult(BaseModel):\n",
    "    name: str = Field(description='Field name that accurately represents the content of the field based on its description.',\n",
    "                     max_length=25, default='effectiveness')\n",
    "    value: str = Field(description='Extracted information from the text based on the field description.',\n",
    "                      max_length=50, default='total of 5% died')\n",
    "    #source_id: conlist(int,min_length=1, max_length=3) = Field(description='Cited document IDs.', examples=[1,3])\n",
    "    \n",
    "class Results(BaseModel):\n",
    "    fieldresult: list[FieldResult]\n",
    "\n",
    "    \n",
    "def populate_with_examples_recursive(model: pydantic.BaseModel) -> dict:\n",
    "    \"\"\"Populate fields with example values\"\"\"\n",
    "\n",
    "    result = {}\n",
    "    \n",
    "    for name, field_info in model.model_fields.items():\n",
    "        if issubclass(field_info.annotation, pydantic.BaseModel):\n",
    "            result[name] = populate_with_examples_recursive(field_info.annotation)\n",
    "        elif field_info.examples:\n",
    "            result[name] = random.choice(field_info.examples)\n",
    "        elif field_info.default:\n",
    "            result[name] = field_info.default\n",
    "\n",
    "    return dict(result)\n",
    "\n",
    "\n",
    "# Execute it:\n",
    "#json.loads(f'''{populate_with_examples_recursive(ExampleData)}''')\n",
    "\n",
    "(populate_with_examples_recursive(Results))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "e47f8ef2-74f7-4614-8c2c-f461044b4c6c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "ename": "ValidationError",
     "evalue": "1 validation error for FieldResult\nsource_id\n  Field required [type=missing, input_value={}, input_type=dict]\n    For further information visit https://errors.pydantic.dev/2.12/v/missing",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mValidationError\u001b[39m                           Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[83]\u001b[39m\u001b[32m, line 11\u001b[39m\n\u001b[32m      8\u001b[39m \u001b[38;5;28;01mclass\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mResults\u001b[39;00m(BaseModel):\n\u001b[32m      9\u001b[39m     fieldresult: \u001b[38;5;28mlist\u001b[39m[FieldResult]\n\u001b[32m---> \u001b[39m\u001b[32m11\u001b[39m a1 = \u001b[43mFieldResult\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     12\u001b[39m a = Results(fieldresult=[a1,a1])\n\u001b[32m     14\u001b[39m \u001b[38;5;28mprint\u001b[39m(a.model_dump_json(indent=\u001b[32m4\u001b[39m))\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\pydantic\\main.py:250\u001b[39m, in \u001b[36mBaseModel.__init__\u001b[39m\u001b[34m(self, **data)\u001b[39m\n\u001b[32m    248\u001b[39m \u001b[38;5;66;03m# `__tracebackhide__` tells pytest and some other tools to omit this function from tracebacks\u001b[39;00m\n\u001b[32m    249\u001b[39m __tracebackhide__ = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m250\u001b[39m validated_self = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__pydantic_validator__\u001b[49m\u001b[43m.\u001b[49m\u001b[43mvalidate_python\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdata\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mself_instance\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m    251\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m validated_self:\n\u001b[32m    252\u001b[39m     warnings.warn(\n\u001b[32m    253\u001b[39m         \u001b[33m'\u001b[39m\u001b[33mA custom validator is returning a value other than `self`.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33m'\u001b[39m\n\u001b[32m    254\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33mReturning anything other than `self` from a top level model validator isn\u001b[39m\u001b[33m'\u001b[39m\u001b[33mt supported when validating via `__init__`.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33m\"\u001b[39m\n\u001b[32m    255\u001b[39m         \u001b[33m'\u001b[39m\u001b[33mSee the `model_validator` docs (https://docs.pydantic.dev/latest/concepts/validators/#model-validators) for more details.\u001b[39m\u001b[33m'\u001b[39m,\n\u001b[32m    256\u001b[39m         stacklevel=\u001b[32m2\u001b[39m,\n\u001b[32m    257\u001b[39m     )\n",
      "\u001b[31mValidationError\u001b[39m: 1 validation error for FieldResult\nsource_id\n  Field required [type=missing, input_value={}, input_type=dict]\n    For further information visit https://errors.pydantic.dev/2.12/v/missing"
     ]
    }
   ],
   "source": [
    "class FieldResult(BaseModel):\n",
    "    name: str = Field(description='Field name that accurately represents the content of the field based on its description.',\n",
    "                     max_length=25, default='effectiveness')\n",
    "    value: str = Field(description='Extracted information from the text based on the field description.',\n",
    "                      max_length=50, default='total of 5% died')\n",
    "    source_id: list[int] = Field(description='Cited document IDs.', examples=[1,3])\n",
    "    #conlist ,min_length=1, max_length=3\n",
    "class Results(BaseModel):\n",
    "    fieldresult: list[FieldResult]\n",
    "\n",
    "a1 = FieldResult()\n",
    "a = Results(fieldresult=[a1,a1])\n",
    "\n",
    "print(a.model_dump_json(indent=4))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "00bbfbcd-bfb7-4126-900e-65b92a036230",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a',\n",
       " 'ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosis.: ARID1A, a subunit of the SWI/SNF chromatin-remodeling complex, functions as a tumor suppressor in various cancer types. Owing to its high frequency of inactivating mutations, ARID1A has emerged as a promising target for the development of anticancer drugs. In this study, we report that ARID1A-deficient colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription factor, which regulates the transcription of GPX4, a key regulator of ferroptosis. ARID1A inactivation reduces c-MET expression, decreasing NRF2 nuclear localization and its binding to the GPX4 promoter, resulting in reduced GPX4 transcription. This creates a cellular dependency on the residual c-MET for minimal GPX4 expression to survive the ferroptotic cell death. Additionally, we demonstrate that ARID1A loss leads to increased intracellular labile iron accumulation by downregulating the iron-exporting protein SLC40A1, thereby increasing cellular susceptibility to ferroptosis. Inhibition of c-MET in ARID1A-deficient CRC cells diminishes GPX4 expression, resulting in elevated lipid peroxidation and glutathione depletion, ultimately inducing ferroptosis. This study reveals a novel synthetic lethal relationship between ARID1A and c-MET signaling in promoting ferroptosis and proposes c-MET inhibitors as a potential therapeutic strategy for ARID1A-deficient CRC.']"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "9b1d2861-abc0-45d6-b7c6-874dfd60514e",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['',\n",
       " 'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a',\n",
       " 'ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosis.: ARID1A, a subunit of the SWI/SNF chromatin-remodeling complex, functions as a tumor suppressor in various cancer types. Owing to its high frequency of inactivating mutations, ARID1A has emerged as a promising target for the development of anticancer drugs. In this study, we report that ARID1A-deficient colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription factor, which regulates the transcription of GPX4, a key regulator of ferroptosis. ARID1A inactivation reduces c-MET expression, decreasing NRF2 nuclear localization and its binding to the GPX4 promoter, resulting in reduced GPX4 transcription. This creates a cellular dependency on the residual c-MET for minimal GPX4 expression to survive the ferroptotic cell death. Additionally, we demonstrate that ARID1A loss leads to increased intracellular labile iron accumulation by downregulating the iron-exporting protein SLC40A1, thereby increasing cellular susceptibility to ferroptosis. Inhibition of c-MET in ARID1A-deficient CRC cells diminishes GPX4 expression, resulting in elevated lipid peroxidation and glutathione depletion, ultimately inducing ferroptosis. This study reveals a novel synthetic lethal relationship between ARID1A and c-MET signaling in promoting ferroptosis and proposes c-MET inhibitors as a potential therapeutic strategy for ARID1A-deficient CRC.']"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "55868094-f476-42b0-bac0-97e87f6babb1",
   "metadata": {},
   "source": [
    "### back"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 278,
   "id": "b6bb58dc-dfcc-4d24-8c9c-4f37c8c13bfa",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Crizotinib', 'Lorlatinib']"
      ]
     },
     "execution_count": 278,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "treatements_eng"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 279,
   "id": "44e8fb88-fddc-4f8a-885d-bc7353bb13c0",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "13"
      ]
     },
     "execution_count": 279,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(papers0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 445,
   "id": "de7b4567-74b3-4477-96d6-8e5082d1a373",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case report.\\nBackground: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (BRAF) V600E had a relatively poor prognosis. Anaplastic lymphoma kinase (ALK) fusion and the mesenchymal-to-epithelial transition factor (MET) amplification have been recognized as potentially important therapeutic targets in non-small cell lung cancer (NSCLC). However, both of them are of extremely lower frequencies (<2%) in metastatic CRC, and few studies have mentioned the real application of their inhibitors in CRC treatment. Case Description: A 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a BRAF V600E mutation. He received an initial combination treatment with cetuximab, dabrafenib, and trametinib with a partial response (PR) assessment. We changed the therapy regimen on this patient several times because of the patient's intolerance to the drugs or the inefficacy of the treatment. During this period, we detected the c-MET amplification and tropomyosin 4 (TPM4)-ALK fusion by NGS after triplet targeted therapy (tislelizumab, dabrafenib, and trametinib), thus he was finally treated with programmed cell death protein 1 (PD-1) inhibitor (tislelizumab), MET/ALK inhibitor (crizotinib) plus multikinase inhibitor (regorafenib). Imageological examinations showed that PR was achieved and ctDNA sequencing results indicated a significantly reduced BRAF mutation frequency, MET amplification and TPM4-ALK fusion were undetectable. NGS analysis of peripheral blood showed a recurrence of the MET acquired resistant amplification mutation over 2 months of ongoing treatment. but the patient was assessed as PR and still under treatment of crizotinib, tislelizumab and regorafenib within good physical condition. At the last follow-up on October 2021, the patient died of symptomatic treatment fail for obstructive jaundice. The patient finally achieved 11 months overall survival. Conclusions: This study reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.\""
      ]
     },
     "execution_count": 445,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers0[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 280,
   "id": "f953f0cd-f988-4110-a195-3442714e1a7a",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are now the following python function: ```\n",
      "def extract_fields_from_input_study(inputs: Dict[str, Any]) -> str:\n",
      "    \"\"\"\n",
      "    This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data and provide citations for the extracted information.\n",
      "    The user will provide a list of fields they are interested in, along with a natural language description for each field to guide you on what content to look for and from which parts of the report to extract it.\n",
      "\n",
      "    IMPORTANT:\n",
      "    For each field described by the user, you need to:\n",
      "    1. Identify and extract the relevant information from the report, based on the provided description.\n",
      "    2. Generate a field name that accurately represents the content of the field based on its description.\n",
      "    3. Structure the extracted information into a standard format whenever possible (e.g., integer, numerical values, dates, keywords, list of terms). \n",
      "        If standardization is not possible, the information should be presented in text format.\n",
      "        If the field is not found in the report, the extracted value should be \"NP\".\n",
      "    4. Provide a reference to the document ID from which this information was extracted.\n",
      "        This citation id should be restricted to be integers only.\n",
      "        You should NOT cite more than three sources for a single field.\n",
      "        You should try your best to provide the most relevant and specific citation for each field.\n",
      "        If two or more sources are equally relevant, you can just cite one of them.\n",
      "\n",
      "    The function returns a string representing a dictionary with each key representing a field and its extracted value.\n",
      "\n",
      "# User provided inputs\n",
      "paper_content = \"\"\"{paper_content}\"\"\"\n",
      "fields = \"\"\"{fields}\"\"\"\n",
      "\n",
      "inputs = {{\n",
      "    \"paper_content\": paper_content,\n",
      "    \"fields\": fields\n",
      "}}\n",
      "\n",
      "# Reply Format: \n",
      "Return the information in the following JSON-format.\n",
      "```json\n",
      "{{        \n",
      "    [\n",
      "        {{\n",
      "            \"name\": \"fieldName1\",\n",
      "            \"value\": \"extractedInfo1\",\n",
      "            \"source_id\":[1, 2, 3]\n",
      "        }},\n",
      "        {{\n",
      "            \"name\":\"fieldName2\",\n",
      "            \"value\":\"extractedInfo2\",\n",
      "            \"source_id\":[4]\n",
      "        }},\n",
      "        ...\n",
      "    ]\n",
      "}}\n",
      "```\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response.\",\\n        \"source_id\": [3]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"The best clinical response was stable disease in seven patients (29%) when treated with crizotinib.\",\\n        \"source_id\": [4]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"Twenty-five patients were recruited.\",\\n        \"source_id\": [5]\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Drugs such as Crizotinib were more sensitive to low-risk group.\",\\n        \"source_id\": [2]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs.\",\\n        \"source_id\": [1, 2]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors.\",\\n        \"source_id\": [2, 3]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"23\",\\n        \"source_id\": [2, 4, 6]\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Crizotinib selectively inhibits the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.\",\\n        \"source_id\": [3]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies.\",\\n        \"source_id\": [4, 6]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"40589\",\\n        \"source_id\": [1, 2]\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.\",\\n        \"source_id\": [2, 8]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"Twenty patients were recruited in 3 cohorts in the dose escalation. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion.\",\\n        \"source_id\": [0, 3]\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Crizotinib effectively overcomes HGF-induced cetuximab resistance.\",\\n        \"source_id\": [1]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"The expression level of SDHB was correlated with drug sensitivity to Crizotinib.\",\\n        \"source_id\": [5, 6]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib Results\",\\n        \"value\": \"The combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.\",\\n        \"source_id\": [0, 3]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_outputs: [[{'name': 'Crizotinib_Results', 'value': 'Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response.', 'source_id': [3]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'The best clinical response was stable disease in seven patients (29%) when treated with crizotinib.', 'source_id': [4]}, {'name': 'Participants', 'value': 'Twenty-five patients were recruited.', 'source_id': [5]}], [{'name': 'Crizotinib_Results', 'value': 'Drugs such as Crizotinib were more sensitive to low-risk group.', 'source_id': [2]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs.', 'source_id': [1, 2]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors.', 'source_id': [2, 3]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'NP', 'source_id': []}, {'name': 'Participants', 'value': '23', 'source_id': [2, 4, 6]}], [{'name': 'Crizotinib_Results', 'value': 'Crizotinib selectively inhibits the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.', 'source_id': [3]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies.', 'source_id': [4, 6]}, {'name': 'Participants', 'value': '40589', 'source_id': [1, 2]}], [{'name': 'Crizotinib_Results', 'value': 'Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.', 'source_id': [2, 8]}, {'name': 'Participants', 'value': 'Twenty patients were recruited in 3 cohorts in the dose escalation. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion.', 'source_id': [0, 3]}], [{'name': 'Crizotinib_Results', 'value': 'Crizotinib effectively overcomes HGF-induced cetuximab resistance.', 'source_id': [1]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'NP', 'source_id': []}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib_Results', 'value': 'The expression level of SDHB was correlated with drug sensitivity to Crizotinib.', 'source_id': [5, 6]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib Results', 'value': 'The combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.', 'source_id': [0, 3]}, {'name': 'Participants', 'value': 'NP', 'source_id': []}]]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib_Results',\n",
       "   'value': 'Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response.',\n",
       "   'source_id': [3],\n",
       "   'cited_blocks': ['reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'The best clinical response was stable disease in seven patients (29%) when treated with crizotinib.',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best clinical response was stable disease in seven patients (29%). CONCLUSIONS: PD-0325901/crizotinib can be given together at pharmacologically-active doses. The MTD for PD-0325901/crizotinib was 8â\\x80\\x89mg B.D (days 1-21) and 200â\\x80\\x89mg B.D continuously in a 28-days cycle. The combination was further explored']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'Twenty-five patients were recruited.',\n",
       "   'source_id': [5],\n",
       "   'cited_blocks': ['using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients were recruited in 4 cohorts up to doses of crizotinib 200â\\x80\\x89mg B.D continuously with PD-0325901 8â\\x80\\x89mg B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best']}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Drugs such as Crizotinib were more sensitive to low-risk group.',\n",
       "   'source_id': [2],\n",
       "   'cited_blocks': ['populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group. UGT1A6 and IRGM were significantly upregulated in tumor group as revealed by qRT-PCR. This study constructed a new prognostic model for CRC patients based on RRAGs, and a series of analysis']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs.',\n",
       "   'source_id': [1, 2],\n",
       "   'cited_blocks': ['Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs. CONCLUSIONS: Overall, this IRGs-based signature not only afforded a useful tool for determining the prognosis and evaluating the TIME features of CRCs, but also shed new light on tailoring CRCs with precise treatment.',\n",
       "    'identify agents with subclass-specific efficacy. RESULTS: The established signature was shown to be a promising biomarker for evaluating clinical outcomes in CRC. The immune risk score as calculated by this classifier was significantly correlated with over-riding malignant phenotypes and immunophenotypes. Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and S-crizotinib might have potential']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors.',\n",
       "   'source_id': [2, 3],\n",
       "   'cited_blocks': ['by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional',\n",
       "    'tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []},\n",
       "  {'name': 'Participants',\n",
       "   'value': '23',\n",
       "   'source_id': [2, 4, 6],\n",
       "   'cited_blocks': ['(FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs according to the efficiency score calculated using target genes expression and molecular pathway activation data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in NRAS, seven others had mutated',\n",
       "    'data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in NRAS, seven others had mutated KRAS gene. Patients were treated by aflibercept, bevacizumab, bortezomib, cabozantinib, cetuximab, crizotinib, denosumab, panitumumab and regorafenib as monotherapy or in combination with chemotherapy, and information on the success of totally 39 lines of therapy was collected. RESULTS: Oncobox drug',\n",
       "    'BACKGROUND: Overall survival of advanced colorectal cancer (CRC) patients remains poor, and gene expression analysis could potentially complement detection of clinically relevant mutations to personalize CRC treatments. METHODS: We performed RNA sequencing of formalin-fixed, paraffin-embedded (FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs']}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Crizotinib selectively inhibits the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.',\n",
       "   'source_id': [3],\n",
       "   'cited_blocks': ['colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies.',\n",
       "   'source_id': [4, 6],\n",
       "   'cited_blocks': ['induced a rapid and sustained partial response. After 15â\\x80\\x89months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements define a small, yet therapeutically actionable molecular subgroup of MSS CRC. In summary, the high prevalence of GOPC-ROS1 and noncanonical ROS1 fusions pose diagnostic challenges. We advocate NGS-based comprehensive molecular profiling of MSS CRCs that are wild type for RAS and BRAF and patient',\n",
       "    'exclusively in microsatellite stable (MSS) CRCs. KRAS mutations were significantly less abundant in ROS1-rearranged vs ROS1 wild type cases. The index patient presented with chemotherapy-refractory metastatic right-sided colon cancer harboring GOPC-ROS1. Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15â\\x80\\x89months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements']},\n",
       "  {'name': 'Participants',\n",
       "   'value': '40589',\n",
       "   'source_id': [1, 2],\n",
       "   'cited_blocks': ['c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of ROS1-driven CRC. We analyzed a clinical dataset of 40â\\x80\\x89589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response',\n",
       "    \"40â\\x80\\x89589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response of an index patient with ROS1-rearranged metastatic CRC. ROS1 genomic rearrangements were identified in 34 (0.08%) CRC samples. GOPC-ROS1 was the most common ROS1 fusion identified (11 samples), followed by TTC28-ROS1 (3 samples). Four novel 5' gene partners of ROS1 were identified (MCM9, SRPK1,\"]}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.',\n",
       "   'source_id': [2, 8],\n",
       "   'cited_blocks': ['allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).',\n",
       "    'MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baselineÂ\\xa0RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baselineÂ\\xa0KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'Twenty patients were recruited in 3 cohorts in the dose escalation. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion.',\n",
       "   'source_id': [0, 3],\n",
       "   'cited_blocks': ['hybridisation (ISH) and MET DNA-ISH analyses were collected. RESULTS: Twenty patients were recruited in 3 cohorts in the dose escalation. The MTD was binimetinib 30 mg B.D, days 1-21 every 28 days, with crizotinib 250 mg O.D continuously. Dose-limiting toxicities included grade â\\x89¥â\\x80\\x893 transaminitis, creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of',\n",
       "    'creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of target engagement. Across the entire study, the most frequent treatment-related adverse events (TR-AE) were rash (80.4%), fatigue (53.4%) and diarrhoea (51.8%) with grade â\\x89¥â\\x80\\x893 TR-AE occurring in 44.6%. Best clinical response within the RASMT CRC cohort was stable disease in seven patients (24%). Tumour']}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Crizotinib effectively overcomes HGF-induced cetuximab resistance.',\n",
       "   'source_id': [1],\n",
       "   'cited_blocks': ['Conversely, HGF overexpression was necessary and sufficient to induce cetuximab resistance and loss of polarity. Moreover, HGF-induced cetuximab resistance could be overcome by the downstream MET inhibitor, crizotinib, and upstream protease inhibitors. Additionally, HAI-1, an endogenous inhibitor of HGF proteases, (i) was downregulated in CRC, (ii) exhibited increased genomic methylation that correlated with poor prognosis, (iii) HAI-1 expression correlated with cetuximab response in a panel of']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'The expression level of SDHB was correlated with drug sensitivity to Crizotinib.',\n",
       "   'source_id': [5, 6],\n",
       "   'cited_blocks': ['healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association between alterations in the expression of genes such as HOXC6, HOXC13, HOXC8, TBX15, SDHB, COX5A, and UQCRC1 and increased mortality rates in CRC patients. As revealed by the PPI network, these genes exhibited the most connections with other genes linked to survival.',\n",
       "    'Applying the risk model developed with the mentioned genes revealed a markedly higher incidence of deceased patients in the high-risk group compared to the low-risk group. RT-qPCR results indicated a decrease in SDHB expression and an elevation in TBX15 levels in cancer samples relative to adjacent healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib Results',\n",
       "   'value': 'The combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.',\n",
       "   'source_id': [0, 3],\n",
       "   'cited_blocks': ['antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer. CONCLUSION: Our findings illuminate the molecular mechanisms underlying EpCAM signaling promotion of colon cancer metastasis, further suggesting that the combination of EpAb2-6 and crizotinib may be an effective strategy for treating cancer patients with high EpCAM expression.',\n",
       "    'epithelial-to-mesenchymal transition and metastatic potential of colon cancer cells by activating ERK and FAK-AKT signaling pathways, and it further stabilizes active Î²-catenin and Snail proteins by decreasing GSK3Î² activity. Finally, we show that the combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer. CONCLUSION: Our']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}]]"
      ]
     },
     "execution_count": 280,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=papers0,\n",
    "    fields=[f'Crizotinib Results, string, the effectiveness of treating {fin_condition} with {treatements_eng[0]}',\n",
    "           'Participants, string, number of participants'],#api.DEFAULT_FIELDS,\n",
    "    llm=os.getenv(\"MODEL_NAME\"),\n",
    "    chunk_size=500,\n",
    "    chunk_overlap=200,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "id": "b1087393-69b0-4308-8d0d-2746e8a9faa3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib_Results',\n",
       "   'value': 'Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response.',\n",
       "   'source_id': [3],\n",
       "   'cited_blocks': ['reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'The best clinical response was stable disease in seven patients (29%) when treated with crizotinib.',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best clinical response was stable disease in seven patients (29%). CONCLUSIONS: PD-0325901/crizotinib can be given together at pharmacologically-active doses. The MTD for PD-0325901/crizotinib was 8â\\x80\\x89mg B.D (days 1-21) and 200â\\x80\\x89mg B.D continuously in a 28-days cycle. The combination was further explored']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'Twenty-five patients were recruited.',\n",
       "   'source_id': [5],\n",
       "   'cited_blocks': ['using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients were recruited in 4 cohorts up to doses of crizotinib 200â\\x80\\x89mg B.D continuously with PD-0325901 8â\\x80\\x89mg B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best']}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Drugs such as Crizotinib were more sensitive to low-risk group.',\n",
       "   'source_id': [2],\n",
       "   'cited_blocks': ['populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group. UGT1A6 and IRGM were significantly upregulated in tumor group as revealed by qRT-PCR. This study constructed a new prognostic model for CRC patients based on RRAGs, and a series of analysis']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs.',\n",
       "   'source_id': [1, 2],\n",
       "   'cited_blocks': ['Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs. CONCLUSIONS: Overall, this IRGs-based signature not only afforded a useful tool for determining the prognosis and evaluating the TIME features of CRCs, but also shed new light on tailoring CRCs with precise treatment.',\n",
       "    'identify agents with subclass-specific efficacy. RESULTS: The established signature was shown to be a promising biomarker for evaluating clinical outcomes in CRC. The immune risk score as calculated by this classifier was significantly correlated with over-riding malignant phenotypes and immunophenotypes. Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and S-crizotinib might have potential']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors.',\n",
       "   'source_id': [2, 3],\n",
       "   'cited_blocks': ['by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional',\n",
       "    'tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []},\n",
       "  {'name': 'Participants',\n",
       "   'value': '23',\n",
       "   'source_id': [2, 4, 6],\n",
       "   'cited_blocks': ['(FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs according to the efficiency score calculated using target genes expression and molecular pathway activation data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in NRAS, seven others had mutated',\n",
       "    'data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in NRAS, seven others had mutated KRAS gene. Patients were treated by aflibercept, bevacizumab, bortezomib, cabozantinib, cetuximab, crizotinib, denosumab, panitumumab and regorafenib as monotherapy or in combination with chemotherapy, and information on the success of totally 39 lines of therapy was collected. RESULTS: Oncobox drug',\n",
       "    'BACKGROUND: Overall survival of advanced colorectal cancer (CRC) patients remains poor, and gene expression analysis could potentially complement detection of clinically relevant mutations to personalize CRC treatments. METHODS: We performed RNA sequencing of formalin-fixed, paraffin-embedded (FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs']}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Crizotinib selectively inhibits the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.',\n",
       "   'source_id': [3],\n",
       "   'cited_blocks': ['colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies.',\n",
       "   'source_id': [4, 6],\n",
       "   'cited_blocks': ['induced a rapid and sustained partial response. After 15â\\x80\\x89months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements define a small, yet therapeutically actionable molecular subgroup of MSS CRC. In summary, the high prevalence of GOPC-ROS1 and noncanonical ROS1 fusions pose diagnostic challenges. We advocate NGS-based comprehensive molecular profiling of MSS CRCs that are wild type for RAS and BRAF and patient',\n",
       "    'exclusively in microsatellite stable (MSS) CRCs. KRAS mutations were significantly less abundant in ROS1-rearranged vs ROS1 wild type cases. The index patient presented with chemotherapy-refractory metastatic right-sided colon cancer harboring GOPC-ROS1. Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15â\\x80\\x89months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements']},\n",
       "  {'name': 'Participants',\n",
       "   'value': '40589',\n",
       "   'source_id': [1, 2],\n",
       "   'cited_blocks': ['c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of ROS1-driven CRC. We analyzed a clinical dataset of 40â\\x80\\x89589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response',\n",
       "    \"40â\\x80\\x89589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response of an index patient with ROS1-rearranged metastatic CRC. ROS1 genomic rearrangements were identified in 34 (0.08%) CRC samples. GOPC-ROS1 was the most common ROS1 fusion identified (11 samples), followed by TTC28-ROS1 (3 samples). Four novel 5' gene partners of ROS1 were identified (MCM9, SRPK1,\"]}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.',\n",
       "   'source_id': [2, 8],\n",
       "   'cited_blocks': ['allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).',\n",
       "    'MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baselineÂ\\xa0RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baselineÂ\\xa0KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'Twenty patients were recruited in 3 cohorts in the dose escalation. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion.',\n",
       "   'source_id': [0, 3],\n",
       "   'cited_blocks': ['hybridisation (ISH) and MET DNA-ISH analyses were collected. RESULTS: Twenty patients were recruited in 3 cohorts in the dose escalation. The MTD was binimetinib 30 mg B.D, days 1-21 every 28 days, with crizotinib 250 mg O.D continuously. Dose-limiting toxicities included grade â\\x89¥â\\x80\\x893 transaminitis, creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of',\n",
       "    'creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of target engagement. Across the entire study, the most frequent treatment-related adverse events (TR-AE) were rash (80.4%), fatigue (53.4%) and diarrhoea (51.8%) with grade â\\x89¥â\\x80\\x893 TR-AE occurring in 44.6%. Best clinical response within the RASMT CRC cohort was stable disease in seven patients (24%). Tumour']}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'Crizotinib effectively overcomes HGF-induced cetuximab resistance.',\n",
       "   'source_id': [1],\n",
       "   'cited_blocks': ['Conversely, HGF overexpression was necessary and sufficient to induce cetuximab resistance and loss of polarity. Moreover, HGF-induced cetuximab resistance could be overcome by the downstream MET inhibitor, crizotinib, and upstream protease inhibitors. Additionally, HAI-1, an endogenous inhibitor of HGF proteases, (i) was downregulated in CRC, (ii) exhibited increased genomic methylation that correlated with poor prognosis, (iii) HAI-1 expression correlated with cetuximab response in a panel of']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib_Results',\n",
       "   'value': 'The expression level of SDHB was correlated with drug sensitivity to Crizotinib.',\n",
       "   'source_id': [5, 6],\n",
       "   'cited_blocks': ['healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association between alterations in the expression of genes such as HOXC6, HOXC13, HOXC8, TBX15, SDHB, COX5A, and UQCRC1 and increased mortality rates in CRC patients. As revealed by the PPI network, these genes exhibited the most connections with other genes linked to survival.',\n",
       "    'Applying the risk model developed with the mentioned genes revealed a markedly higher incidence of deceased patients in the high-risk group compared to the low-risk group. RT-qPCR results indicated a decrease in SDHB expression and an elevation in TBX15 levels in cancer samples relative to adjacent healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib Results',\n",
       "   'value': 'The combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.',\n",
       "   'source_id': [0, 3],\n",
       "   'cited_blocks': ['antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer. CONCLUSION: Our findings illuminate the molecular mechanisms underlying EpCAM signaling promotion of colon cancer metastasis, further suggesting that the combination of EpAb2-6 and crizotinib may be an effective strategy for treating cancer patients with high EpCAM expression.',\n",
       "    'epithelial-to-mesenchymal transition and metastatic potential of colon cancer cells by activating ERK and FAK-AKT signaling pathways, and it further stabilizes active Î²-catenin and Snail proteins by decreasing GSK3Î² activity. Finally, we show that the combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer. CONCLUSION: Our']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}]]"
      ]
     },
     "execution_count": 281,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extracted_gm = extracted\n",
    "extracted_gm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 255,
   "id": "d71c255e-1f6c-429c-8e14-3c03f724a1bd",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are now the following python function: ```\n",
      "def extract_fields_from_input_study(inputs: Dict[str, Any]) -> str:\n",
      "    \"\"\"\n",
      "    This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data and provide citations for the extracted information.\n",
      "    The user will provide a list of fields they are interested in, along with a natural language description for each field to guide you on what content to look for and from which parts of the report to extract it.\n",
      "\n",
      "    IMPORTANT:\n",
      "    For each field described by the user, you need to:\n",
      "    1. Identify and extract the relevant information from the report, based on the provided description.\n",
      "    2. Generate a field name that accurately represents the content of the field based on its description.\n",
      "    3. Structure the extracted information into a standard format whenever possible (e.g., integer, numerical values, dates, keywords, list of terms). \n",
      "        If standardization is not possible, the information should be presented in text format.\n",
      "        If the field is not found in the report, the extracted value should be \"NP\".\n",
      "    4. Provide a reference to the document ID from which this information was extracted.\n",
      "        This citation id should be restricted to be integers only.\n",
      "        You should NOT cite more than three sources for a single field.\n",
      "        You should try your best to provide the most relevant and specific citation for each field.\n",
      "        If two or more sources are equally relevant, you can just cite one of them.\n",
      "\n",
      "    The function returns a string representing a dictionary with each key representing a field and its extracted value.\n",
      "\n",
      "# User provided inputs\n",
      "paper_content = \"\"\"{paper_content}\"\"\"\n",
      "fields = \"\"\"{fields}\"\"\"\n",
      "\n",
      "inputs = {{\n",
      "    \"paper_content\": paper_content,\n",
      "    \"fields\": fields\n",
      "}}\n",
      "\n",
      "# Reply Format: \n",
      "Return the information in the following JSON-format.\n",
      "```json\n",
      "{{        \n",
      "    [\n",
      "        {{\n",
      "            \"name\": \"fieldName1\",\n",
      "            \"value\": \"extractedInfo1\",\n",
      "            \"source_id\":[1, 2, 3]\n",
      "        }},\n",
      "        {{\n",
      "            \"name\":\"fieldName2\",\n",
      "            \"value\":\"extractedInfo2\",\n",
      "            \"source_id\":[4]\n",
      "        }},\n",
      "        ...\n",
      "    ]\n",
      "}}\n",
      "```\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"fields\": [\\n        {\\n            \"name\": \"Crizotinib_Results\",\\n            \"value\": \"The combined therapy of crizotinib, tislelizumab, and regorafenib resulted in a Partial Response (PR) and significant reduction in BRAF mutation frequency, making it a more effective and safer option for patients with co-existing BRAF V600E mutation, c-MET amplification, and TPM4-ALK fusion.\",\\n            \"source_id\": [2, 6, 12, 35, 37]\\n        },\\n        {\\n            \"name\": \"Participants\",\\n            \"value\": \"NP\"\\n        }\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"fields\": [\\n        {\\n            \"name\": \"Crizotinib_Results\",\\n            \"value\": \"The combination of crizotinib and PD-0325901 was well tolerated with a manageable toxicity profile, but showed limited activity in unselected heavily pre-treated patients with advanced solid tumours. Further exploration in a biomarker-selected population of patients with advanced CRC was not pursued due to the termination of the clinical development of PD-0325901.\",\\n            \"source_id\": [4, 11]\\n        },\\n        {\\n            \"name\": \"Participants\",\\n            \"value\": \"25\",\\n            \"source_id\": [33]\\n        }\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"fields\": [\\n        {\\n            \"name\": \"Crizotinib_Results\",\\n            \"value\": \"NP\",\\n            \"source_id\": []\\n        },\\n        {\\n            \"name\": \"Participants\",\\n            \"value\": \"NP\",\\n            \"source_id\": []\\n        }\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Crizotinib restored cetuximab sensitivity in the HCA-7 CRC cell line.\",\\n        \"source_id\": [53]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\"\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"fields\": [\\n        {\\n            \"name\": \"Crizotinib_Results\",\\n            \"value\": \"The dye IR808 was covalently combined with the drug molecule Crizotinib, resulting in the synthesis of a NIR fluorescent probe Crizotinib-IR808 targeting c-Met positive tumor cells. Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors under 808 nm laser irradiation.\",\\n            \"source_id\": [0, 4, 3]\\n        },\\n        {\\n            \"name\": \"Participants\",\\n            \"value\": \"NP\"\\n        }\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"NP\",\\n        \"source_id\": []\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"23\",\\n        \"source_id\": [118]\\n    }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n    {\\n        \"name\": \"Crizotinib_Results\",\\n        \"value\": \"Crizotinib, an FDA-approved drug for the treatment of advanced non-small cell lung cancer and ROS1-positive lung cancer, has demonstrated enhanced cytotoxicity in ARID1A-deficient cancers, facilitating the translation of these approved drugs for repurposing in ARID1A-targeted precision cancer medicine.\",\\n        \"source_id\": [44, 120, 162]\\n    },\\n    {\\n        \"name\": \"Participants\",\\n        \"value\": \"NP\"\\n    }\\n]\\n```']\n"
     ]
    },
    {
     "ename": "RetryError",
     "evalue": "RetryError[<Future at 0x1a2d1f324d0 state=finished raised APIStatusError>]",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mAPIStatusError\u001b[39m                            Traceback (most recent call last)",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\tenacity\\asyncio\\__init__.py:114\u001b[39m, in \u001b[36mAsyncRetrying.__call__\u001b[39m\u001b[34m(self, fn, *args, **kwargs)\u001b[39m\n\u001b[32m    113\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m114\u001b[39m     result = \u001b[38;5;28;01mawait\u001b[39;00m fn(*args, **kwargs)\n\u001b[32m    115\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m:  \u001b[38;5;66;03m# noqa: B902\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\llm_utils\\openai_async.py:77\u001b[39m, in \u001b[36mapi_function_call_single\u001b[39m\u001b[34m(client, model, messages, tools, temperature, thinking, **kwargs)\u001b[39m\n\u001b[32m     75\u001b[39m     messages[\u001b[32m0\u001b[39m][\u001b[33m'\u001b[39m\u001b[33mcontent\u001b[39m\u001b[33m'\u001b[39m] = \u001b[33m'\u001b[39m\u001b[33m/no_think \u001b[39m\u001b[33m'\u001b[39m+messages[\u001b[32m0\u001b[39m][\u001b[33m'\u001b[39m\u001b[33mcontent\u001b[39m\u001b[33m'\u001b[39m]\n\u001b[32m---> \u001b[39m\u001b[32m77\u001b[39m response = \u001b[38;5;28;01mawait\u001b[39;00m client.chat.completions.create(\n\u001b[32m     78\u001b[39m     model=model,\n\u001b[32m     79\u001b[39m     messages=messages,\n\u001b[32m     80\u001b[39m     \u001b[38;5;66;03m#tools=tools,\u001b[39;00m\n\u001b[32m     81\u001b[39m     temperature=temperature,\n\u001b[32m     82\u001b[39m     \u001b[38;5;66;03m#extra_body={\"structured_outputs\": {\"json\": tools[0]}},\u001b[39;00m\n\u001b[32m     83\u001b[39m     response_format={\n\u001b[32m     84\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33mtype\u001b[39m\u001b[33m\"\u001b[39m: \u001b[33m\"\u001b[39m\u001b[33mjson_object\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m     85\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33mjson_schema\u001b[39m\u001b[33m\"\u001b[39m: {\n\u001b[32m     86\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mname\u001b[39m\u001b[33m\"\u001b[39m: \u001b[33m\"\u001b[39m\u001b[33mschema\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m     87\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mschema\u001b[39m\u001b[33m\"\u001b[39m: tools[\u001b[32m0\u001b[39m]\n\u001b[32m     88\u001b[39m         },\n\u001b[32m     89\u001b[39m     },\n\u001b[32m     90\u001b[39m     **kwargs\n\u001b[32m     91\u001b[39m )\n\u001b[32m     92\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:2678\u001b[39m, in \u001b[36mAsyncCompletions.create\u001b[39m\u001b[34m(self, messages, model, audio, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, prompt_cache_key, prompt_cache_retention, reasoning_effort, response_format, safety_identifier, seed, service_tier, stop, store, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, verbosity, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[39m\n\u001b[32m   2677\u001b[39m validate_response_format(response_format)\n\u001b[32m-> \u001b[39m\u001b[32m2678\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m._post(\n\u001b[32m   2679\u001b[39m     \u001b[33m\"\u001b[39m\u001b[33m/chat/completions\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m   2680\u001b[39m     body=\u001b[38;5;28;01mawait\u001b[39;00m async_maybe_transform(\n\u001b[32m   2681\u001b[39m         {\n\u001b[32m   2682\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mmessages\u001b[39m\u001b[33m\"\u001b[39m: messages,\n\u001b[32m   2683\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mmodel\u001b[39m\u001b[33m\"\u001b[39m: model,\n\u001b[32m   2684\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33maudio\u001b[39m\u001b[33m\"\u001b[39m: audio,\n\u001b[32m   2685\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mfrequency_penalty\u001b[39m\u001b[33m\"\u001b[39m: frequency_penalty,\n\u001b[32m   2686\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mfunction_call\u001b[39m\u001b[33m\"\u001b[39m: function_call,\n\u001b[32m   2687\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mfunctions\u001b[39m\u001b[33m\"\u001b[39m: functions,\n\u001b[32m   2688\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mlogit_bias\u001b[39m\u001b[33m\"\u001b[39m: logit_bias,\n\u001b[32m   2689\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mlogprobs\u001b[39m\u001b[33m\"\u001b[39m: logprobs,\n\u001b[32m   2690\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mmax_completion_tokens\u001b[39m\u001b[33m\"\u001b[39m: max_completion_tokens,\n\u001b[32m   2691\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mmax_tokens\u001b[39m\u001b[33m\"\u001b[39m: max_tokens,\n\u001b[32m   2692\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mmetadata\u001b[39m\u001b[33m\"\u001b[39m: metadata,\n\u001b[32m   2693\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mmodalities\u001b[39m\u001b[33m\"\u001b[39m: modalities,\n\u001b[32m   2694\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mn\u001b[39m\u001b[33m\"\u001b[39m: n,\n\u001b[32m   2695\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mparallel_tool_calls\u001b[39m\u001b[33m\"\u001b[39m: parallel_tool_calls,\n\u001b[32m   2696\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mprediction\u001b[39m\u001b[33m\"\u001b[39m: prediction,\n\u001b[32m   2697\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mpresence_penalty\u001b[39m\u001b[33m\"\u001b[39m: presence_penalty,\n\u001b[32m   2698\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mprompt_cache_key\u001b[39m\u001b[33m\"\u001b[39m: prompt_cache_key,\n\u001b[32m   2699\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mprompt_cache_retention\u001b[39m\u001b[33m\"\u001b[39m: prompt_cache_retention,\n\u001b[32m   2700\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mreasoning_effort\u001b[39m\u001b[33m\"\u001b[39m: reasoning_effort,\n\u001b[32m   2701\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mresponse_format\u001b[39m\u001b[33m\"\u001b[39m: response_format,\n\u001b[32m   2702\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33msafety_identifier\u001b[39m\u001b[33m\"\u001b[39m: safety_identifier,\n\u001b[32m   2703\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mseed\u001b[39m\u001b[33m\"\u001b[39m: seed,\n\u001b[32m   2704\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mservice_tier\u001b[39m\u001b[33m\"\u001b[39m: service_tier,\n\u001b[32m   2705\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mstop\u001b[39m\u001b[33m\"\u001b[39m: stop,\n\u001b[32m   2706\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mstore\u001b[39m\u001b[33m\"\u001b[39m: store,\n\u001b[32m   2707\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mstream\u001b[39m\u001b[33m\"\u001b[39m: stream,\n\u001b[32m   2708\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mstream_options\u001b[39m\u001b[33m\"\u001b[39m: stream_options,\n\u001b[32m   2709\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mtemperature\u001b[39m\u001b[33m\"\u001b[39m: temperature,\n\u001b[32m   2710\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mtool_choice\u001b[39m\u001b[33m\"\u001b[39m: tool_choice,\n\u001b[32m   2711\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mtools\u001b[39m\u001b[33m\"\u001b[39m: tools,\n\u001b[32m   2712\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mtop_logprobs\u001b[39m\u001b[33m\"\u001b[39m: top_logprobs,\n\u001b[32m   2713\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mtop_p\u001b[39m\u001b[33m\"\u001b[39m: top_p,\n\u001b[32m   2714\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33muser\u001b[39m\u001b[33m\"\u001b[39m: user,\n\u001b[32m   2715\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mverbosity\u001b[39m\u001b[33m\"\u001b[39m: verbosity,\n\u001b[32m   2716\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mweb_search_options\u001b[39m\u001b[33m\"\u001b[39m: web_search_options,\n\u001b[32m   2717\u001b[39m         },\n\u001b[32m   2718\u001b[39m         completion_create_params.CompletionCreateParamsStreaming\n\u001b[32m   2719\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m stream\n\u001b[32m   2720\u001b[39m         \u001b[38;5;28;01melse\u001b[39;00m completion_create_params.CompletionCreateParamsNonStreaming,\n\u001b[32m   2721\u001b[39m     ),\n\u001b[32m   2722\u001b[39m     options=make_request_options(\n\u001b[32m   2723\u001b[39m         extra_headers=extra_headers, extra_query=extra_query, extra_body=extra_body, timeout=timeout\n\u001b[32m   2724\u001b[39m     ),\n\u001b[32m   2725\u001b[39m     cast_to=ChatCompletion,\n\u001b[32m   2726\u001b[39m     stream=stream \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28;01mFalse\u001b[39;00m,\n\u001b[32m   2727\u001b[39m     stream_cls=AsyncStream[ChatCompletionChunk],\n\u001b[32m   2728\u001b[39m )\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\_base_client.py:1797\u001b[39m, in \u001b[36mAsyncAPIClient.post\u001b[39m\u001b[34m(self, path, cast_to, body, files, options, stream, stream_cls)\u001b[39m\n\u001b[32m   1794\u001b[39m opts = FinalRequestOptions.construct(\n\u001b[32m   1795\u001b[39m     method=\u001b[33m\"\u001b[39m\u001b[33mpost\u001b[39m\u001b[33m\"\u001b[39m, url=path, json_data=body, files=\u001b[38;5;28;01mawait\u001b[39;00m async_to_httpx_files(files), **options\n\u001b[32m   1796\u001b[39m )\n\u001b[32m-> \u001b[39m\u001b[32m1797\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m.request(cast_to, opts, stream=stream, stream_cls=stream_cls)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\_base_client.py:1597\u001b[39m, in \u001b[36mAsyncAPIClient.request\u001b[39m\u001b[34m(self, cast_to, options, stream, stream_cls)\u001b[39m\n\u001b[32m   1596\u001b[39m     log.debug(\u001b[33m\"\u001b[39m\u001b[33mRe-raising status error\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m-> \u001b[39m\u001b[32m1597\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._make_status_error_from_response(err.response) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m   1599\u001b[39m \u001b[38;5;28;01mbreak\u001b[39;00m\n",
      "\u001b[31mAPIStatusError\u001b[39m: Error code: 402 - {'status': 402, 'message': 'Payment Required'}",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[31mRetryError\u001b[39m                                Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[255]\u001b[39m\u001b[32m, line 2\u001b[39m\n\u001b[32m      1\u001b[39m api = StudyCharacteristicsExtraction()\n\u001b[32m----> \u001b[39m\u001b[32m2\u001b[39m extracted = \u001b[43mapi\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m      3\u001b[39m \u001b[43m    \u001b[49m\u001b[43mpapers\u001b[49m\u001b[43m=\u001b[49m\u001b[43mpapers0\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m      4\u001b[39m \u001b[43m    \u001b[49m\u001b[43mfields\u001b[49m\u001b[43m=\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43mf\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[33;43mCrizotinib Results, string, the effectiveness of treating \u001b[39;49m\u001b[38;5;132;43;01m{\u001b[39;49;00m\u001b[43mfin_condition\u001b[49m\u001b[38;5;132;43;01m}\u001b[39;49;00m\u001b[33;43m with \u001b[39;49m\u001b[38;5;132;43;01m{\u001b[39;49;00m\u001b[43mtreatements_eng\u001b[49m\u001b[43m[\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[38;5;132;43;01m}\u001b[39;49;00m\u001b[33;43m'\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m      5\u001b[39m \u001b[43m           \u001b[49m\u001b[33;43m'\u001b[39;49m\u001b[33;43mParticipants, string, number of participants\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[38;5;66;43;03m#api.DEFAULT_FIELDS,\u001b[39;49;00m\n\u001b[32m      6\u001b[39m \u001b[43m    \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m=\u001b[49m\u001b[43mos\u001b[49m\u001b[43m.\u001b[49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mMODEL_NAME\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m      7\u001b[39m \u001b[43m    \u001b[49m\u001b[43mchunk_size\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m500\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m      8\u001b[39m \u001b[43m    \u001b[49m\u001b[43mchunk_overlap\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m200\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m      9\u001b[39m \u001b[43m    \u001b[49m\u001b[43mthinking\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m     10\u001b[39m \u001b[43m)\u001b[49m\n\u001b[32m     11\u001b[39m extracted\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\api.py:405\u001b[39m, in \u001b[36mStudyCharacteristicsExtraction.run\u001b[39m\u001b[34m(self, papers, fields, llm, batch_size, semantic_filtering, semantic_filtering_top_k, chunk_size, chunk_overlap, thinking)\u001b[39m\n\u001b[32m    402\u001b[39m     fieldresult: \u001b[38;5;28mlist\u001b[39m[FieldResult]\u001b[38;5;66;03m#FieldResult\u001b[39;00m\n\u001b[32m    404\u001b[39m \u001b[38;5;28mprint\u001b[39m(STUDY_FIELDS_EXTRACTION_2)\n\u001b[32m--> \u001b[39m\u001b[32m405\u001b[39m outputs = \u001b[43mbatch_function_call_llm\u001b[49m\u001b[43m(\u001b[49m\u001b[43mSTUDY_FIELDS_EXTRACTION_2\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mbatch_inputs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    406\u001b[39m \u001b[43m                         \u001b[49m\u001b[43m[\u001b[49m\u001b[43mResults\u001b[49m\u001b[43m.\u001b[49m\u001b[43mmodel_json_schema\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    407\u001b[39m \u001b[43m                         \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m=\u001b[49m\u001b[43mllm\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mbatch_size\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbatch_size\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    409\u001b[39m \u001b[38;5;66;03m# call llm\u001b[39;00m\n\u001b[32m    410\u001b[39m \u001b[38;5;66;03m#outputs = batch_call_llm(STUDY_FIELDS_EXTRACTION_2, batch_inputs, \u001b[39;00m\n\u001b[32m    411\u001b[39m \u001b[38;5;66;03m#                         llm=llm, batch_size=batch_size, thinking=thinking)\u001b[39;00m\n\u001b[32m    412\u001b[39m \u001b[38;5;66;03m#print('\\noutputs:',outputs)\u001b[39;00m\n\u001b[32m    413\u001b[39m \u001b[38;5;66;03m#parsed_outputs = extract_json(outputs[0])\u001b[39;00m\n\u001b[32m    414\u001b[39m parsed_outputs = parse_json_outputs(outputs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\llm.py:152\u001b[39m, in \u001b[36mbatch_function_call_llm\u001b[39m\u001b[34m(prompt_template, batch_inputs, schema, llm, temperature, batch_size)\u001b[39m\n\u001b[32m    150\u001b[39m     results = []\n\u001b[32m    151\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(\u001b[32m0\u001b[39m, \u001b[38;5;28mlen\u001b[39m(batch_messages), batch_size):\n\u001b[32m--> \u001b[39m\u001b[32m152\u001b[39m         batch_results = \u001b[43mbatch_function_call_openai\u001b[49m\u001b[43m(\u001b[49m\u001b[43mbatch_messages\u001b[49m\u001b[43m[\u001b[49m\u001b[43mi\u001b[49m\u001b[43m:\u001b[49m\u001b[43mi\u001b[49m\u001b[43m+\u001b[49m\u001b[43mbatch_size\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m=\u001b[49m\u001b[43mllm\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    153\u001b[39m         results.extend(batch_results)\n\u001b[32m    154\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\llm_utils\\openai_async.py:149\u001b[39m, in \u001b[36mbatch_function_call_openai\u001b[39m\u001b[34m(batch_messages, llm, tools, temperature, thinking)\u001b[39m\n\u001b[32m    147\u001b[39m model = llm\u001b[38;5;66;03m#OPENAI_MODEL_NAME_MAP.get(llm)\u001b[39;00m\n\u001b[32m    148\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m model \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m149\u001b[39m     results = \u001b[43m_async_execute\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    150\u001b[39m \u001b[43m        \u001b[49m\u001b[43masync_function\u001b[49m\u001b[43m \u001b[49m\u001b[43m=\u001b[49m\u001b[43m \u001b[49m\u001b[43mapply_function_call_async\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    151\u001b[39m \u001b[43m        \u001b[49m\u001b[43mclient\u001b[49m\u001b[43m \u001b[49m\u001b[43m=\u001b[49m\u001b[43m \u001b[49m\u001b[43masync_openai_client\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    152\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    153\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmessages_list\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbatch_messages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    154\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    155\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[32m    156\u001b[39m \u001b[43m        \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    157\u001b[39m \u001b[43m        \u001b[49m\u001b[43mthinking\u001b[49m\u001b[43m=\u001b[49m\u001b[43mthinking\u001b[49m\n\u001b[32m    158\u001b[39m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    159\u001b[39m     \u001b[38;5;66;03m#print('batch_function_call_openai in asynch',results)\u001b[39;00m\n\u001b[32m    160\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    161\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mUnknown llm: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mllm\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m\"\u001b[39m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\llm_utils\\openai_async.py:198\u001b[39m, in \u001b[36m_async_execute\u001b[39m\u001b[34m(async_function, **kwargs)\u001b[39m\n\u001b[32m    196\u001b[39m     \u001b[38;5;28;01mwith\u001b[39;00m ThreadPoolExecutor(\u001b[32m1\u001b[39m) \u001b[38;5;28;01mas\u001b[39;00m executor:\n\u001b[32m    197\u001b[39m         results = executor.submit(\u001b[38;5;28;01mlambda\u001b[39;00m: asyncio.run(async_function(**kwargs)))\n\u001b[32m--> \u001b[39m\u001b[32m198\u001b[39m         results = \u001b[43mresults\u001b[49m\u001b[43m.\u001b[49m\u001b[43mresult\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    199\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m:\n\u001b[32m    200\u001b[39m     results = async_function(**kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\concurrent\\futures\\_base.py:450\u001b[39m, in \u001b[36mFuture.result\u001b[39m\u001b[34m(self, timeout)\u001b[39m\n\u001b[32m    448\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m CancelledError()\n\u001b[32m    449\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._state == FINISHED:\n\u001b[32m--> \u001b[39m\u001b[32m450\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__get_result\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    451\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    452\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTimeoutError\u001b[39;00m()\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\concurrent\\futures\\_base.py:395\u001b[39m, in \u001b[36mFuture.__get_result\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    393\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._exception \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m    394\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m395\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._exception\n\u001b[32m    396\u001b[39m     \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[32m    397\u001b[39m         \u001b[38;5;66;03m# Break a reference cycle with the exception in self._exception\u001b[39;00m\n\u001b[32m    398\u001b[39m         \u001b[38;5;28mself\u001b[39m = \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\concurrent\\futures\\thread.py:86\u001b[39m, in \u001b[36m_WorkItem.run\u001b[39m\u001b[34m(self, ctx)\u001b[39m\n\u001b[32m     83\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m\n\u001b[32m     85\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m---> \u001b[39m\u001b[32m86\u001b[39m     result = \u001b[43mctx\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mtask\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     87\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[32m     88\u001b[39m     \u001b[38;5;28mself\u001b[39m.future.set_exception(exc)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\concurrent\\futures\\thread.py:73\u001b[39m, in \u001b[36mWorkerContext.run\u001b[39m\u001b[34m(self, task)\u001b[39m\n\u001b[32m     71\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mrun\u001b[39m(\u001b[38;5;28mself\u001b[39m, task):\n\u001b[32m     72\u001b[39m     fn, args, kwargs = task\n\u001b[32m---> \u001b[39m\u001b[32m73\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfn\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\llm_utils\\openai_async.py:197\u001b[39m, in \u001b[36m_async_execute.<locals>.<lambda>\u001b[39m\u001b[34m()\u001b[39m\n\u001b[32m    195\u001b[39m     loop = asyncio.get_running_loop()\n\u001b[32m    196\u001b[39m     \u001b[38;5;28;01mwith\u001b[39;00m ThreadPoolExecutor(\u001b[32m1\u001b[39m) \u001b[38;5;28;01mas\u001b[39;00m executor:\n\u001b[32m--> \u001b[39m\u001b[32m197\u001b[39m         results = executor.submit(\u001b[38;5;28;01mlambda\u001b[39;00m: \u001b[43masyncio\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[43masync_function\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m)\n\u001b[32m    198\u001b[39m         results = results.result()\n\u001b[32m    199\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\asyncio\\runners.py:204\u001b[39m, in \u001b[36mrun\u001b[39m\u001b[34m(main, debug, loop_factory)\u001b[39m\n\u001b[32m    200\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\n\u001b[32m    201\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33masyncio.run() cannot be called from a running event loop\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m    203\u001b[39m \u001b[38;5;28;01mwith\u001b[39;00m Runner(debug=debug, loop_factory=loop_factory) \u001b[38;5;28;01mas\u001b[39;00m runner:\n\u001b[32m--> \u001b[39m\u001b[32m204\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mrunner\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmain\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\asyncio\\runners.py:127\u001b[39m, in \u001b[36mRunner.run\u001b[39m\u001b[34m(self, coro, context)\u001b[39m\n\u001b[32m    125\u001b[39m \u001b[38;5;28mself\u001b[39m._interrupt_count = \u001b[32m0\u001b[39m\n\u001b[32m    126\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m127\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_loop\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun_until_complete\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtask\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    128\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m exceptions.CancelledError:\n\u001b[32m    129\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._interrupt_count > \u001b[32m0\u001b[39m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\asyncio\\base_events.py:719\u001b[39m, in \u001b[36mBaseEventLoop.run_until_complete\u001b[39m\u001b[34m(self, future)\u001b[39m\n\u001b[32m    716\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m future.done():\n\u001b[32m    717\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\u001b[33m'\u001b[39m\u001b[33mEvent loop stopped before Future completed.\u001b[39m\u001b[33m'\u001b[39m)\n\u001b[32m--> \u001b[39m\u001b[32m719\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfuture\u001b[49m\u001b[43m.\u001b[49m\u001b[43mresult\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\llm_utils\\openai_async.py:107\u001b[39m, in \u001b[36mapply_function_call_async\u001b[39m\u001b[34m(client, model, messages_list, tools, **kwargs)\u001b[39m\n\u001b[32m    103\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m    104\u001b[39m \u001b[33;03mApply the OpenAI API asynchronously to a list of messages using high-level asyncio APIs.\u001b[39;00m\n\u001b[32m    105\u001b[39m \u001b[33;03m\"\"\"\u001b[39;00m\n\u001b[32m    106\u001b[39m tasks = [api_function_call_single(client, model, messages, tools, **kwargs) \u001b[38;5;28;01mfor\u001b[39;00m messages \u001b[38;5;129;01min\u001b[39;00m messages_list]\n\u001b[32m--> \u001b[39m\u001b[32m107\u001b[39m results = \u001b[38;5;28;01mawait\u001b[39;00m asyncio.gather(*tasks)\n\u001b[32m    108\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m results\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\tenacity\\asyncio\\__init__.py:189\u001b[39m, in \u001b[36mAsyncRetrying.wraps.<locals>.async_wrapped\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    187\u001b[39m copy = \u001b[38;5;28mself\u001b[39m.copy()\n\u001b[32m    188\u001b[39m async_wrapped.statistics = copy.statistics  \u001b[38;5;66;03m# type: ignore[attr-defined]\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m189\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mawait\u001b[39;00m copy(fn, *args, **kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\tenacity\\asyncio\\__init__.py:111\u001b[39m, in \u001b[36mAsyncRetrying.__call__\u001b[39m\u001b[34m(self, fn, *args, **kwargs)\u001b[39m\n\u001b[32m    109\u001b[39m retry_state = RetryCallState(retry_object=\u001b[38;5;28mself\u001b[39m, fn=fn, args=args, kwargs=kwargs)\n\u001b[32m    110\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m111\u001b[39m     do = \u001b[38;5;28;01mawait\u001b[39;00m \u001b[38;5;28mself\u001b[39m.iter(retry_state=retry_state)\n\u001b[32m    112\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(do, DoAttempt):\n\u001b[32m    113\u001b[39m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\tenacity\\asyncio\\__init__.py:153\u001b[39m, in \u001b[36mAsyncRetrying.iter\u001b[39m\u001b[34m(self, retry_state)\u001b[39m\n\u001b[32m    151\u001b[39m result = \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m    152\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m action \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.iter_state.actions:\n\u001b[32m--> \u001b[39m\u001b[32m153\u001b[39m     result = \u001b[38;5;28;01mawait\u001b[39;00m action(retry_state)\n\u001b[32m    154\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m result\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\tenacity\\_utils.py:99\u001b[39m, in \u001b[36mwrap_to_async_func.<locals>.inner\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m     98\u001b[39m \u001b[38;5;28;01masync\u001b[39;00m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34minner\u001b[39m(*args: typing.Any, **kwargs: typing.Any) -> typing.Any:\n\u001b[32m---> \u001b[39m\u001b[32m99\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mcall\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\tenacity\\__init__.py:421\u001b[39m, in \u001b[36mBaseRetrying._post_stop_check_actions.<locals>.exc_check\u001b[39m\u001b[34m(rs)\u001b[39m\n\u001b[32m    419\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.reraise:\n\u001b[32m    420\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m retry_exc.reraise()\n\u001b[32m--> \u001b[39m\u001b[32m421\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m retry_exc \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mfut\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mexception\u001b[39;00m()\n",
      "\u001b[31mRetryError\u001b[39m: RetryError[<Future at 0x1a2d1f324d0 state=finished raised APIStatusError>]"
     ]
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=papers0,\n",
    "    fields=[f'Crizotinib Results, string, the effectiveness of treating {fin_condition} with {treatements_eng[0]}',\n",
    "           'Participants, string, number of participants'],#api.DEFAULT_FIELDS,\n",
    "    llm=os.getenv(\"MODEL_NAME\"),\n",
    "    chunk_size=500,\n",
    "    chunk_overlap=200,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "83e803e5-ed70-4876-ab09-1a7d7a5cafd2",
   "metadata": {
    "tags": []
   },
   "source": [
    "### with hf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "id": "6c56a5d4-cb26-4961-8f94-dd99ca18b60f",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "os.environ[\"BASE_URL\"] = \"https://router.huggingface.co/v1\"\n",
    "os.environ[\"MODEL_NAME\"] ='zai-org/GLM-4.7'#'meta-llama/Llama-3.3-70B-Instruct'\n",
    "os.environ[\"OPENAI_API_KEY\"] = os.getenv(\"HUGGINGFACE_HUB_TOKEN2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 271,
   "id": "c0ac0fe2-424f-4c3b-afb6-a2e48916737a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are now the following python function: ```\n",
      "def extract_fields_from_input_study(inputs: Dict[str, Any]) -> str:\n",
      "    \"\"\"\n",
      "    This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data and provide citations for the extracted information.\n",
      "    The user will provide a list of fields they are interested in, along with a natural language description for each field to guide you on what content to look for and from which parts of the report to extract it.\n",
      "\n",
      "    IMPORTANT:\n",
      "    For each field described by the user, you need to:\n",
      "    1. Identify and extract the relevant information from the report, based on the provided description.\n",
      "    2. Generate a field name that accurately represents the content of the field based on its description.\n",
      "    3. Structure the extracted information into a standard format whenever possible (e.g., integer, numerical values, dates, keywords, list of terms). \n",
      "        If standardization is not possible, the information should be presented in text format.\n",
      "        If the field is not found in the report, the extracted value should be \"NP\".\n",
      "    4. Provide a reference to the document ID from which this information was extracted.\n",
      "        This citation id should be restricted to be integers only.\n",
      "        You should NOT cite more than three sources for a single field.\n",
      "        You should try your best to provide the most relevant and specific citation for each field.\n",
      "        If two or more sources are equally relevant, you can just cite one of them.\n",
      "\n",
      "    The function returns a string representing a dictionary with each key representing a field and its extracted value.\n",
      "\n",
      "# User provided inputs\n",
      "paper_content = \"\"\"{paper_content}\"\"\"\n",
      "fields = \"\"\"{fields}\"\"\"\n",
      "\n",
      "inputs = {{\n",
      "    \"paper_content\": paper_content,\n",
      "    \"fields\": fields\n",
      "}}\n",
      "\n",
      "# Reply Format: \n",
      "Return the information in the following JSON-format.\n",
      "```json\n",
      "{{        \n",
      "    [\n",
      "        {{\n",
      "            \"name\": \"fieldName1\",\n",
      "            \"value\": \"extractedInfo1\",\n",
      "            \"source_id\":[1, 2, 3]\n",
      "        }},\n",
      "        {{\n",
      "            \"name\":\"fieldName2\",\n",
      "            \"value\":\"extractedInfo2\",\n",
      "            \"source_id\":[4]\n",
      "        }},\n",
      "        ...\n",
      "    ]\n",
      "}}\n",
      "```\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['[{\"name\":\"Crizotinib Results\",\"value\":\"Partial response (PR) was achieved when crizotinib was combined with regorafenib and tislelizumab. The treatment resulted in significantly reduced BRAF mutation frequency, and MET amplification and TPM4-ALK fusion became undetectable. The patient achieved 11 months overall survival.\",\"source_id\":[3,4,8]},{\"name\":\"Participants\",\"value\":\"1\",\"source_id\":[0]}]']\n",
      "\n",
      "parsed_results in asynch ['[{\"name\": \"Crizotinib Results\", \"value\": \"The best clinical response was stable disease in seven patients (29%).\", \"source_id\": [4]}, {\"name\": \"Participants\", \"value\": \"Twenty-five patients\", \"source_id\": [1, 5]}]']\n",
      "\n",
      "parsed_outputs: [[{'name': 'Crizotinib Results', 'value': 'Partial response (PR) was achieved when crizotinib was combined with regorafenib and tislelizumab. The treatment resulted in significantly reduced BRAF mutation frequency, and MET amplification and TPM4-ALK fusion became undetectable. The patient achieved 11 months overall survival.', 'source_id': [3, 4, 8]}, {'name': 'Participants', 'value': '1', 'source_id': [0]}], [{'name': 'Crizotinib Results', 'value': 'The best clinical response was stable disease in seven patients (29%).', 'source_id': [4]}, {'name': 'Participants', 'value': 'Twenty-five patients', 'source_id': [1, 5]}]]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib Results',\n",
       "   'value': 'Partial response (PR) was achieved when crizotinib was combined with regorafenib and tislelizumab. The treatment resulted in significantly reduced BRAF mutation frequency, and MET amplification and TPM4-ALK fusion became undetectable. The patient achieved 11 months overall survival.',\n",
       "   'source_id': [3, 4, 8],\n",
       "   'cited_blocks': ['reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.',\n",
       "    'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case report.',\n",
       "    '(tislelizumab, dabrafenib, and trametinib), thus he was finally treated with programmed cell death protein 1 (PD-1) inhibitor (tislelizumab), MET/ALK inhibitor (crizotinib) plus multikinase inhibitor (regorafenib). Imageological examinations showed that PR was achieved and ctDNA sequencing results indicated a significantly reduced BRAF mutation frequency, MET amplification and TPM4-ALK fusion were undetectable. NGS analysis of peripheral blood showed a recurrence of the MET acquired resistant']},\n",
       "  {'name': 'Participants',\n",
       "   'value': '1',\n",
       "   'source_id': [0],\n",
       "   'cited_blocks': ['targets in non-small cell lung cancer (NSCLC). However, both of them are of extremely lower frequencies (<2%) in metastatic CRC, and few studies have mentioned the real application of their inhibitors in CRC treatment. Case Description: A 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a BRAF V600E mutation. He']}],\n",
       " [{'name': 'Crizotinib Results',\n",
       "   'value': 'The best clinical response was stable disease in seven patients (29%).',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best clinical response was stable disease in seven patients (29%). CONCLUSIONS: PD-0325901/crizotinib can be given together at pharmacologically-active doses. The MTD for PD-0325901/crizotinib was 8â\\x80\\x89mg B.D (days 1-21) and 200â\\x80\\x89mg B.D continuously in a 28-days cycle. The combination was further explored']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'Twenty-five patients',\n",
       "   'source_id': [1, 5],\n",
       "   'cited_blocks': ['growth. In this study, we assessed safety of MEK1/2 inhibitor PD-0325901 with c-MET inhibitor crizotinib and determined the optimal biological doses for subsequent clinical trials. METHODS: In this dose-escalation phase I trial, patients with advanced solid tumours received PD-0325901 with crizotinib, using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients',\n",
       "    'using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients were recruited in 4 cohorts up to doses of crizotinib 200â\\x80\\x89mg B.D continuously with PD-0325901 8â\\x80\\x89mg B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best']}]]"
      ]
     },
     "execution_count": 271,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=papers0[:2],\n",
    "    fields=[f'Crizotinib Results, string, the effectiveness of treating {fin_condition} with {treatements_eng[0]}',\n",
    "           'Participants, string, number of participants'],#api.DEFAULT_FIELDS,\n",
    "    llm=os.getenv(\"MODEL_NAME\"),\n",
    "    chunk_size=500,\n",
    "    chunk_overlap=200,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 272,
   "id": "c434d7cc-b1e7-4bd2-8026-865118571b0b",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1"
      ]
     },
     "execution_count": 272,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 273,
   "id": "5e61ac04-7dd4-40fa-801b-2c681c814abd",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib Results',\n",
       "   'value': 'Partial response (PR) was achieved when crizotinib was combined with regorafenib and tislelizumab. The treatment resulted in significantly reduced BRAF mutation frequency, and MET amplification and TPM4-ALK fusion became undetectable. The patient achieved 11 months overall survival.',\n",
       "   'source_id': [3, 4, 8],\n",
       "   'cited_blocks': ['reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.',\n",
       "    'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case report.',\n",
       "    '(tislelizumab, dabrafenib, and trametinib), thus he was finally treated with programmed cell death protein 1 (PD-1) inhibitor (tislelizumab), MET/ALK inhibitor (crizotinib) plus multikinase inhibitor (regorafenib). Imageological examinations showed that PR was achieved and ctDNA sequencing results indicated a significantly reduced BRAF mutation frequency, MET amplification and TPM4-ALK fusion were undetectable. NGS analysis of peripheral blood showed a recurrence of the MET acquired resistant']},\n",
       "  {'name': 'Participants',\n",
       "   'value': '1',\n",
       "   'source_id': [0],\n",
       "   'cited_blocks': ['targets in non-small cell lung cancer (NSCLC). However, both of them are of extremely lower frequencies (<2%) in metastatic CRC, and few studies have mentioned the real application of their inhibitors in CRC treatment. Case Description: A 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a BRAF V600E mutation. He']}],\n",
       " [{'name': 'Crizotinib Results',\n",
       "   'value': 'The best clinical response was stable disease in seven patients (29%).',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best clinical response was stable disease in seven patients (29%). CONCLUSIONS: PD-0325901/crizotinib can be given together at pharmacologically-active doses. The MTD for PD-0325901/crizotinib was 8â\\x80\\x89mg B.D (days 1-21) and 200â\\x80\\x89mg B.D continuously in a 28-days cycle. The combination was further explored']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'Twenty-five patients',\n",
       "   'source_id': [1, 5],\n",
       "   'cited_blocks': ['growth. In this study, we assessed safety of MEK1/2 inhibitor PD-0325901 with c-MET inhibitor crizotinib and determined the optimal biological doses for subsequent clinical trials. METHODS: In this dose-escalation phase I trial, patients with advanced solid tumours received PD-0325901 with crizotinib, using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients',\n",
       "    'using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients were recruited in 4 cohorts up to doses of crizotinib 200â\\x80\\x89mg B.D continuously with PD-0325901 8â\\x80\\x89mg B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best']}]]"
      ]
     },
     "execution_count": 273,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fc0adba9-8f0c-48b3-9ac0-e31d659a2303",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "85c23433-d9c9-4d58-ada3-0240ee934f22",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "cbd45cdb-aaae-4b5b-bd60-b5b67a2255b3",
   "metadata": {},
   "source": [
    "### all in one "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "id": "e6851581-7194-4798-a091-468786a6734a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('Colorectal cancer', 'Crizotinib')"
      ]
     },
     "execution_count": 121,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fin_condition, treatements_eng[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "id": "00b85b16-e42a-4131-a1be-853b3fe797aa",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\"Does the title mention 'colorectal cancer'?\",\n",
       " \"Does the title mention 'crizotinib'?\",\n",
       " 'Is there evidence of randomization or control group in the abstract?',\n",
       " 'Are outcomes related to tumor response, progression-free survival, overall survival, or adverse events mentioned in the abstract?']"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ecs['title_criteria']+ecs['content_criteria']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "id": "97dc5bc6-d4a1-400f-8048-4bc264b8b7d7",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>screening</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02568267</td>\n",
       "      <td>Basket Study of Entrectinib (RXDX-101) for the...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This is an open-label, multicenter, global Pha...</td>\n",
       "      <td>[Breast Cancer, Cholangiocarcinoma, Colorectal...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[entrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-3</td>\n",
       "      <td>{'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "      <td>{'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UN...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT06214793</td>\n",
       "      <td>Taletrectinib in Previously Treated Metastatic...</td>\n",
       "      <td>SUSPENDED</td>\n",
       "      <td>The purpose of this study is to evaluate the s...</td>\n",
       "      <td>[Breast Cancer, Metastatic Breast Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[taletrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-3</td>\n",
       "      <td>{'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This phase II MATCH screening and multi-sub-tr...</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "      <td>{'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UN...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "1       False  NCT02568267  Basket Study of Entrectinib (RXDX-101) for the...   \n",
       "2        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "4       False  NCT06214793  Taletrectinib in Previously Treated Metastatic...   \n",
       "5       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "6       False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "\n",
       "           overallStatus                                       briefSummary  \\\n",
       "0                UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "1  ACTIVE_NOT_RECRUITING  This is an open-label, multicenter, global Pha...   \n",
       "2              COMPLETED  This trial is designed to try two new cancer d...   \n",
       "3             RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "4              SUSPENDED  The purpose of this study is to evaluate the s...   \n",
       "5             RECRUITING  The purpose of the study is to investigate the...   \n",
       "6  ACTIVE_NOT_RECRUITING  This phase II MATCH screening and multi-sub-tr...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "1  [Breast Cancer, Cholangiocarcinoma, Colorectal...  INTERVENTIONAL   \n",
       "2                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "4          [Breast Cancer, Metastatic Breast Cancer]  INTERVENTIONAL   \n",
       "5                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "6  [Advanced Lymphoma, Advanced Malignant Solid N...  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0              [NA]                                                 []   \n",
       "1          [PHASE2]                                      [entrectinib]   \n",
       "2          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "4          [PHASE2]                                    [taletrectinib]   \n",
       "5          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "6          [PHASE2]  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \\\n",
       "0                                                NaN            3   \n",
       "1                                                NaN           -3   \n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1   \n",
       "3                                                NaN            0   \n",
       "4                                                NaN           -3   \n",
       "5                                                NaN            3   \n",
       "6                                                NaN            0   \n",
       "\n",
       "                                           screening  \n",
       "0  {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...  \n",
       "1  {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'...  \n",
       "2  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...  \n",
       "3  {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UN...  \n",
       "4  {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'NO'...  \n",
       "5  {'evaluations': ['YES', 'YES', 'UNCERTAIN', 'Y...  \n",
       "6  {'evaluations': ['NO', 'YES', 'UNCERTAIN', 'UN...  "
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies['screening'] = ec_pred\n",
    "#[all_studies.screen_eval>=0]\n",
    "all_studies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "id": "fbc7e828-0a3c-4085-80df-fee7b79486cb",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "resultsct"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ced0195c-835c-4ebe-8f12-e04bbf282a18",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "id": "ad9ea449-2c10-4a9f-be0d-29011056c0e4",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\"Does the content mention 'colorectal cancer'?\",\n",
       " \"Does content mention 'Crizotinib'?\",\n",
       " 'Is there a description of treatement results?']"
      ]
     },
     "execution_count": 136,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[\"Does the content mention 'colorectal cancer'?\",\n",
    "                 \"Does content mention 'Crizotinib'?\", \n",
    "                'Is there a description of treatement results?']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "id": "75abf5c1-4f9c-468e-b77a-75caa8f3d4d1",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "18"
      ]
     },
     "execution_count": 207,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(extracted)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 456,
   "id": "1d31835c-bd81-47ec-b90c-8b62d4e37217",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(13,)"
      ]
     },
     "execution_count": 456,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0].loc[df_papers[0].screen_eval>=total_ev, 'res_extr'].shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 457,
   "id": "6977a908-b44e-4935-a3a0-52657cc1515f",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "df_papers[0]['screening'] = ec_predP\n",
    "df_papers[0]['res_extr'] = ''\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 458,
   "id": "6577f446-2c72-4bc3-99ac-6445a480edb6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>FullText</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_extr</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "      <td>2</td>\n",
       "      <td></td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN'], '...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "      <td>3</td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "      <td>3</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>35343863</td>\n",
       "      <td>Expert opinion on therapeutic patents</td>\n",
       "      <td>2022</td>\n",
       "      <td>Jun</td>\n",
       "      <td></td>\n",
       "      <td>An updated patent review of small-molecule ROS...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...</td>\n",
       "      <td>C-ros oncogene 1 (ROS1) is the sole member of ...</td>\n",
       "      <td>2</td>\n",
       "      <td></td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN'], '...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       PMID                                Journal  Year Month Day  \\\n",
       "0  40526090                             Oncotarget  2025   Jun  17   \n",
       "1  38711893                       AME case reports  2024             \n",
       "2  40140597                            BJC reports  2025   Mar  26   \n",
       "3  35343863  Expert opinion on therapeutic patents  2022   Jun       \n",
       "\n",
       "                                               Title  \\\n",
       "0  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "1  Partial response to crizotinib + regorafenib +...   \n",
       "2  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "3  An updated patent review of small-molecule ROS...   \n",
       "\n",
       "                Publication Type  \\\n",
       "0  Journal Article, Case Reports   \n",
       "1  Case Reports, Journal Article   \n",
       "2                Journal Article   \n",
       "3        Journal Article, Review   \n",
       "\n",
       "                                             Authors  \\\n",
       "0  Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "1  Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "2  Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "3  Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...   \n",
       "\n",
       "                                            Abstract  screen_eval  \\\n",
       "0  Heavily pretreated metastatic colorectal cance...            2   \n",
       "1  Colorectal cancer (CRC) with the Raf murine sa...            3   \n",
       "2  Single-agent MEK1/2 inhibition has been disapp...            3   \n",
       "3  C-ros oncogene 1 (ROS1) is the sole member of ...            2   \n",
       "\n",
       "                                            FullText  \\\n",
       "0                                                      \n",
       "1  Partial response to crizotinib + regorafenib +...   \n",
       "2  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "3                                                      \n",
       "\n",
       "                                           screening res_extr  \n",
       "0  {'evaluations': ['YES', 'YES', 'UNCERTAIN'], '...           \n",
       "1  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "2  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "3  {'evaluations': ['YES', 'YES', 'UNCERTAIN'], '...           "
      ]
     },
     "execution_count": 458,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0].head(4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 459,
   "id": "8e6ac0fc-47de-4b64-bce1-64b687f6fd20",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([{'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'metastatic colorectal cancer', which implies colorectal cancer.\", \"The term 'Crizotinib' is explicitly mentioned in the title and abstract.\", 'There is no detailed description of treatment outcomes; only brief mention of treatment.']},\n",
       "       {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'ascending colon adenocarcinoma', which is part of colorectal cancer.\", \"The term 'Crizotinib' is explicitly mentioned in the title and throughout the abstract and body of the paper.\", 'The paper describes treatment outcomes including partial response to Crizotinib, regorafenib, and PD-1 inhibitor.']},\n",
       "       {'evaluations': ['YES', 'YES', 'YES'], 'rationale': [\"The paper mentions 'advanced solid cancers', but explicitly states 'Patients with Colorectal cancer undergoing treatment with Crizotinib'\", \"The intervention described is 'Crizotinib'\", \"The paper reports 'best clinical response was stable disease in seven patients (29%)', which describes treatment results\"]},\n",
       "       {'evaluations': ['YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The paper mentions 'Colorectal cancer' in the context of ROS1 mutations.\", 'The paper explicitly states that Crizotinib is used for treating ROS1-positive NSCLC, implying its use in colorectal cancer.', 'The paper provides an overview of patents related to ROS1 inhibitors but does not describe detailed treatment outcomes.']}],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 459,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0].head(4).screening.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 550,
   "id": "b9850a26-e8d7-464a-9648-09fa76d2ec77",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>screening</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                   briefTitle  \\\n",
       "2        True  NCT02510001  MEK and MET Inhibition in Colorectal Cancer   \n",
       "\n",
       "  overallStatus                                       briefSummary  \\\n",
       "2     COMPLETED  This trial is designed to try two new cancer d...   \n",
       "\n",
       "                         conditions       studyType    phases  \\\n",
       "2  [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL  [PHASE1]   \n",
       "\n",
       "                            interventions  \\\n",
       "2  [pf-02341066, pd-0325901, binimetinib]   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \\\n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1   \n",
       "\n",
       "                                           screening  \n",
       "2  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...  "
      ]
     },
     "execution_count": 550,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 551,
   "id": "ad96275f-7f7a-4e50-b616-f5e0412ee579",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['```json\\n[\\n    {\\n        \"population\": 30,\\n        \"time_frame\": \"Dose Expansion phase: change from baseline and up to 12 months.\",\\n        \"outcomes\": [\\n            {\\n                \"category_name\": \"Stable Disease\",\\n                \"outcome\": 7\\n            },\\n            {\\n                \"category_name\": \"Progressive Disease\",\\n                \"outcome\": 22\\n            },\\n            {\\n                \"category_name\": \"Early death from malignant disease\",\\n                \"outcome\": 1\\n            }\\n        ]\\n    }\\n]\\n```']"
      ]
     },
     "execution_count": 551,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "resultsct"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 558,
   "id": "d3031eac-3e6d-4ea6-b87e-3bffade67042",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_with_part</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Clinical Respon...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                   briefTitle  \\\n",
       "2        True  NCT02510001  MEK and MET Inhibition in Colorectal Cancer   \n",
       "\n",
       "  overallStatus                                       briefSummary  \\\n",
       "2     COMPLETED  This trial is designed to try two new cancer d...   \n",
       "\n",
       "                         conditions       studyType    phases  \\\n",
       "2  [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL  [PHASE1]   \n",
       "\n",
       "                            interventions  \\\n",
       "2  [pf-02341066, pd-0325901, binimetinib]   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \\\n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1   \n",
       "\n",
       "                                           screening  \\\n",
       "2  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...   \n",
       "\n",
       "                                       res_with_part  \n",
       "2  [{'type': 'PRIMARY', 'title': 'Clinical Respon...  "
      ]
     },
     "execution_count": 558,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_work#.res_with_part#.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 559,
   "id": "1f753ce1-fed0-4c4f-be26-85ba1391b99d",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "\n",
    "ids_ct = to_work#all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults)]#.nctId.values\n",
    "ids_p = df_papers[0][df_papers[0].screen_eval>=total_ev]#.PMID.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 462,
   "id": "41fa2ed4-2f46-4839-a913-8a8e82638ac1",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>screening</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>1</td>\n",
       "      <td>{'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                   briefTitle  \\\n",
       "2        True  NCT02510001  MEK and MET Inhibition in Colorectal Cancer   \n",
       "\n",
       "  overallStatus                                       briefSummary  \\\n",
       "2     COMPLETED  This trial is designed to try two new cancer d...   \n",
       "\n",
       "                         conditions       studyType    phases  \\\n",
       "2  [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL  [PHASE1]   \n",
       "\n",
       "                            interventions  \\\n",
       "2  [pf-02341066, pd-0325901, binimetinib]   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \\\n",
       "2  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            1   \n",
       "\n",
       "                                           screening  \n",
       "2  {'evaluations': ['YES', 'NO', 'UNCERTAIN', 'YE...  "
      ]
     },
     "execution_count": 462,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 178,
   "id": "a5cde2df-7152-48e3-a0eb-48fefdc0a8c8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(1, 12)"
      ]
     },
     "execution_count": 178,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults)].values.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "id": "40200d76-0427-4428-a0bf-2edeab93111e",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>FullText</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_extr</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "      <td>2</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'UNCERTAIN'], '...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       PMID     Journal  Year Month Day  \\\n",
       "0  40526090  Oncotarget  2025   Jun  17   \n",
       "\n",
       "                                               Title  \\\n",
       "0  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "\n",
       "                Publication Type  \\\n",
       "0  Journal Article, Case Reports   \n",
       "\n",
       "                                             Authors  \\\n",
       "0  Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "\n",
       "                                            Abstract  screen_eval  \\\n",
       "0  Heavily pretreated metastatic colorectal cance...            2   \n",
       "\n",
       "                                            FullText  \\\n",
       "0  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "\n",
       "                                           screening res_extr  \n",
       "0  {'evaluations': ['YES', 'YES', 'UNCERTAIN'], '...           "
      ]
     },
     "execution_count": 193,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0].head(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 302,
   "id": "57c99600-b227-47ca-89cb-5a50f4930ceb",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1344"
      ]
     },
     "execution_count": 302,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import itertools\n",
    "a = [i['value'] for i in gg[:,0] if i['value']!='NP' ]\n",
    "#list(itertools.chain.from_iterable(a))\n",
    "len(' '.join(a))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 549,
   "id": "51d22501-d5e0-45d4-9f88-066007bfc084",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['```json\\n[\\n    {\\n        \"population\": 30,\\n        \"time_frame\": \"Dose Expansion phase: change from baseline and up to 12 months.\",\\n        \"outcomes\": [\\n            {\\n                \"category_name\": \"Stable Disease\",\\n                \"outcome\": 7\\n            },\\n            {\\n                \"category_name\": \"Progressive Disease\",\\n                \"outcome\": 22\\n            },\\n            {\\n                \"category_name\": \"Early death from malignant disease\",\\n                \"outcome\": 1\\n            }\\n        ]\\n    }\\n]\\n```']"
      ]
     },
     "execution_count": 549,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "resultsct"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 463,
   "id": "47472c10-5124-46cf-a9b6-3be4e2668f5a",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Condition: Colorectal cancer \n",
      "\n",
      "Treatement 1: Crizotinib\n",
      "\n",
      "Chosen clinical trials:\n",
      "- https://clinicaltrials.gov/study/NCT02510001 'MEK and MET Inhibition in Colorectal Cancer'\n",
      "For the PRIMARY outcome measure \"Clinical Response to Binimetinib Combined With PF-02341066\":\n",
      "\n",
      "- **Population Description**: Evaluable patients include those completing a response assessment post-cycle 1 or experiencing early progression.\n",
      "- **Reporting Status**: POSTED\n",
      "- **Parameter Type**: COUNT_OF_PARTICIPANTS\n",
      "- **Unit of Measure**: Participants\n",
      "- **Time Frame**: Dose expansion phase - changes observed within 12 months\n",
      "\n",
      "**Efficiency Statistics**:\n",
      "- Total participants evaluated: 30\n",
      "- Outcomes:\n",
      "  - Stable Disease: 7 participants\n",
      "  - Progressive Disease: 22 participants\n",
      "  - Early Death from Malignant Disease: 1 participa\n",
      "\n",
      "Chosen Papers:\n",
      "- https://pubmed.ncbi.nlm.nih.gov/38711893 'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic'\n",
      "    Crizotinib Results: 'Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response.'\n",
      "['reported a co-existence of a BRAF V600E mutation, c-MET amplification and TPM4-ALK fusion in a CRC patient. Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response. Furthermore, continuous ctDNA detection appears to be a promising technique to monitor tumor burden, which may provide better clinical decision support during the disease course.']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/40140597 'A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.'\n",
      "    Crizotinib Results: 'The best clinical response was stable disease in seven patients (29%) when treated with crizotinib.'\n",
      "['B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best clinical response was stable disease in seven patients (29%). CONCLUSIONS: PD-0325901/crizotinib can be given together at pharmacologically-active doses. The MTD for PD-0325901/crizotinib was 8â\\x80\\x89mg B.D (days 1-21) and 200â\\x80\\x89mg B.D continuously in a 28-days cycle. The combination was further explored']\n",
      "    Participants: 'Twenty-five patients were recruited.'\n",
      "['using a rolling-6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. Blood samples for pharmacokinetics and skin biopsies were collected. RESULTS: Twenty-five patients were recruited in 4 cohorts up to doses of crizotinib 200â\\x80\\x89mg B.D continuously with PD-0325901 8â\\x80\\x89mg B.D, days 1-21 every 28 days. One in six patients exhibited a dose-limiting toxicity at this dose level. Drug-related adverse events were in keeping with single-agent toxicity profiles. The best']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/41213063 'Radiotherapy-Related Autophagy Genes Predict Prognosis and Reveal Immunoscape Features and Immunotherapeutic Agents in Colorectal Cancer Patients.'\n",
      "    Crizotinib Results: 'Drugs such as Crizotinib were more sensitive to low-risk group.'\n",
      "['populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group. UGT1A6 and IRGM were significantly upregulated in tumor group as revealed by qRT-PCR. This study constructed a new prognostic model for CRC patients based on RRAGs, and a series of analysis']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/34898475 'Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.'\n",
      "    Crizotinib Results: 'AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs.'\n",
      "['Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs. CONCLUSIONS: Overall, this IRGs-based signature not only afforded a useful tool for determining the prognosis and evaluating the TIME features of CRCs, but also shed new light on tailoring CRCs with precise treatment.', 'identify agents with subclass-specific efficacy. RESULTS: The established signature was shown to be a promising biomarker for evaluating clinical outcomes in CRC. The immune risk score as calculated by this classifier was significantly correlated with over-riding malignant phenotypes and immunophenotypes. Further analyses demonstrated that CRCs with low immune risk scores achieved better therapeutic benefits from immunotherapy, while AZD4547, Cytochalasin B and S-crizotinib might have potential']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/37418240 'Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy.'\n",
      "    Crizotinib Results: 'Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors.'\n",
      "['by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional', 'tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/36316649 'Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data.'\n",
      "    Participants: '23'\n",
      "['(FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs according to the efficiency score calculated using target genes expression and molecular pathway activation data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in NRAS, seven others had mutated', 'data. The patients had primary and metastatic CRC with metastases in liver, peritoneum, brain, adrenal gland, lymph nodes and ovary. Two patients had mutations in NRAS, seven others had mutated KRAS gene. Patients were treated by aflibercept, bevacizumab, bortezomib, cabozantinib, cetuximab, crizotinib, denosumab, panitumumab and regorafenib as monotherapy or in combination with chemotherapy, and information on the success of totally 39 lines of therapy was collected. RESULTS: Oncobox drug', 'BACKGROUND: Overall survival of advanced colorectal cancer (CRC) patients remains poor, and gene expression analysis could potentially complement detection of clinically relevant mutations to personalize CRC treatments. METHODS: We performed RNA sequencing of formalin-fixed, paraffin-embedded (FFPE) cancer tissue samples of 23 CRC patients and interpreted the data obtained using bioinformatic method Oncobox for expression-based rating of targeted therapeutics. Oncobox ranks cancer drugs']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/40369167 'ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosis.'\n",
      "    Crizotinib Results: 'Crizotinib selectively inhibits the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.'\n",
      "['colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/36053834 'ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.'\n",
      "    Crizotinib Results: 'Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies.'\n",
      "['induced a rapid and sustained partial response. After 15â\\x80\\x89months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements define a small, yet therapeutically actionable molecular subgroup of MSS CRC. In summary, the high prevalence of GOPC-ROS1 and noncanonical ROS1 fusions pose diagnostic challenges. We advocate NGS-based comprehensive molecular profiling of MSS CRCs that are wild type for RAS and BRAF and patient', 'exclusively in microsatellite stable (MSS) CRCs. KRAS mutations were significantly less abundant in ROS1-rearranged vs ROS1 wild type cases. The index patient presented with chemotherapy-refractory metastatic right-sided colon cancer harboring GOPC-ROS1. Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15â\\x80\\x89months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies. ROS1 rearrangements']\n",
      "    Participants: '40589'\n",
      "['c-Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of ROS1-driven CRC. We analyzed a clinical dataset of 40â\\x80\\x89589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response', \"40â\\x80\\x89589 patients with CRC for ROS1 genomic rearrangements and their associated genomic characteristics (Foundation Medicine, Inc [FMI]). We moreover report the disease course and treatment response of an index patient with ROS1-rearranged metastatic CRC. ROS1 genomic rearrangements were identified in 34 (0.08%) CRC samples. GOPC-ROS1 was the most common ROS1 fusion identified (11 samples), followed by TTC28-ROS1 (3 samples). Four novel 5' gene partners of ROS1 were identified (MCM9, SRPK1,\"]\n",
      "- https://pubmed.ncbi.nlm.nih.gov/40211189 'A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).'\n",
      "    Crizotinib Results: 'Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.'\n",
      "['allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).', 'MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baselineÂ\\xa0RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baselineÂ\\xa0KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940']\n",
      "    Participants: 'Twenty patients were recruited in 3 cohorts in the dose escalation. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion.'\n",
      "['hybridisation (ISH) and MET DNA-ISH analyses were collected. RESULTS: Twenty patients were recruited in 3 cohorts in the dose escalation. The MTD was binimetinib 30 mg B.D, days 1-21 every 28 days, with crizotinib 250 mg O.D continuously. Dose-limiting toxicities included grade â\\x89¥â\\x80\\x893 transaminitis, creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of', 'creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of target engagement. Across the entire study, the most frequent treatment-related adverse events (TR-AE) were rash (80.4%), fatigue (53.4%) and diarrhoea (51.8%) with grade â\\x89¥â\\x80\\x893 TR-AE occurring in 44.6%. Best clinical response within the RASMT CRC cohort was stable disease in seven patients (24%). Tumour']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/38212428 'Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.'\n",
      "    Crizotinib Results: 'Crizotinib effectively overcomes HGF-induced cetuximab resistance.'\n",
      "['Conversely, HGF overexpression was necessary and sufficient to induce cetuximab resistance and loss of polarity. Moreover, HGF-induced cetuximab resistance could be overcome by the downstream MET inhibitor, crizotinib, and upstream protease inhibitors. Additionally, HAI-1, an endogenous inhibitor of HGF proteases, (i) was downregulated in CRC, (ii) exhibited increased genomic methylation that correlated with poor prognosis, (iii) HAI-1 expression correlated with cetuximab response in a panel of']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/37773318 'ALK fusions in the pan-cancer setting: another tumor-agnostic target?'\n",
      "- https://pubmed.ncbi.nlm.nih.gov/38378070 'TBX15 and SDHB expression changes in colorectal cancer serve as potential prognostic biomarkers.'\n",
      "    Crizotinib Results: 'The expression level of SDHB was correlated with drug sensitivity to Crizotinib.'\n",
      "['healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association between alterations in the expression of genes such as HOXC6, HOXC13, HOXC8, TBX15, SDHB, COX5A, and UQCRC1 and increased mortality rates in CRC patients. As revealed by the PPI network, these genes exhibited the most connections with other genes linked to survival.', 'Applying the risk model developed with the mentioned genes revealed a markedly higher incidence of deceased patients in the high-risk group compared to the low-risk group. RT-qPCR results indicated a decrease in SDHB expression and an elevation in TBX15 levels in cancer samples relative to adjacent healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association']\n",
      "- https://pubmed.ncbi.nlm.nih.gov/37543570 'Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis.'\n",
      "    Crizotinib Results: 'The combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.'\n",
      "['antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer. CONCLUSION: Our findings illuminate the molecular mechanisms underlying EpCAM signaling promotion of colon cancer metastasis, further suggesting that the combination of EpAb2-6 and crizotinib may be an effective strategy for treating cancer patients with high EpCAM expression.', 'epithelial-to-mesenchymal transition and metastatic potential of colon cancer cells by activating ERK and FAK-AKT signaling pathways, and it further stabilizes active Î²-catenin and Snail proteins by decreasing GSK3Î² activity. Finally, we show that the combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer. CONCLUSION: Our']\n"
     ]
    }
   ],
   "source": [
    "print(f'Condition: {fin_condition} \\n\\nTreatement 1: {treatements_eng[0]}')\n",
    "print(f'\\nChosen clinical trials:')\n",
    "for i, ext_res in zip(ids_ct.values,resultsct):\n",
    "    print('- https://clinicaltrials.gov/study/'+i[1]+' '+f\"'{i[2]}'\")\n",
    "    print(ext_res)\n",
    "print(f'\\nChosen Papers:')\n",
    "for i, ext_res in zip(ids_p.values, extracted_gm):\n",
    "    print('- https://pubmed.ncbi.nlm.nih.gov/'+i[0]+' '+f\"'{i[5]}'\")\n",
    "    for field in ext_res:\n",
    "        if field['source_id']:\n",
    "            print(f\"    {field['name'].replace('_',' ')}: '{field['value']}'\")\n",
    "            print(field['cited_blocks'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "beecc6c5-2077-4e89-8980-ae83b7895bc3",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 467,
   "id": "4b938a22-404f-493d-bd86-f32257d6bc47",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>FullText</th>\n",
       "      <th>screening</th>\n",
       "      <th>res_extr</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "      <td>3</td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "      <td>3</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "      <td>3</td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>34898475</td>\n",
       "      <td>Aging</td>\n",
       "      <td>2021</td>\n",
       "      <td>Dec</td>\n",
       "      <td>13</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...</td>\n",
       "      <td>Globally, colorectal cancer (CRC) is one of th...</td>\n",
       "      <td>3</td>\n",
       "      <td>Identification of a novel immune signature for...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>37418240</td>\n",
       "      <td>ACS applied materials &amp; interfaces</td>\n",
       "      <td>2023</td>\n",
       "      <td>Jul</td>\n",
       "      <td>19</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen</td>\n",
       "      <td>Colorectal cancer (CRC) is presently the third...</td>\n",
       "      <td>3</td>\n",
       "      <td>Albumin-Based Cyanine Crizotinib Conjugate Nan...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>36316649</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Oct</td>\n",
       "      <td>31</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Maxim Sorokin, Marianna Zolotovskaia, Daniil N...</td>\n",
       "      <td>Overall survival of advanced colorectal cancer...</td>\n",
       "      <td>3</td>\n",
       "      <td>Personalized targeted therapy prescription in ...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "      <td>3</td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>36053834</td>\n",
       "      <td>International journal of cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Dec</td>\n",
       "      <td>15</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Dilara Akhoundova, Saskia Hussung, Smruthy Siv...</td>\n",
       "      <td>c-Ros oncogene 1, receptor tyrosine kinase (RO...</td>\n",
       "      <td>3</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "      <td>3</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>38212428</td>\n",
       "      <td>Cellular and molecular life sciences : CMLS</td>\n",
       "      <td>2024</td>\n",
       "      <td>Jan</td>\n",
       "      <td>12</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Vivian Truong Jones, Ramona Graves-Deal, Zheng...</td>\n",
       "      <td>Although amplifications and mutations in recep...</td>\n",
       "      <td>3</td>\n",
       "      <td>Inhibition of autocrine HGF maturation overcom...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>37773318</td>\n",
       "      <td>NPJ precision oncology</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>29</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Aditya Shreenivas, Filip Janku, Mohamed A Goud...</td>\n",
       "      <td>Anaplastic lymphoma kinase (ALK) alterations (...</td>\n",
       "      <td>3</td>\n",
       "      <td>ALK fusions in the pan-cancer setting: another...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>38378070</td>\n",
       "      <td>Experimental and molecular pathology</td>\n",
       "      <td>2024</td>\n",
       "      <td>Apr</td>\n",
       "      <td></td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Melika Golozar, Ali Valipour Motlagh, Mohammad...</td>\n",
       "      <td>Alterations in the expression of certain genes...</td>\n",
       "      <td>3</td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>37543570</td>\n",
       "      <td>Journal of translational medicine</td>\n",
       "      <td>2023</td>\n",
       "      <td>Aug</td>\n",
       "      <td>05</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>Journal Article, Research Support, Non-U.S. Gov't</td>\n",
       "      <td>Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) is k...</td>\n",
       "      <td>3</td>\n",
       "      <td>Epithelial cell adhesion molecule (EpCAM) regu...</td>\n",
       "      <td>{'evaluations': ['YES', 'YES', 'YES'], 'ration...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        PMID                                            Journal  Year Month  \\\n",
       "1   38711893                                   AME case reports  2024         \n",
       "2   40140597                                        BJC reports  2025   Mar   \n",
       "4   41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "6   34898475                                              Aging  2021   Dec   \n",
       "8   37418240                 ACS applied materials & interfaces  2023   Jul   \n",
       "9   36316649                                         BMC cancer  2022   Oct   \n",
       "10  40369167                     Cell death and differentiation  2025   Nov   \n",
       "11  36053834                    International journal of cancer  2022   Dec   \n",
       "13  40211189                                         BMC cancer  2025   Apr   \n",
       "14  38212428        Cellular and molecular life sciences : CMLS  2024   Jan   \n",
       "16  37773318                             NPJ precision oncology  2023   Sep   \n",
       "17  38378070               Experimental and molecular pathology  2024   Apr   \n",
       "19  37543570                  Journal of translational medicine  2023   Aug   \n",
       "\n",
       "   Day                                              Title  \\\n",
       "1       Partial response to crizotinib + regorafenib +...   \n",
       "2   26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "4       Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "6   13  Identification of a novel immune signature for...   \n",
       "8   19  Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   31  Personalized targeted therapy prescription in ...   \n",
       "10      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11  15  ROS1 genomic rearrangements are rare actionabl...   \n",
       "13  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  12  Inhibition of autocrine HGF maturation overcom...   \n",
       "16  29  ALK fusions in the pan-cancer setting: another...   \n",
       "17      TBX15 and SDHB expression changes in colorecta...   \n",
       "19  05  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                     Publication Type  \\\n",
       "1                       Case Reports, Journal Article   \n",
       "2                                     Journal Article   \n",
       "4                                     Journal Article   \n",
       "6   Journal Article, Research Support, Non-U.S. Gov't   \n",
       "8                                     Journal Article   \n",
       "9                                     Journal Article   \n",
       "10                                    Journal Article   \n",
       "11                                    Journal Article   \n",
       "13           Journal Article, Clinical Trial, Phase I   \n",
       "14                                    Journal Article   \n",
       "16                            Journal Article, Review   \n",
       "17                                    Journal Article   \n",
       "19  Journal Article, Research Support, Non-U.S. Gov't   \n",
       "\n",
       "                                              Authors  \\\n",
       "1   Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "2   Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "4                    Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "6   Yan Li, Yiyi Li, Zijin Xia, Dun Zhang, Xiaomei...   \n",
       "8        Zhuang Hu, Ruihan Li, Xinyue Cui, Zilin Chen   \n",
       "9   Maxim Sorokin, Marianna Zolotovskaia, Daniil N...   \n",
       "10  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "11  Dilara Akhoundova, Saskia Hussung, Smruthy Siv...   \n",
       "13  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "14  Vivian Truong Jones, Ramona Graves-Deal, Zheng...   \n",
       "16  Aditya Shreenivas, Filip Janku, Mohamed A Goud...   \n",
       "17  Melika Golozar, Ali Valipour Motlagh, Mohammad...   \n",
       "19  Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Pan...   \n",
       "\n",
       "                                             Abstract  screen_eval  \\\n",
       "1   Colorectal cancer (CRC) with the Raf murine sa...            3   \n",
       "2   Single-agent MEK1/2 inhibition has been disapp...            3   \n",
       "4   Numerous genes have been associated with color...            3   \n",
       "6   Globally, colorectal cancer (CRC) is one of th...            3   \n",
       "8   Colorectal cancer (CRC) is presently the third...            3   \n",
       "9   Overall survival of advanced colorectal cancer...            3   \n",
       "10  ARID1A, a subunit of the SWI/SNF chromatin-rem...            3   \n",
       "11  c-Ros oncogene 1, receptor tyrosine kinase (RO...            3   \n",
       "13  Targeting RAS mutant (MT) colorectal cancer (C...            3   \n",
       "14  Although amplifications and mutations in recep...            3   \n",
       "16  Anaplastic lymphoma kinase (ALK) alterations (...            3   \n",
       "17  Alterations in the expression of certain genes...            3   \n",
       "19  Epithelial cell adhesion molecule (EpCAM) is k...            3   \n",
       "\n",
       "                                             FullText  \\\n",
       "1   Partial response to crizotinib + regorafenib +...   \n",
       "2   A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "4   Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "6   Identification of a novel immune signature for...   \n",
       "8   Albumin-Based Cyanine Crizotinib Conjugate Nan...   \n",
       "9   Personalized targeted therapy prescription in ...   \n",
       "10  ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "11  ROS1 genomic rearrangements are rare actionabl...   \n",
       "13  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "14  Inhibition of autocrine HGF maturation overcom...   \n",
       "16  ALK fusions in the pan-cancer setting: another...   \n",
       "17  TBX15 and SDHB expression changes in colorecta...   \n",
       "19  Epithelial cell adhesion molecule (EpCAM) regu...   \n",
       "\n",
       "                                            screening res_extr  \n",
       "1   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "2   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "4   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "6   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "8   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "9   {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "10  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "11  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "13  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "14  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "16  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "17  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           \n",
       "19  {'evaluations': ['YES', 'YES', 'YES'], 'ration...           "
      ]
     },
     "execution_count": 467,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0][df_papers[0].screen_eval>=3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 407,
   "id": "e174b630-ec0b-40f5-bd32-f544950f4ad4",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'COMPLETED'"
      ]
     },
     "execution_count": 407,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ids_ct.values[0][3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 421,
   "id": "972f6c2c-b000-4dcf-8440-d4cc098c918b",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'name': 'Crizotinib_Results',\n",
       "  'value': 'NP',\n",
       "  'source_id': [],\n",
       "  'cited_blocks': []},\n",
       " {'name': 'Participants', 'value': 'NP', 'source_id': [], 'cited_blocks': []}]"
      ]
     },
     "execution_count": 421,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extracted_gm[10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 528,
   "id": "2230986a-dd55-4e42-a703-20d2796e7f5e",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'population': 30,\n",
       "   'time_frame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "   'outcomes': [{'category_name': 'Stable Disease', 'outcome': 7},\n",
       "    {'category_name': 'Progressive Disease', 'outcome': 22},\n",
       "    {'category_name': 'Early death from malignant disease', 'outcome': 1}]}]]"
      ]
     },
     "execution_count": 528,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_resultsct = parse_json_outputs(resultsct)\n",
    "json_resultsct"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 544,
   "id": "2c4627f4-5b8e-4463-afc6-456f044e5bcc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'PRIMARY',\n",
       "  'title': 'Clinical Response to Binimetinib Combined With PF-02341066',\n",
       "  'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD',\n",
       "  'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "  'unitOfMeasure': 'Participants',\n",
       "  'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '30'}]}],\n",
       "  'classes': [{'categories': [{'title': 'Stable Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '7'}]},\n",
       "     {'title': 'Progressive Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '22'}]},\n",
       "     {'title': 'Early death from malignant disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]}]"
      ]
     },
     "execution_count": 544,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_work.res_with_part.values[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 548,
   "id": "45df4511-2c18-48de-bf71-431946111415",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'PRIMARY',\n",
       "  'title': 'Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066',\n",
       "  'description': 'Determine maximum tolerated dose (MTD) of PD-0325901 with Crizotinib (PF-02341066) according to toxicities graded by NCI CTCAE v4.03, in patients with advanced solid tumours.',\n",
       "  'populationDescription': 'Evaluable patients are those patients who completed cycle 1 or withdrew early for experiencing a DLT. Four patients withdrew early from the study not for DLTs, consequently 21 patients remained for the dose escalation primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'NUMBER',\n",
       "  'unitOfMeasure': 'Dose Limiting Toxicities (DLTs)',\n",
       "  'timeFrame': 'Dose Escalation Phase: treatment Cycle 1 28 days (plus 7 day run-in for PD-0325901/PF-02341066 combination)',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Cohort 1 Dose Level 1',\n",
       "    'description': 'Crizotinib (PF-02341066) 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Cohort 2 Dose Level 2',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Cohort 3 Dose Level 3',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Cohort 4 Dose Level 4',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '4'},\n",
       "     {'groupId': 'OG003', 'value': '6'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0'},\n",
       "       {'groupId': 'OG001', 'value': '0'},\n",
       "       {'groupId': 'OG002', 'value': '0'},\n",
       "       {'groupId': 'OG003', 'value': '1'}]}]}],\n",
       "  'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'],\n",
       "    'nonInferiorityType': 'OTHER',\n",
       "    'otherAnalysisDescription': 'The primary dose escalation analysis was to find the MTD, which was defined as the dose of PF-02341066 in combination with PD-0325901 at which no more than one out of six patients experience a DLT (dose limiting toxicity). The DLT was based on observed toxicity in cycle 1, and was defined as an almost certainly or probably drug-related adverse event to PF-02341066 and/or PD-0325901.\\n\\nThe MTD for the PD 0325901/PF-02341066 combination was 8mg BD(days1-21) and 200mg BD continuously in a 28 day cycle (Dose Level 4).'}]},\n",
       " {'type': 'PRIMARY',\n",
       "  'title': 'Clinical Response to Binimetinib Combined With PF-02341066',\n",
       "  'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD',\n",
       "  'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "  'unitOfMeasure': 'Participants',\n",
       "  'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '30'}]}],\n",
       "  'classes': [{'categories': [{'title': 'Stable Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '7'}]},\n",
       "     {'title': 'Progressive Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '22'}]},\n",
       "     {'title': 'Early death from malignant disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]},\n",
       " {'type': 'PRIMARY',\n",
       "  'title': 'Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066',\n",
       "  'description': 'To determine the maximal tolerated dose (MTD) of Binimetinib with PF-02341066 according to toxicities graded by NCI CTCAE V4.03 in cycle 1 of treatment.',\n",
       "  'populationDescription': 'Evaluable patients are those patients who completed cycle 1 or who withdraw early for experiencing a DLT. Three patients withdrew early from the study not for DLTs, consequently 17 of the 20 recruited patients are evaluable for this analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'NUMBER',\n",
       "  'unitOfMeasure': 'Dose Limiting Toxicities (DLTs)',\n",
       "  'timeFrame': 'Dose Escalation Phase: treatment Cycle 1 28 days',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Cohort 7 Dose Level 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Cohort 12 Dose Level 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Cohort 13 Dose Level 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '6'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2'},\n",
       "       {'groupId': 'OG001', 'value': '2'},\n",
       "       {'groupId': 'OG002', 'value': '1'}]}]}],\n",
       "  'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002'],\n",
       "    'groupDescription': 'The primary dose escalation analysis was to find the MTD, which was defined as the dose of PF-02341066 in combination with Binimetinib at which no more than one out of six patients experience a DLT (dose limiting toxicity). The DLT was based on observed toxicity in cycle 1, and was defined as an almost certainly or probably drug-related adverse event to PF-02341066 and/or Binimetinib.',\n",
       "    'nonInferiorityType': 'OTHER',\n",
       "    'otherAnalysisDescription': 'Binimetinib 30mg BD on days 1 - 21 every 28 days with Crizotinib 250 mg OD continuously is the MTD, the recommended dose and schedule for further evaluation in our and other trials.\\n\\nThis was as only one DLT was experienced in 6 evaluable patients at this final dose escalation level.'}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901.',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma Cmax of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation:Up to 12 months. PK profile at pre-dose and up to 10 hrs post dose on Day - 1, Day 21 and Day 28 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '77.8',\n",
       "        'spread': '41.9'},\n",
       "       {'groupId': 'OG001', 'value': '129', 'spread': '50.5'},\n",
       "       {'groupId': 'OG002', 'value': '226', 'spread': '66.1'},\n",
       "       {'groupId': 'OG003', 'value': '484', 'spread': '84.1'}]}]},\n",
       "   {'title': 'Summary PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '70.3',\n",
       "        'spread': '43.1'},\n",
       "       {'groupId': 'OG001', 'value': '62.3', 'spread': '34.7'},\n",
       "       {'groupId': 'OG002', 'value': '135', 'spread': '36.2'},\n",
       "       {'groupId': 'OG003', 'value': '219', 'spread': '93.6'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '53.1',\n",
       "        'spread': '30.7'},\n",
       "       {'groupId': 'OG001', 'value': '59.4', 'spread': '35.3'},\n",
       "       {'groupId': 'OG002', 'value': '117', 'spread': '44.3'},\n",
       "       {'groupId': 'OG003', 'value': '195', 'spread': '55.6'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '52.0',\n",
       "        'spread': '24.8'},\n",
       "       {'groupId': 'OG001', 'value': '46.7', 'spread': '29.5'},\n",
       "       {'groupId': 'OG002', 'value': '103', 'spread': '40.5'},\n",
       "       {'groupId': 'OG003', 'value': '117', 'spread': '57.6'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '170',\n",
       "        'spread': '81.3'},\n",
       "       {'groupId': 'OG001', 'value': '300', 'spread': '53.9'},\n",
       "       {'groupId': 'OG002', 'value': '235', 'spread': '35.3'},\n",
       "       {'groupId': 'OG003', 'value': '269', 'spread': '157'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '164',\n",
       "        'spread': '59.8'},\n",
       "       {'groupId': 'OG001', 'value': '281', 'spread': '118'},\n",
       "       {'groupId': 'OG002', 'value': '341', 'spread': '133'},\n",
       "       {'groupId': 'OG003', 'value': '275', 'spread': '105'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Minimum Plasma Trough Concentration (Cmin) for PF-02341066 and PD-0325901',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma Cmin of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'PK analysis performed on Cycle 1 Day -1 and Day 21 only for PD-0325901 and PD-0315209 and on Cycle 1 Day 21 and Day 28 only for PF-02341066 according to dosing schedule Day -7 to Day 21 for PD-0325901 and Day 1 to Day 28 for PF-02341066.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation:Up to 12 mths. Cycle 1 PK profile up to 10 hrs post dose on Day -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '23.6',\n",
       "        'spread': '9.3'},\n",
       "       {'groupId': 'OG001', 'value': '18.7', 'spread': '5.83'},\n",
       "       {'groupId': 'OG002', 'value': '37.9', 'spread': '5.89'},\n",
       "       {'groupId': 'OG003', 'value': '89.2', 'spread': '24.3'}]}]},\n",
       "   {'title': 'Summary PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '26.0',\n",
       "        'spread': '16.1'},\n",
       "       {'groupId': 'OG001', 'value': '17.6', 'spread': '3.12'},\n",
       "       {'groupId': 'OG002', 'value': '35.8', 'spread': '13.3'},\n",
       "       {'groupId': 'OG003', 'value': '45.4', 'spread': '13.0'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '44.0',\n",
       "        'spread': '29.6'},\n",
       "       {'groupId': 'OG001', 'value': '40.4', 'spread': '26.3'},\n",
       "       {'groupId': 'OG002', 'value': '80.6', 'spread': '22.1'},\n",
       "       {'groupId': 'OG003', 'value': '147', 'spread': '47.7'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '41.3',\n",
       "        'spread': '23.3'},\n",
       "       {'groupId': 'OG001', 'value': '37.3', 'spread': '25.4'},\n",
       "       {'groupId': 'OG002', 'value': '66.6', 'spread': '18.8'},\n",
       "       {'groupId': 'OG003', 'value': '73.1', 'spread': '31.7'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '115',\n",
       "        'spread': '64.4'},\n",
       "       {'groupId': 'OG001', 'value': '186', 'spread': '55.8'},\n",
       "       {'groupId': 'OG002', 'value': '172', 'spread': '43.6'},\n",
       "       {'groupId': 'OG003', 'value': '203', 'spread': '121'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '119',\n",
       "        'spread': '44.4'},\n",
       "       {'groupId': 'OG001', 'value': '183', 'spread': '66.3'},\n",
       "       {'groupId': 'OG002', 'value': '259', 'spread': '96.0'},\n",
       "       {'groupId': 'OG003', 'value': '211', 'spread': '78.6'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Area Under the Plasma Concentration Versus Time Curve (AUC) for PF-02341066 and PD-0325901(and Its Metabolite)',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma AUC of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'PK analysis performed on Cycle 1 Day -1 and Day 21 only for PD-0325901 and PD-0315209 and on Cycle 1 Day 21 and Day 28 only for PF-02341066 according to dosing schedule Day -7 to Day 21 for PD-0325901 and Day 1 to Day 28 for PF-02341066.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng*hr/mL',\n",
       "  'timeFrame': 'Dose Escalation:Up to12 months. Cycle 1 PK profile up to 10 hrs on Day -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '400',\n",
       "        'spread': '117'},\n",
       "       {'groupId': 'OG001', 'value': '432', 'spread': '129'},\n",
       "       {'groupId': 'OG002', 'value': '796', 'spread': '120'},\n",
       "       {'groupId': 'OG003', 'value': '1907', 'spread': '254'}]}]},\n",
       "   {'title': 'Summary PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '400',\n",
       "        'spread': '160'},\n",
       "       {'groupId': 'OG001', 'value': '301', 'spread': '106'},\n",
       "       {'groupId': 'OG002', 'value': '683', 'spread': '51.7'},\n",
       "       {'groupId': 'OG003', 'value': '1162', 'spread': '190'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '498',\n",
       "        'spread': '304'},\n",
       "       {'groupId': 'OG001', 'value': '508', 'spread': '318'},\n",
       "       {'groupId': 'OG002', 'value': '954', 'spread': '301'},\n",
       "       {'groupId': 'OG003', 'value': '1726', 'spread': '501'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '487',\n",
       "        'spread': '226'},\n",
       "       {'groupId': 'OG001', 'value': '413', 'spread': '273'},\n",
       "       {'groupId': 'OG002', 'value': '831', 'spread': '246'},\n",
       "       {'groupId': 'OG003', 'value': '1092', 'spread': '228'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1341',\n",
       "        'spread': '688'},\n",
       "       {'groupId': 'OG001', 'value': '2115', 'spread': '448'},\n",
       "       {'groupId': 'OG002', 'value': '2034', 'spread': '397'},\n",
       "       {'groupId': 'OG003', 'value': '2336', 'spread': '1414'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1378',\n",
       "        'spread': '567'},\n",
       "       {'groupId': 'OG001', 'value': '2358', 'spread': '905'},\n",
       "       {'groupId': 'OG002', 'value': '2919', 'spread': '1207'},\n",
       "       {'groupId': 'OG003', 'value': '2402', 'spread': '873'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma Oral Clearance for PF-02341066 and PD-0325901',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma oral clearance of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Oral clearance could not be calculated, as pre-specified, as bioavailability and full Area Under the Curve (AUC) data, specifically 0 to ∞ (infinity), was not available. Even though AUC data is available on Days -1, 21 and 28 for 0-10 hours, residual drug at time of next twice daily dose administration meant oral clearance could not be determined for most patients.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'timeFrame': 'Dose Escalation:Up to12 months.PK profile at Cycle 1 up to 10 hrs post dose on Days -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib (PF-02341066) 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '0'},\n",
       "     {'groupId': 'OG001', 'value': '0'},\n",
       "     {'groupId': 'OG002', 'value': '0'},\n",
       "     {'groupId': 'OG003', 'value': '0'}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Progression Free Survival (Dose Expansion)',\n",
       "  'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \\\\>=20% increase in the sum of diameters of target lesions (also demonstrating an absolute increase of at least 5mm) or the appearance of new lesions.',\n",
       "  'populationDescription': 'All 37 registered patients are included in this analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of progression or date of death, assessed up to study completion, an average of 6 months (dose expansion)).',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'All of the patients registered for this expansion phase are included in this survival analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '37'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1.81',\n",
       "        'lowerLimit': '1.51',\n",
       "        'upperLimit': '1.91'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Overall Survival (Dose Expansion)',\n",
       "  'description': 'Overall survival (dose expansion).',\n",
       "  'populationDescription': 'All 37 registered patients are included in this analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of death, assessed up to study completion, an average of 6 months (dose escalation).',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'All of the patients registered for this expansion phase are included in this survival analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '37'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '5.42',\n",
       "        'lowerLimit': '2.79',\n",
       "        'upperLimit': '7.33'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic (PK) Peak Plasma Concentration (Cmax) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetic (PK) peak plasma concentration (Cmax) of PF-02341066 and Binimetinib and its metabolite, AR00426032, in blood.',\n",
       "  'populationDescription': 'Data not available for 2 patients in PF-02341066 outcome measure and 8 patients each in binimetinib and AR00426032 outcome measures',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Expansion: PK profile up to 10 hrs at Cycle 1 Day 21',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '24'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '197',\n",
       "        'spread': '112'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '357',\n",
       "        'spread': '171'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '22.7',\n",
       "        'spread': '16.0'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Minimum Plasma Trough Concentration (Cmin) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic plasma trough concentration Cmin of PF-02341066 and Binimetinib and its metabolite, AR00426032, in blood.',\n",
       "  'populationDescription': 'No data available for 8 patients for binimetinib outcome and for 16 patients in AR00426032 outcome measure.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'Cmin (ng/ml)',\n",
       "  'timeFrame': 'Dose Expansion: PK profile on Cycle 1 Day 21 up to 10 hrs .',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '24'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '149',\n",
       "        'spread': '85.3'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '103',\n",
       "        'spread': '58.5'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '12.1',\n",
       "        'spread': '4.80'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Area Under the Plasma Concentration Versus Time Curve (AUC) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic area under the plasma concentration versus time curve (AUC) of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for 2 patients in PF-02341066 outcome measure, 8 for binimetinib outcome measure and 13 for AR00426032 outcome measure',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng.h/ml (0-10h )',\n",
       "  'timeFrame': 'Dose Expansion: PK profile on Cycle 1 Day 21 up to 10 hrs',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '24'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '3478',\n",
       "        'spread': '2083'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2129',\n",
       "        'spread': '1152'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '194',\n",
       "        'spread': '85.2'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Oral Clearance for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic (PK) oral clearance of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'Oral clearance could not be calculated, as pre-specified, as bioavailability and full Area Under the Curve (AUC) data, specifically 0 to ∞ (infinity), was not available. Even though AUC data is available on Day 21 for 0-10 hours, residual drug at time of next twice daily dose administration meant oral clearance could not be determined for most patients.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'timeFrame': 'Dose Escalation: PK profile at up to 10 hrs post dose on Cycle 1 Day 21',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. Crizotinib (PF-02341066) 200mg BD continuous administration'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. Crizotinib (PF-02341066) 250mg OD continuous administration'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. Crizotinib (PF-02341066) 200mg BD continuous administration'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '0'},\n",
       "     {'groupId': 'OG001', 'value': '0'},\n",
       "     {'groupId': 'OG002', 'value': '0'}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With PD-0325901 or Binimetinib in Paired Skin Biopsies - Measurement of phosphoMEK1/2.',\n",
       "  'description': 'Measurement of phosphoMEK1/2 in skin biopsies to investigate the pharmacodynamic (PD) effect of PF-02341066 in combination with PD-0325901 or Binimetinib in paired skin biopsies to determine objective response to treatment.\\n\\nWestern blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'For the Dose Escalation phases of the study the paired skin biopsies were collected and analysed for eligible patients (achieving end of Cycle 1) where available. Samples for Collection of paired skin biopsies were mandatory for first 10 patients registered to the expansion phase of the study only. An additional 3 samples were collected and analysed in the Expansion phase due to multiple screening performed over several participating sites.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Escalation and Expansion: at baseline and Cycle1, D15.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG004',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration. PF-02341066 200mg BD continuous administration'},\n",
       "   {'id': 'OG005',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG006',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG007',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '5'},\n",
       "     {'groupId': 'OG003', 'value': '5'},\n",
       "     {'groupId': 'OG004', 'value': '5'},\n",
       "     {'groupId': 'OG005', 'value': '5'},\n",
       "     {'groupId': 'OG006', 'value': '3'},\n",
       "     {'groupId': 'OG007', 'value': '13'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '3.74',\n",
       "        'spread': '2.366'},\n",
       "       {'groupId': 'OG001', 'value': '1.89', 'spread': '1.425'},\n",
       "       {'groupId': 'OG002', 'value': '6.52', 'spread': '5.982'},\n",
       "       {'groupId': 'OG003', 'value': '5.74', 'spread': '3.067'},\n",
       "       {'groupId': 'OG004', 'value': '1.93', 'spread': '0.844'},\n",
       "       {'groupId': 'OG005', 'value': '1.03', 'spread': '0.28'},\n",
       "       {'groupId': 'OG006', 'value': '0.93', 'spread': '0.418'},\n",
       "       {'groupId': 'OG007', 'value': '1.11', 'spread': '0.697'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With PD-0325901 or Binimetinib in Paired Tumour Biopsies (Where Possible).',\n",
       "  'description': 'Measurement of pSTAT3Y705 to investigate the pharmacodynamic (PD) effect of PF-02341066 in combination with PD-0325901 or Binimetinib in paired tumour biopsies to determine objective response to treatment. Western blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'Biopsies optional for this phase and only consented to by 2 patients for the combination of PF-02341066 with Binimetinib.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Escalation: Biopsies at baseline and Cycle1 D15 - both optional.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '2'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0.35',\n",
       "        'spread': '0.2687'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With Binimetinib in Paired Tumour Biopsies (Where Possible).',\n",
       "  'description': 'Measurement of phosphoERK1/2 to investigate the pharmacodynamic (PD) effect of PF-02341066 in combination with Binimetinib in paired tumour biopsies (where possible) to determine objective response to treatment. Western blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'Most patients in expansion phase did not have biopsy collection at Day 15 despite consenting to this procedure prior to commencement of the trial mainly for ethical reasons or inability to access suitable tumour biopsy site.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Expansion: Biopsies at baseline and Cycle1 D15. Optional metastic tumour biopsy within 28 days following radiological confirmation of disease progression.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '2'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0.155',\n",
       "        'spread': '0.0212'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Progression Free Survival (Dose Escalation Binimetinib/PF-02341066).',\n",
       "  'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \\\\>=20% increase in the sum of diameters of target lesions (also demonstrating an absolute increase of at least 5mm) or the appearance of new lesions.',\n",
       "  'populationDescription': 'All patients registered for this escalation phase are included in this Intention to Treat analysis, as the number of patients in each arm are separately too small for survival analysis, and it is only to preliminarily assess efficacy of the drug. The data is presented as pre-specified in the Statistical Analysis Plan Version 1.0\\\\_09Jun2016.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of progression or date of death, assessed up to study completion, an average of 6 months',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Binimetinib/PF-02341066',\n",
       "    'description': 'All of the patients registered for this escalation phase are included in this progression free analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '20'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2.3',\n",
       "        'lowerLimit': '1.78',\n",
       "        'upperLimit': '5.36'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Overall Survival (Dose Escalation Binimetinib/PF-02341066)',\n",
       "  'description': 'Overall survival (Dose escalation Binimetinib/PF-02341066).',\n",
       "  'populationDescription': 'All patients registered for this escalation phase are included in this Intention to Treat analysis, as the number of patients in each arm are separately too small for survival analysis, and it is only to preliminarily assess efficacy of the drug. The data is present as pre-specified in the Statistical Analysis Plan Version 1.0\\\\_09June2016.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of death, assessed up to study completion, an average of 6 months',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Binimetinib/PF-02341066',\n",
       "    'description': 'All of the patients registered for this escalation phase are included in this survival analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '20'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '8.78',\n",
       "        'lowerLimit': '5.16',\n",
       "        'upperLimit': '14.5'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma Cmax of Binimetinib (and its metabolite AR00426032) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Dose Escalation phase using binimetinib with PF-02341066. Sample data not available in each outcome measure for 2 patients in Dose level 5 and 1 in Dose level 5 (interval dosing) .',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation:Up to 12 months. PK profile at pre-dose and up to 10 hrs post dose on Day 21 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '5'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '6'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '273',\n",
       "        'spread': '118'},\n",
       "       {'groupId': 'OG001', 'value': '250', 'spread': '145'},\n",
       "       {'groupId': 'OG002', 'value': '186', 'spread': '36.8'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '265',\n",
       "        'spread': '83.4'},\n",
       "       {'groupId': 'OG001', 'value': '386', 'spread': '189'},\n",
       "       {'groupId': 'OG002', 'value': '320', 'spread': '136'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '25.1',\n",
       "        'spread': '15.1'},\n",
       "       {'groupId': 'OG001', 'value': '29.5', 'spread': '8.62'},\n",
       "       {'groupId': 'OG002', 'value': '23.4', 'spread': '8.04'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic (PK) Minimum Plasma Trough Concentration (Cmin) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetic (PK) minimum plasma trough concentration (Cmin) of PF-02341066 and binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for 4 patients in dose level 5, for 2 patients in dose level 5 (interval dosing) and for 1 patient in dose level 5a',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation phase :Up to 12 months. PK profile at pre-dose and up to 10 hrs post dose on Day 21 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '3'},\n",
       "     {'groupId': 'OG001', 'value': '3'},\n",
       "     {'groupId': 'OG002', 'value': '5'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '205',\n",
       "        'spread': '78.0'},\n",
       "       {'groupId': 'OG001', 'value': '181', 'spread': '136'},\n",
       "       {'groupId': 'OG002', 'value': '114', 'spread': '43.1'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '77.1',\n",
       "        'spread': '40.3'},\n",
       "       {'groupId': 'OG001', 'value': '85.8', 'spread': '51.9'},\n",
       "       {'groupId': 'OG002', 'value': '64.0', 'spread': '28.9'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '10.4',\n",
       "        'spread': '2.66'},\n",
       "       {'groupId': 'OG001', 'value': '10.2', 'spread': '2.47'},\n",
       "       {'groupId': 'OG002', 'value': '6.95', 'spread': '1.60'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Area Under the Plasma Concentration Versus Time Curve (AUC) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetic (PK) area under the plasma concentration versus time curve (AUC) of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for dose level 5 for 3 patients and for 2 patients in dose level 5 (interval dosing)',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng.h/ml (0-10h )',\n",
       "  'timeFrame': 'Dose Escalation :Up to 12 months. PK profile pre-dose and up to 10 hrs post dose on Day 21 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '4'},\n",
       "     {'groupId': 'OG001', 'value': '3'},\n",
       "     {'groupId': 'OG002', 'value': '6'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2481',\n",
       "        'spread': '980'},\n",
       "       {'groupId': 'OG001', 'value': '2119', 'spread': '1341'},\n",
       "       {'groupId': 'OG002', 'value': '1467', 'spread': '410'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1604',\n",
       "        'spread': '554'},\n",
       "       {'groupId': 'OG001', 'value': '1780', 'spread': '706'},\n",
       "       {'groupId': 'OG002', 'value': '1402', 'spread': '666'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '203',\n",
       "        'spread': '112'},\n",
       "       {'groupId': 'OG001', 'value': '183', 'spread': '24.8'},\n",
       "       {'groupId': 'OG002', 'value': '121', 'spread': '28.9'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma Oral Clearance for PF-02341066 and Binimetinib',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma oral clearance of binimetinib (and its metabolite,AR00426032 ) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Oral clearance could not be calculated, as pre-specified, as bioavailability and full Area Under the Curve (AUC) data, specifically 0 to ∞ (infinity), was not available. Even though AUC data is available on Day 21 for 0-10 hours, residual drug at time of next twice daily dose administration meant oral clearance could not be determined for most patients.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'timeFrame': 'Dose Expansion phase at Cycle 1 Day 21 up to 10 hours binimetinib and its metabolite, AR00426032, and up to 24 hours for PF-02341066',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '0'}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With PD-0325901 or Binimetinib in Paired Skin Biopsies - Measurement of phosphoERK1/2.',\n",
       "  'description': 'Measurement of phosphoERK1/2 to investigte the pharmacodynamic (PD) effect of PF-02341066 in combination with PD-0325901 or Binimetinib in paired skin biopsies to determine objective response to treatment. Western blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'For the Dose Escalation phases of the study the paired skin biopsies were collected and analysed for eligible patients (achieving end of Cycle 1) where available. Samples for Collection of paired skin biopsies were mandatory for first 10 patients registered to the expansion phase of the study only. An additional 3 samples were collected and analysed in the Expansion phase due to multiple screening performed over several participating sites.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Escalation and Expansion: at baseline and Cycle1, D15.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG004',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration. PF-02341066 200mg BD continuous administration'},\n",
       "   {'id': 'OG005',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG006',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG007',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '5'},\n",
       "     {'groupId': 'OG003', 'value': '5'},\n",
       "     {'groupId': 'OG004', 'value': '5'},\n",
       "     {'groupId': 'OG005', 'value': '5'},\n",
       "     {'groupId': 'OG006', 'value': '3'},\n",
       "     {'groupId': 'OG007', 'value': '13'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0.47',\n",
       "        'spread': '0.277'},\n",
       "       {'groupId': 'OG001', 'value': '0.35', 'spread': '0.356'},\n",
       "       {'groupId': 'OG002', 'value': '0.49', 'spread': '0.727'},\n",
       "       {'groupId': 'OG003', 'value': '0.34', 'spread': '0.218'},\n",
       "       {'groupId': 'OG004', 'value': '0.38', 'spread': '0.238'},\n",
       "       {'groupId': 'OG005', 'value': '0.69', 'spread': '0.147'},\n",
       "       {'groupId': 'OG006', 'value': '0.23', 'spread': '0.166'},\n",
       "       {'groupId': 'OG007', 'value': '0.44', 'spread': '0.309'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and PD-0325901',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma half life of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'PK analysis performed on Cycle 1 Day -1 and Day 21 only for PD-0325901 and PD-0315209 and on Cycle 1 Day 21 and Day 28 only for PF-02341066 according to dosing schedule Day -7 to Day 21 for PD-0325901 and Day 1 to Day 28 for PF-02341066.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'h',\n",
       "  'timeFrame': 'Dose Escalation:Up to12 months.PK profile at Cycle 1 up to 10 hrs post dose on Days -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary Half Life of PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '7.9',\n",
       "        'spread': '4.1'},\n",
       "       {'groupId': 'OG001', 'value': '16.8', 'spread': '13.9'},\n",
       "       {'groupId': 'OG002', 'value': '9.9', 'spread': '3.2'},\n",
       "       {'groupId': 'OG003', 'value': '15.1', 'spread': '12.5'}]}]},\n",
       "   {'title': 'Summary Half Life of PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.5',\n",
       "        'spread': '0.7'},\n",
       "       {'groupId': 'OG001', 'value': '9.7', 'spread': '2.8'},\n",
       "       {'groupId': 'OG002', 'value': '6.3', 'spread': '3.2'},\n",
       "       {'groupId': 'OG003', 'value': '24.8', 'spread': '27.9'}]}]},\n",
       "   {'title': 'Summary Half Life of PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '18.0',\n",
       "        'spread': '5.66'},\n",
       "       {'groupId': 'OG001', 'value': '11.3', 'spread': '1.2'},\n",
       "       {'groupId': 'OG002', 'value': '16.0', 'spread': '6.2'},\n",
       "       {'groupId': 'OG003', 'value': '15.0', 'spread': '2.0'}]}]},\n",
       "   {'title': 'Summary Half Life of PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '10.6',\n",
       "        'spread': '4.88'},\n",
       "       {'groupId': 'OG001', 'value': '19.3', 'spread': '3.8'},\n",
       "       {'groupId': 'OG002', 'value': '11.0', 'spread': '1.4'},\n",
       "       {'groupId': 'OG003', 'value': '6.6', 'spread': '0.6'}]}]},\n",
       "   {'title': 'Summary Half Life of PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '31.5',\n",
       "        'spread': '22.4'},\n",
       "       {'groupId': 'OG001', 'value': '10.0', 'spread': '3.0'},\n",
       "       {'groupId': 'OG002', 'value': '20.0', 'spread': '12.3'},\n",
       "       {'groupId': 'OG003', 'value': '16.0', 'spread': '10.0'}]}]},\n",
       "   {'title': 'Summary Half Life of PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '31.2',\n",
       "        'spread': '16.3'},\n",
       "       {'groupId': 'OG001', 'value': '12.0', 'spread': '3.3'},\n",
       "       {'groupId': 'OG002', 'value': '18.5', 'spread': '12.0'},\n",
       "       {'groupId': 'OG003', 'value': '22.0', 'spread': '13.4'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma t1/2 for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic (PK) t1/2 of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for Half Life for Dose Escalation phase outcome measure for PF-02341066 due to limitations of limited time-points available and missing samples, minimal clearance over the 10hr.\\n\\nNo data available for 3 patients in dose level 5 and 2 in dose level 5 (interval dosing) and 1 in dose level 5a.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'h',\n",
       "  'timeFrame': 'Dose Escalation: PK profile at up to 10 hrs post dose on Cycle 1 Day 21',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '4'},\n",
       "     {'groupId': 'OG001', 'value': '3'},\n",
       "     {'groupId': 'OG002', 'value': '5'}]}],\n",
       "  'classes': [{'title': 'Summary Half Life for Binimetinib for PK Day 21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.3',\n",
       "        'spread': '1.7'},\n",
       "       {'groupId': 'OG001', 'value': '5.5', 'spread': '2.9'},\n",
       "       {'groupId': 'OG002', 'value': '4.7', 'spread': '1.0'}]}]},\n",
       "   {'title': 'Summary Half Life for AR00426032 (binimetinib metabolite) for PK Day 21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.3',\n",
       "        'spread': '1.9'},\n",
       "       {'groupId': 'OG001', 'value': '5.3', 'spread': '2.2'},\n",
       "       {'groupId': 'OG002', 'value': '5.4', 'spread': '1.8'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma half life of binimetinib (and its metabolite,AR00426032 ) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Data not available for 8 patients in PF-02341066 outcome measure, 11 patients in binimetinib outcome measure and 16 patients in AR00426032 outcome measure.\\n\\nData for PF-02341066 taken at 24 hour time point due to once daily dosing.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'h',\n",
       "  'timeFrame': 'Dose Expansion phase at Cycle 1 Day 21 up to 10 hours binimetinib and its metabolite, AR00426032, and up to 24 hours for PF-02341066',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary t1/2 life for PF-02341066 PK Cycle 1 D21 up to 24 h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '21',\n",
       "        'spread': '11'}]}]},\n",
       "   {'title': 'Summary t1/2 life for binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '6.32',\n",
       "        'spread': '8.06'}]}]},\n",
       "   {'title': 'Summary t1/2 life for AR00426032 PK Cycle 1 D21 up to 10 hr',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.70',\n",
       "        'spread': '1.39'}]}]}]}]"
      ]
     },
     "execution_count": 548,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ids_ct.values[0][9]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 545,
   "id": "da5426a7-403c-4a34-8891-5df77c429651",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'population': 30,\n",
       "   'time_frame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "   'outcomes': [{'category_name': 'Stable Disease', 'outcome': 7},\n",
       "    {'category_name': 'Progressive Disease', 'outcome': 22},\n",
       "    {'category_name': 'Early death from malignant disease', 'outcome': 1}]}]]"
      ]
     },
     "execution_count": 545,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_resultsct"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 567,
   "id": "ccabc643-4511-4d41-b41e-afccbed1fd18",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'PRIMARY',\n",
       "  'title': 'Clinical Response to Binimetinib Combined With PF-02341066',\n",
       "  'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD',\n",
       "  'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "  'unitOfMeasure': 'Participants',\n",
       "  'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '30'}]}],\n",
       "  'classes': [{'categories': [{'title': 'Stable Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '7'}]},\n",
       "     {'title': 'Progressive Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '22'}]},\n",
       "     {'title': 'Early death from malignant disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]}]"
      ]
     },
     "execution_count": 567,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_work.values[0][-1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 572,
   "id": "e236b240-caf5-41a1-a7b7-2561a0846cc1",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'PRIMARY',\n",
       "  'title': 'Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066',\n",
       "  'description': 'Determine maximum tolerated dose (MTD) of PD-0325901 with Crizotinib (PF-02341066) according to toxicities graded by NCI CTCAE v4.03, in patients with advanced solid tumours.',\n",
       "  'populationDescription': 'Evaluable patients are those patients who completed cycle 1 or withdrew early for experiencing a DLT. Four patients withdrew early from the study not for DLTs, consequently 21 patients remained for the dose escalation primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'NUMBER',\n",
       "  'unitOfMeasure': 'Dose Limiting Toxicities (DLTs)',\n",
       "  'timeFrame': 'Dose Escalation Phase: treatment Cycle 1 28 days (plus 7 day run-in for PD-0325901/PF-02341066 combination)',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Cohort 1 Dose Level 1',\n",
       "    'description': 'Crizotinib (PF-02341066) 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Cohort 2 Dose Level 2',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Cohort 3 Dose Level 3',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Cohort 4 Dose Level 4',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '4'},\n",
       "     {'groupId': 'OG003', 'value': '6'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0'},\n",
       "       {'groupId': 'OG001', 'value': '0'},\n",
       "       {'groupId': 'OG002', 'value': '0'},\n",
       "       {'groupId': 'OG003', 'value': '1'}]}]}],\n",
       "  'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'],\n",
       "    'nonInferiorityType': 'OTHER',\n",
       "    'otherAnalysisDescription': 'The primary dose escalation analysis was to find the MTD, which was defined as the dose of PF-02341066 in combination with PD-0325901 at which no more than one out of six patients experience a DLT (dose limiting toxicity). The DLT was based on observed toxicity in cycle 1, and was defined as an almost certainly or probably drug-related adverse event to PF-02341066 and/or PD-0325901.\\n\\nThe MTD for the PD 0325901/PF-02341066 combination was 8mg BD(days1-21) and 200mg BD continuously in a 28 day cycle (Dose Level 4).'}]},\n",
       " {'type': 'PRIMARY',\n",
       "  'title': 'Clinical Response to Binimetinib Combined With PF-02341066',\n",
       "  'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD',\n",
       "  'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "  'unitOfMeasure': 'Participants',\n",
       "  'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '30'}]}],\n",
       "  'classes': [{'categories': [{'title': 'Stable Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '7'}]},\n",
       "     {'title': 'Progressive Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '22'}]},\n",
       "     {'title': 'Early death from malignant disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]},\n",
       " {'type': 'PRIMARY',\n",
       "  'title': 'Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066',\n",
       "  'description': 'To determine the maximal tolerated dose (MTD) of Binimetinib with PF-02341066 according to toxicities graded by NCI CTCAE V4.03 in cycle 1 of treatment.',\n",
       "  'populationDescription': 'Evaluable patients are those patients who completed cycle 1 or who withdraw early for experiencing a DLT. Three patients withdrew early from the study not for DLTs, consequently 17 of the 20 recruited patients are evaluable for this analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'NUMBER',\n",
       "  'unitOfMeasure': 'Dose Limiting Toxicities (DLTs)',\n",
       "  'timeFrame': 'Dose Escalation Phase: treatment Cycle 1 28 days',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Cohort 7 Dose Level 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Cohort 12 Dose Level 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Cohort 13 Dose Level 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '6'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2'},\n",
       "       {'groupId': 'OG001', 'value': '2'},\n",
       "       {'groupId': 'OG002', 'value': '1'}]}]}],\n",
       "  'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002'],\n",
       "    'groupDescription': 'The primary dose escalation analysis was to find the MTD, which was defined as the dose of PF-02341066 in combination with Binimetinib at which no more than one out of six patients experience a DLT (dose limiting toxicity). The DLT was based on observed toxicity in cycle 1, and was defined as an almost certainly or probably drug-related adverse event to PF-02341066 and/or Binimetinib.',\n",
       "    'nonInferiorityType': 'OTHER',\n",
       "    'otherAnalysisDescription': 'Binimetinib 30mg BD on days 1 - 21 every 28 days with Crizotinib 250 mg OD continuously is the MTD, the recommended dose and schedule for further evaluation in our and other trials.\\n\\nThis was as only one DLT was experienced in 6 evaluable patients at this final dose escalation level.'}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901.',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma Cmax of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation:Up to 12 months. PK profile at pre-dose and up to 10 hrs post dose on Day - 1, Day 21 and Day 28 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '77.8',\n",
       "        'spread': '41.9'},\n",
       "       {'groupId': 'OG001', 'value': '129', 'spread': '50.5'},\n",
       "       {'groupId': 'OG002', 'value': '226', 'spread': '66.1'},\n",
       "       {'groupId': 'OG003', 'value': '484', 'spread': '84.1'}]}]},\n",
       "   {'title': 'Summary PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '70.3',\n",
       "        'spread': '43.1'},\n",
       "       {'groupId': 'OG001', 'value': '62.3', 'spread': '34.7'},\n",
       "       {'groupId': 'OG002', 'value': '135', 'spread': '36.2'},\n",
       "       {'groupId': 'OG003', 'value': '219', 'spread': '93.6'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '53.1',\n",
       "        'spread': '30.7'},\n",
       "       {'groupId': 'OG001', 'value': '59.4', 'spread': '35.3'},\n",
       "       {'groupId': 'OG002', 'value': '117', 'spread': '44.3'},\n",
       "       {'groupId': 'OG003', 'value': '195', 'spread': '55.6'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '52.0',\n",
       "        'spread': '24.8'},\n",
       "       {'groupId': 'OG001', 'value': '46.7', 'spread': '29.5'},\n",
       "       {'groupId': 'OG002', 'value': '103', 'spread': '40.5'},\n",
       "       {'groupId': 'OG003', 'value': '117', 'spread': '57.6'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '170',\n",
       "        'spread': '81.3'},\n",
       "       {'groupId': 'OG001', 'value': '300', 'spread': '53.9'},\n",
       "       {'groupId': 'OG002', 'value': '235', 'spread': '35.3'},\n",
       "       {'groupId': 'OG003', 'value': '269', 'spread': '157'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '164',\n",
       "        'spread': '59.8'},\n",
       "       {'groupId': 'OG001', 'value': '281', 'spread': '118'},\n",
       "       {'groupId': 'OG002', 'value': '341', 'spread': '133'},\n",
       "       {'groupId': 'OG003', 'value': '275', 'spread': '105'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Minimum Plasma Trough Concentration (Cmin) for PF-02341066 and PD-0325901',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma Cmin of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'PK analysis performed on Cycle 1 Day -1 and Day 21 only for PD-0325901 and PD-0315209 and on Cycle 1 Day 21 and Day 28 only for PF-02341066 according to dosing schedule Day -7 to Day 21 for PD-0325901 and Day 1 to Day 28 for PF-02341066.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation:Up to 12 mths. Cycle 1 PK profile up to 10 hrs post dose on Day -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '23.6',\n",
       "        'spread': '9.3'},\n",
       "       {'groupId': 'OG001', 'value': '18.7', 'spread': '5.83'},\n",
       "       {'groupId': 'OG002', 'value': '37.9', 'spread': '5.89'},\n",
       "       {'groupId': 'OG003', 'value': '89.2', 'spread': '24.3'}]}]},\n",
       "   {'title': 'Summary PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '26.0',\n",
       "        'spread': '16.1'},\n",
       "       {'groupId': 'OG001', 'value': '17.6', 'spread': '3.12'},\n",
       "       {'groupId': 'OG002', 'value': '35.8', 'spread': '13.3'},\n",
       "       {'groupId': 'OG003', 'value': '45.4', 'spread': '13.0'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '44.0',\n",
       "        'spread': '29.6'},\n",
       "       {'groupId': 'OG001', 'value': '40.4', 'spread': '26.3'},\n",
       "       {'groupId': 'OG002', 'value': '80.6', 'spread': '22.1'},\n",
       "       {'groupId': 'OG003', 'value': '147', 'spread': '47.7'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '41.3',\n",
       "        'spread': '23.3'},\n",
       "       {'groupId': 'OG001', 'value': '37.3', 'spread': '25.4'},\n",
       "       {'groupId': 'OG002', 'value': '66.6', 'spread': '18.8'},\n",
       "       {'groupId': 'OG003', 'value': '73.1', 'spread': '31.7'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '115',\n",
       "        'spread': '64.4'},\n",
       "       {'groupId': 'OG001', 'value': '186', 'spread': '55.8'},\n",
       "       {'groupId': 'OG002', 'value': '172', 'spread': '43.6'},\n",
       "       {'groupId': 'OG003', 'value': '203', 'spread': '121'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '119',\n",
       "        'spread': '44.4'},\n",
       "       {'groupId': 'OG001', 'value': '183', 'spread': '66.3'},\n",
       "       {'groupId': 'OG002', 'value': '259', 'spread': '96.0'},\n",
       "       {'groupId': 'OG003', 'value': '211', 'spread': '78.6'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Area Under the Plasma Concentration Versus Time Curve (AUC) for PF-02341066 and PD-0325901(and Its Metabolite)',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma AUC of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'PK analysis performed on Cycle 1 Day -1 and Day 21 only for PD-0325901 and PD-0315209 and on Cycle 1 Day 21 and Day 28 only for PF-02341066 according to dosing schedule Day -7 to Day 21 for PD-0325901 and Day 1 to Day 28 for PF-02341066.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng*hr/mL',\n",
       "  'timeFrame': 'Dose Escalation:Up to12 months. Cycle 1 PK profile up to 10 hrs on Day -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '400',\n",
       "        'spread': '117'},\n",
       "       {'groupId': 'OG001', 'value': '432', 'spread': '129'},\n",
       "       {'groupId': 'OG002', 'value': '796', 'spread': '120'},\n",
       "       {'groupId': 'OG003', 'value': '1907', 'spread': '254'}]}]},\n",
       "   {'title': 'Summary PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '400',\n",
       "        'spread': '160'},\n",
       "       {'groupId': 'OG001', 'value': '301', 'spread': '106'},\n",
       "       {'groupId': 'OG002', 'value': '683', 'spread': '51.7'},\n",
       "       {'groupId': 'OG003', 'value': '1162', 'spread': '190'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '498',\n",
       "        'spread': '304'},\n",
       "       {'groupId': 'OG001', 'value': '508', 'spread': '318'},\n",
       "       {'groupId': 'OG002', 'value': '954', 'spread': '301'},\n",
       "       {'groupId': 'OG003', 'value': '1726', 'spread': '501'}]}]},\n",
       "   {'title': 'Summary PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '487',\n",
       "        'spread': '226'},\n",
       "       {'groupId': 'OG001', 'value': '413', 'spread': '273'},\n",
       "       {'groupId': 'OG002', 'value': '831', 'spread': '246'},\n",
       "       {'groupId': 'OG003', 'value': '1092', 'spread': '228'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1341',\n",
       "        'spread': '688'},\n",
       "       {'groupId': 'OG001', 'value': '2115', 'spread': '448'},\n",
       "       {'groupId': 'OG002', 'value': '2034', 'spread': '397'},\n",
       "       {'groupId': 'OG003', 'value': '2336', 'spread': '1414'}]}]},\n",
       "   {'title': 'Summary PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1378',\n",
       "        'spread': '567'},\n",
       "       {'groupId': 'OG001', 'value': '2358', 'spread': '905'},\n",
       "       {'groupId': 'OG002', 'value': '2919', 'spread': '1207'},\n",
       "       {'groupId': 'OG003', 'value': '2402', 'spread': '873'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma Oral Clearance for PF-02341066 and PD-0325901',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma oral clearance of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Oral clearance could not be calculated, as pre-specified, as bioavailability and full Area Under the Curve (AUC) data, specifically 0 to ∞ (infinity), was not available. Even though AUC data is available on Days -1, 21 and 28 for 0-10 hours, residual drug at time of next twice daily dose administration meant oral clearance could not be determined for most patients.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'timeFrame': 'Dose Escalation:Up to12 months.PK profile at Cycle 1 up to 10 hrs post dose on Days -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib (PF-02341066) 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib (PF-02341066) 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day -1, then Day 1-21 every 28 day cycle'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '0'},\n",
       "     {'groupId': 'OG001', 'value': '0'},\n",
       "     {'groupId': 'OG002', 'value': '0'},\n",
       "     {'groupId': 'OG003', 'value': '0'}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Progression Free Survival (Dose Expansion)',\n",
       "  'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \\\\>=20% increase in the sum of diameters of target lesions (also demonstrating an absolute increase of at least 5mm) or the appearance of new lesions.',\n",
       "  'populationDescription': 'All 37 registered patients are included in this analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of progression or date of death, assessed up to study completion, an average of 6 months (dose expansion)).',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'All of the patients registered for this expansion phase are included in this survival analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '37'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1.81',\n",
       "        'lowerLimit': '1.51',\n",
       "        'upperLimit': '1.91'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Overall Survival (Dose Expansion)',\n",
       "  'description': 'Overall survival (dose expansion).',\n",
       "  'populationDescription': 'All 37 registered patients are included in this analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of death, assessed up to study completion, an average of 6 months (dose escalation).',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'All of the patients registered for this expansion phase are included in this survival analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '37'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '5.42',\n",
       "        'lowerLimit': '2.79',\n",
       "        'upperLimit': '7.33'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic (PK) Peak Plasma Concentration (Cmax) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetic (PK) peak plasma concentration (Cmax) of PF-02341066 and Binimetinib and its metabolite, AR00426032, in blood.',\n",
       "  'populationDescription': 'Data not available for 2 patients in PF-02341066 outcome measure and 8 patients each in binimetinib and AR00426032 outcome measures',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Expansion: PK profile up to 10 hrs at Cycle 1 Day 21',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '24'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '197',\n",
       "        'spread': '112'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '357',\n",
       "        'spread': '171'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '22.7',\n",
       "        'spread': '16.0'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Minimum Plasma Trough Concentration (Cmin) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic plasma trough concentration Cmin of PF-02341066 and Binimetinib and its metabolite, AR00426032, in blood.',\n",
       "  'populationDescription': 'No data available for 8 patients for binimetinib outcome and for 16 patients in AR00426032 outcome measure.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'Cmin (ng/ml)',\n",
       "  'timeFrame': 'Dose Expansion: PK profile on Cycle 1 Day 21 up to 10 hrs .',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '24'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '149',\n",
       "        'spread': '85.3'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '103',\n",
       "        'spread': '58.5'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '12.1',\n",
       "        'spread': '4.80'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Area Under the Plasma Concentration Versus Time Curve (AUC) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic area under the plasma concentration versus time curve (AUC) of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for 2 patients in PF-02341066 outcome measure, 8 for binimetinib outcome measure and 13 for AR00426032 outcome measure',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng.h/ml (0-10h )',\n",
       "  'timeFrame': 'Dose Expansion: PK profile on Cycle 1 Day 21 up to 10 hrs',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '24'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '3478',\n",
       "        'spread': '2083'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2129',\n",
       "        'spread': '1152'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'denoms': [{'units': 'Participants',\n",
       "      'counts': [{'groupId': 'OG000', 'value': '18'}]}],\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '194',\n",
       "        'spread': '85.2'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Oral Clearance for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic (PK) oral clearance of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'Oral clearance could not be calculated, as pre-specified, as bioavailability and full Area Under the Curve (AUC) data, specifically 0 to ∞ (infinity), was not available. Even though AUC data is available on Day 21 for 0-10 hours, residual drug at time of next twice daily dose administration meant oral clearance could not be determined for most patients.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'timeFrame': 'Dose Escalation: PK profile at up to 10 hrs post dose on Cycle 1 Day 21',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. Crizotinib (PF-02341066) 200mg BD continuous administration'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. Crizotinib (PF-02341066) 250mg OD continuous administration'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. Crizotinib (PF-02341066) 200mg BD continuous administration'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '0'},\n",
       "     {'groupId': 'OG001', 'value': '0'},\n",
       "     {'groupId': 'OG002', 'value': '0'}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With PD-0325901 or Binimetinib in Paired Skin Biopsies - Measurement of phosphoMEK1/2.',\n",
       "  'description': 'Measurement of phosphoMEK1/2 in skin biopsies to investigate the pharmacodynamic (PD) effect of PF-02341066 in combination with PD-0325901 or Binimetinib in paired skin biopsies to determine objective response to treatment.\\n\\nWestern blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'For the Dose Escalation phases of the study the paired skin biopsies were collected and analysed for eligible patients (achieving end of Cycle 1) where available. Samples for Collection of paired skin biopsies were mandatory for first 10 patients registered to the expansion phase of the study only. An additional 3 samples were collected and analysed in the Expansion phase due to multiple screening performed over several participating sites.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Escalation and Expansion: at baseline and Cycle1, D15.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG004',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration. PF-02341066 200mg BD continuous administration'},\n",
       "   {'id': 'OG005',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG006',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG007',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '5'},\n",
       "     {'groupId': 'OG003', 'value': '5'},\n",
       "     {'groupId': 'OG004', 'value': '5'},\n",
       "     {'groupId': 'OG005', 'value': '5'},\n",
       "     {'groupId': 'OG006', 'value': '3'},\n",
       "     {'groupId': 'OG007', 'value': '13'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '3.74',\n",
       "        'spread': '2.366'},\n",
       "       {'groupId': 'OG001', 'value': '1.89', 'spread': '1.425'},\n",
       "       {'groupId': 'OG002', 'value': '6.52', 'spread': '5.982'},\n",
       "       {'groupId': 'OG003', 'value': '5.74', 'spread': '3.067'},\n",
       "       {'groupId': 'OG004', 'value': '1.93', 'spread': '0.844'},\n",
       "       {'groupId': 'OG005', 'value': '1.03', 'spread': '0.28'},\n",
       "       {'groupId': 'OG006', 'value': '0.93', 'spread': '0.418'},\n",
       "       {'groupId': 'OG007', 'value': '1.11', 'spread': '0.697'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With PD-0325901 or Binimetinib in Paired Tumour Biopsies (Where Possible).',\n",
       "  'description': 'Measurement of pSTAT3Y705 to investigate the pharmacodynamic (PD) effect of PF-02341066 in combination with PD-0325901 or Binimetinib in paired tumour biopsies to determine objective response to treatment. Western blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'Biopsies optional for this phase and only consented to by 2 patients for the combination of PF-02341066 with Binimetinib.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Escalation: Biopsies at baseline and Cycle1 D15 - both optional.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '2'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0.35',\n",
       "        'spread': '0.2687'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With Binimetinib in Paired Tumour Biopsies (Where Possible).',\n",
       "  'description': 'Measurement of phosphoERK1/2 to investigate the pharmacodynamic (PD) effect of PF-02341066 in combination with Binimetinib in paired tumour biopsies (where possible) to determine objective response to treatment. Western blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'Most patients in expansion phase did not have biopsy collection at Day 15 despite consenting to this procedure prior to commencement of the trial mainly for ethical reasons or inability to access suitable tumour biopsy site.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Expansion: Biopsies at baseline and Cycle1 D15. Optional metastic tumour biopsy within 28 days following radiological confirmation of disease progression.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '2'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0.155',\n",
       "        'spread': '0.0212'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Progression Free Survival (Dose Escalation Binimetinib/PF-02341066).',\n",
       "  'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a \\\\>=20% increase in the sum of diameters of target lesions (also demonstrating an absolute increase of at least 5mm) or the appearance of new lesions.',\n",
       "  'populationDescription': 'All patients registered for this escalation phase are included in this Intention to Treat analysis, as the number of patients in each arm are separately too small for survival analysis, and it is only to preliminarily assess efficacy of the drug. The data is presented as pre-specified in the Statistical Analysis Plan Version 1.0\\\\_09Jun2016.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of progression or date of death, assessed up to study completion, an average of 6 months',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Binimetinib/PF-02341066',\n",
       "    'description': 'All of the patients registered for this escalation phase are included in this progression free analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '20'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2.3',\n",
       "        'lowerLimit': '1.78',\n",
       "        'upperLimit': '5.36'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Overall Survival (Dose Escalation Binimetinib/PF-02341066)',\n",
       "  'description': 'Overall survival (Dose escalation Binimetinib/PF-02341066).',\n",
       "  'populationDescription': 'All patients registered for this escalation phase are included in this Intention to Treat analysis, as the number of patients in each arm are separately too small for survival analysis, and it is only to preliminarily assess efficacy of the drug. The data is present as pre-specified in the Statistical Analysis Plan Version 1.0\\\\_09June2016.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEDIAN',\n",
       "  'dispersionType': '95% Confidence Interval',\n",
       "  'unitOfMeasure': 'months',\n",
       "  'timeFrame': 'From date of study entry until the date of death, assessed up to study completion, an average of 6 months',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Binimetinib/PF-02341066',\n",
       "    'description': 'All of the patients registered for this escalation phase are included in this survival analysis, to preliminarily assess the efficacy of the drug combination.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '20'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '8.78',\n",
       "        'lowerLimit': '5.16',\n",
       "        'upperLimit': '14.5'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma Cmax of Binimetinib (and its metabolite AR00426032) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Dose Escalation phase using binimetinib with PF-02341066. Sample data not available in each outcome measure for 2 patients in Dose level 5 and 1 in Dose level 5 (interval dosing) .',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation:Up to 12 months. PK profile at pre-dose and up to 10 hrs post dose on Day 21 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '5'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '6'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '273',\n",
       "        'spread': '118'},\n",
       "       {'groupId': 'OG001', 'value': '250', 'spread': '145'},\n",
       "       {'groupId': 'OG002', 'value': '186', 'spread': '36.8'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '265',\n",
       "        'spread': '83.4'},\n",
       "       {'groupId': 'OG001', 'value': '386', 'spread': '189'},\n",
       "       {'groupId': 'OG002', 'value': '320', 'spread': '136'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '25.1',\n",
       "        'spread': '15.1'},\n",
       "       {'groupId': 'OG001', 'value': '29.5', 'spread': '8.62'},\n",
       "       {'groupId': 'OG002', 'value': '23.4', 'spread': '8.04'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic (PK) Minimum Plasma Trough Concentration (Cmin) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetic (PK) minimum plasma trough concentration (Cmin) of PF-02341066 and binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for 4 patients in dose level 5, for 2 patients in dose level 5 (interval dosing) and for 1 patient in dose level 5a',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng/ml',\n",
       "  'timeFrame': 'Dose Escalation phase :Up to 12 months. PK profile at pre-dose and up to 10 hrs post dose on Day 21 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '3'},\n",
       "     {'groupId': 'OG001', 'value': '3'},\n",
       "     {'groupId': 'OG002', 'value': '5'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '205',\n",
       "        'spread': '78.0'},\n",
       "       {'groupId': 'OG001', 'value': '181', 'spread': '136'},\n",
       "       {'groupId': 'OG002', 'value': '114', 'spread': '43.1'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '77.1',\n",
       "        'spread': '40.3'},\n",
       "       {'groupId': 'OG001', 'value': '85.8', 'spread': '51.9'},\n",
       "       {'groupId': 'OG002', 'value': '64.0', 'spread': '28.9'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '10.4',\n",
       "        'spread': '2.66'},\n",
       "       {'groupId': 'OG001', 'value': '10.2', 'spread': '2.47'},\n",
       "       {'groupId': 'OG002', 'value': '6.95', 'spread': '1.60'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Area Under the Plasma Concentration Versus Time Curve (AUC) for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate the pharmacokinetic (PK) area under the plasma concentration versus time curve (AUC) of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for dose level 5 for 3 patients and for 2 patients in dose level 5 (interval dosing)',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ng.h/ml (0-10h )',\n",
       "  'timeFrame': 'Dose Escalation :Up to 12 months. PK profile pre-dose and up to 10 hrs post dose on Day 21 of Cycle 1',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 5',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '4'},\n",
       "     {'groupId': 'OG001', 'value': '3'},\n",
       "     {'groupId': 'OG002', 'value': '6'}]}],\n",
       "  'classes': [{'title': 'Summary PF-02341066 PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '2481',\n",
       "        'spread': '980'},\n",
       "       {'groupId': 'OG001', 'value': '2119', 'spread': '1341'},\n",
       "       {'groupId': 'OG002', 'value': '1467', 'spread': '410'}]}]},\n",
       "   {'title': 'Summary binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '1604',\n",
       "        'spread': '554'},\n",
       "       {'groupId': 'OG001', 'value': '1780', 'spread': '706'},\n",
       "       {'groupId': 'OG002', 'value': '1402', 'spread': '666'}]}]},\n",
       "   {'title': 'Summary AR00426032 PK Cycle 1 D21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '203',\n",
       "        'spread': '112'},\n",
       "       {'groupId': 'OG001', 'value': '183', 'spread': '24.8'},\n",
       "       {'groupId': 'OG002', 'value': '121', 'spread': '28.9'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma Oral Clearance for PF-02341066 and Binimetinib',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma oral clearance of binimetinib (and its metabolite,AR00426032 ) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Oral clearance could not be calculated, as pre-specified, as bioavailability and full Area Under the Curve (AUC) data, specifically 0 to ∞ (infinity), was not available. Even though AUC data is available on Day 21 for 0-10 hours, residual drug at time of next twice daily dose administration meant oral clearance could not be determined for most patients.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'timeFrame': 'Dose Expansion phase at Cycle 1 Day 21 up to 10 hours binimetinib and its metabolite, AR00426032, and up to 24 hours for PF-02341066',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '0'}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacodynamic (PD) Effect of PF-02341066 in Combination With PD-0325901 or Binimetinib in Paired Skin Biopsies - Measurement of phosphoERK1/2.',\n",
       "  'description': 'Measurement of phosphoERK1/2 to investigte the pharmacodynamic (PD) effect of PF-02341066 in combination with PD-0325901 or Binimetinib in paired skin biopsies to determine objective response to treatment. Western blots are used to measure levels of expression and images are taken of the gels. Image J is used to measure pixels. The minimum is 0 and there is no maximum.',\n",
       "  'populationDescription': 'For the Dose Escalation phases of the study the paired skin biopsies were collected and analysed for eligible patients (achieving end of Cycle 1) where available. Samples for Collection of paired skin biopsies were mandatory for first 10 patients registered to the expansion phase of the study only. An additional 3 samples were collected and analysed in the Expansion phase due to multiple screening performed over several participating sites.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'ratio',\n",
       "  'timeFrame': 'Dose Escalation and Expansion: at baseline and Cycle1, D15.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG004',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration. PF-02341066 200mg BD continuous administration'},\n",
       "   {'id': 'OG005',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG006',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG007',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '5'},\n",
       "     {'groupId': 'OG002', 'value': '5'},\n",
       "     {'groupId': 'OG003', 'value': '5'},\n",
       "     {'groupId': 'OG004', 'value': '5'},\n",
       "     {'groupId': 'OG005', 'value': '5'},\n",
       "     {'groupId': 'OG006', 'value': '3'},\n",
       "     {'groupId': 'OG007', 'value': '13'}]}],\n",
       "  'classes': [{'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '0.47',\n",
       "        'spread': '0.277'},\n",
       "       {'groupId': 'OG001', 'value': '0.35', 'spread': '0.356'},\n",
       "       {'groupId': 'OG002', 'value': '0.49', 'spread': '0.727'},\n",
       "       {'groupId': 'OG003', 'value': '0.34', 'spread': '0.218'},\n",
       "       {'groupId': 'OG004', 'value': '0.38', 'spread': '0.238'},\n",
       "       {'groupId': 'OG005', 'value': '0.69', 'spread': '0.147'},\n",
       "       {'groupId': 'OG006', 'value': '0.23', 'spread': '0.166'},\n",
       "       {'groupId': 'OG007', 'value': '0.44', 'spread': '0.309'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and PD-0325901',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma half life of PD-0325901 (and its metabolite, PD-0315209) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'PK analysis performed on Cycle 1 Day -1 and Day 21 only for PD-0325901 and PD-0315209 and on Cycle 1 Day 21 and Day 28 only for PF-02341066 according to dosing schedule Day -7 to Day 21 for PD-0325901 and Day 1 to Day 28 for PF-02341066.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'h',\n",
       "  'timeFrame': 'Dose Escalation:Up to12 months.PK profile at Cycle 1 up to 10 hrs post dose on Days -1, 21 and 28',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase Dose 1.',\n",
       "    'description': 'Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 2.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 3.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'},\n",
       "   {'id': 'OG003',\n",
       "    'title': 'Dose Escalation Phase Dose 4.',\n",
       "    'description': 'Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '6'},\n",
       "     {'groupId': 'OG001', 'value': '4'},\n",
       "     {'groupId': 'OG002', 'value': '3'},\n",
       "     {'groupId': 'OG003', 'value': '4'}]}],\n",
       "  'classes': [{'title': 'Summary Half Life of PD-0325901 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '7.9',\n",
       "        'spread': '4.1'},\n",
       "       {'groupId': 'OG001', 'value': '16.8', 'spread': '13.9'},\n",
       "       {'groupId': 'OG002', 'value': '9.9', 'spread': '3.2'},\n",
       "       {'groupId': 'OG003', 'value': '15.1', 'spread': '12.5'}]}]},\n",
       "   {'title': 'Summary Half Life of PD-0325901 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.5',\n",
       "        'spread': '0.7'},\n",
       "       {'groupId': 'OG001', 'value': '9.7', 'spread': '2.8'},\n",
       "       {'groupId': 'OG002', 'value': '6.3', 'spread': '3.2'},\n",
       "       {'groupId': 'OG003', 'value': '24.8', 'spread': '27.9'}]}]},\n",
       "   {'title': 'Summary Half Life of PD-0315209 PK Day -1',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '18.0',\n",
       "        'spread': '5.66'},\n",
       "       {'groupId': 'OG001', 'value': '11.3', 'spread': '1.2'},\n",
       "       {'groupId': 'OG002', 'value': '16.0', 'spread': '6.2'},\n",
       "       {'groupId': 'OG003', 'value': '15.0', 'spread': '2.0'}]}]},\n",
       "   {'title': 'Summary Half Life of PD-0315209 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '10.6',\n",
       "        'spread': '4.88'},\n",
       "       {'groupId': 'OG001', 'value': '19.3', 'spread': '3.8'},\n",
       "       {'groupId': 'OG002', 'value': '11.0', 'spread': '1.4'},\n",
       "       {'groupId': 'OG003', 'value': '6.6', 'spread': '0.6'}]}]},\n",
       "   {'title': 'Summary Half Life of PF-02341066 PK Day 21',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '31.5',\n",
       "        'spread': '22.4'},\n",
       "       {'groupId': 'OG001', 'value': '10.0', 'spread': '3.0'},\n",
       "       {'groupId': 'OG002', 'value': '20.0', 'spread': '12.3'},\n",
       "       {'groupId': 'OG003', 'value': '16.0', 'spread': '10.0'}]}]},\n",
       "   {'title': 'Summary Half Life of PF-02341066 PK Day 28',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '31.2',\n",
       "        'spread': '16.3'},\n",
       "       {'groupId': 'OG001', 'value': '12.0', 'spread': '3.3'},\n",
       "       {'groupId': 'OG002', 'value': '18.5', 'spread': '12.0'},\n",
       "       {'groupId': 'OG003', 'value': '22.0', 'spread': '13.4'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma t1/2 for PF-02341066 and Binimetinib.',\n",
       "  'description': 'To investigate pharmacokinetic (PK) t1/2 of PF-02341066 and Binimetinib in blood.',\n",
       "  'populationDescription': 'No data available for Half Life for Dose Escalation phase outcome measure for PF-02341066 due to limitations of limited time-points available and missing samples, minimal clearance over the 10hr.\\n\\nNo data available for 3 patients in dose level 5 and 2 in dose level 5 (interval dosing) and 1 in dose level 5a.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'h',\n",
       "  'timeFrame': 'Dose Escalation: PK profile at up to 10 hrs post dose on Cycle 1 Day 21',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Escalation Phase 5.',\n",
       "    'description': 'Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nPD-0325901: PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG001',\n",
       "    'title': 'Dose Escalation Phase Dose 5 (Interval Dosing)',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'},\n",
       "   {'id': 'OG002',\n",
       "    'title': 'Dose Escalation Phase Dose 5a',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '4'},\n",
       "     {'groupId': 'OG001', 'value': '3'},\n",
       "     {'groupId': 'OG002', 'value': '5'}]}],\n",
       "  'classes': [{'title': 'Summary Half Life for Binimetinib for PK Day 21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.3',\n",
       "        'spread': '1.7'},\n",
       "       {'groupId': 'OG001', 'value': '5.5', 'spread': '2.9'},\n",
       "       {'groupId': 'OG002', 'value': '4.7', 'spread': '1.0'}]}]},\n",
       "   {'title': 'Summary Half Life for AR00426032 (binimetinib metabolite) for PK Day 21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.3',\n",
       "        'spread': '1.9'},\n",
       "       {'groupId': 'OG001', 'value': '5.3', 'spread': '2.2'},\n",
       "       {'groupId': 'OG002', 'value': '5.4', 'spread': '1.8'}]}]}]},\n",
       " {'type': 'SECONDARY',\n",
       "  'title': 'Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib',\n",
       "  'description': 'To investigate the pharmacokinetics (PK) plasma half life of binimetinib (and its metabolite,AR00426032 ) with PF-023241066 when administered in combination.',\n",
       "  'populationDescription': 'Data not available for 8 patients in PF-02341066 outcome measure, 11 patients in binimetinib outcome measure and 16 patients in AR00426032 outcome measure.\\n\\nData for PF-02341066 taken at 24 hour time point due to once daily dosing.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'MEAN',\n",
       "  'dispersionType': 'Standard Deviation',\n",
       "  'unitOfMeasure': 'h',\n",
       "  'timeFrame': 'Dose Expansion phase at Cycle 1 Day 21 up to 10 hours binimetinib and its metabolite, AR00426032, and up to 24 hours for PF-02341066',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '26'}]}],\n",
       "  'classes': [{'title': 'Summary t1/2 life for PF-02341066 PK Cycle 1 D21 up to 24 h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '21',\n",
       "        'spread': '11'}]}]},\n",
       "   {'title': 'Summary t1/2 life for binimetinib PK Cycle 1 D21 up to 10h',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '6.32',\n",
       "        'spread': '8.06'}]}]},\n",
       "   {'title': 'Summary t1/2 life for AR00426032 PK Cycle 1 D21 up to 10 hr',\n",
       "    'categories': [{'measurements': [{'groupId': 'OG000',\n",
       "        'value': '4.70',\n",
       "        'spread': '1.39'}]}]}]}]"
      ]
     },
     "execution_count": 572,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies[all_studies.screen_eval>=0]['outcomeMeasures'].values[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 588,
   "id": "ed961d95-4ccd-4e8e-b28b-ea26eb5fe0de",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Administration of crizotinib combined with regorafenib and tislelizumab obtained an obvious response.',\n",
       " 'The best clinical response was stable disease in seven patients (29%) when treated with crizotinib.',\n",
       " 'Drugs such as Crizotinib were more sensitive to low-risk group.',\n",
       " 'AZD4547, Cytochalasin B and S-crizotinib might have potential therapeutic implications in the immune risk score-high CRCs.',\n",
       " 'Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors.',\n",
       " 'Crizotinib selectively inhibits the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.',\n",
       " 'Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response. After 15 months on crizotinib disseminated tumor progression occurred and KRAS Q61H emerged in tissue and liquid biopsies.',\n",
       " 'Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients.',\n",
       " 'Crizotinib effectively overcomes HGF-induced cetuximab resistance.',\n",
       " 'The expression level of SDHB was correlated with drug sensitivity to Crizotinib.',\n",
       " 'The combined treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib) significantly inhibits tumor progression and prolongs survival in metastatic and orthotopic animal models of colon cancer.']"
      ]
     },
     "execution_count": 588,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[i[0]['value'] for i in extracted_gm if i[0]['value']!='NP']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 601,
   "id": "4fe595d6-67a8-408f-9bd2-061db8b64236",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'You are a clinical specialist conducting a clinicial meta-analysis on treating Colorectal cancer with Crizotinib. \\n\\nThe user will provide a list of text sources.\\nYour task is to summarize results regarding Crizotinib effectiviness from several sources.\\n\\nGive a short summary in 3-4 sentences.\\nYour answer will be shown to a doctor for desicion making, do not include any additional text.\\n'"
      ]
     },
     "execution_count": 601,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "SUMMARY  = f'''You are a clinical specialist conducting a clinicial meta-analysis on treating {fin_condition} with {treatements_eng[0]}. \n",
    "\n",
    "The user will provide a list of text sources.\n",
    "Your task is to summarize results regarding Crizotinib effectiviness from several sources.\n",
    "\n",
    "Give a short summary in 3-4 sentences.\n",
    "Your answer will be shown to a doctor for desicion making, do not include any additional text.\n",
    "'''\n",
    "SUMMARY"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 602,
   "id": "270e1090-4442-4589-b59e-438a885c4fdd",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Crizotinib demonstrates effectiveness in combination therapies for colorectal cancer, particularly enhancing responses when paired with other agents like regorafenib or tislelizumab. It shows selective inhibition against specific mutations, including ARID1A deficiency and HGF-mediated cetuximab resistance. However, its efficacy varies across different patient groups; while it can induce partial responses, some combinations exhibit poor tolerability without significant benefits. Additionally, biomarkers like SDHB levels correlate with drug sensitivity.'"
      ]
     },
     "execution_count": 602,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "at_once = False\n",
    "openai_client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(verify=False)\n",
    ")\n",
    "ss = [i[0]['value'] for i in extracted_gm if i[0]['value']!='NP']\n",
    "messages2 = [{'role':'system', 'content':SUMMARY+' \\no_think'},\n",
    "                {'role':'user', 'content':f\"{ss}\"}]\n",
    "   \n",
    "response2 = openai_client.chat.completions.create(\n",
    "    model=os.getenv('MODEL_NAME'),\n",
    "    messages=messages2,\n",
    "    temperature=0,\n",
    ")\n",
    "fin2 = response2.choices[0].message.content\n",
    "answer2 = fin2.strip('<think>\\n\\n</think>\\n\\n')\n",
    "answer2\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 603,
   "id": "a821989e-9143-4156-b042-8d2f482fd626",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Crizotinib demonstrates effectiveness in combination therapies for colorectal cancer, particularly enhancing responses when paired with other agents like regorafenib or tislelizumab. It shows selective inhibition against specific mutations, including ARID1A deficiency and HGF-mediated cetuximab resistance. However, its efficacy varies across different patient groups; while it can induce partial responses, some combinations exhibit poor tolerability without significant benefits. Additionally, biomarkers like SDHB levels correlate with drug sensitivity.\n"
     ]
    }
   ],
   "source": [
    "print(answer2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "26104b32-6ea0-42ec-8d78-24915267662e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8913fa8b-3836-47f4-b888-37d8c163e43f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 606,
   "id": "202c9136-c778-46b2-b07b-21eeb82749a7",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "import random\n",
    "\n",
    "from pdfme import build_pdf\n",
    "\n",
    "\n",
    "random.seed(1)\n",
    "abc = 'abcdefghijklmnñopqrstuvwxyzABCDEFGHIJKLMNÑOPQRSTUVWXYZáéíóúÁÉÍÓÚ'\n",
    "\n",
    "def gen_word():\n",
    "    return ''.join(random.choice(abc) for _ in range(random.randint(1, 10)))\n",
    "\n",
    "def gen_text(n):\n",
    "    return random.choice(['',' ']) + (' '.join(gen_word() for _ in range(n))) + random.choice(['',' '])\n",
    "\n",
    "def gen_paragraphs(n):\n",
    "    return [gen_text(random.randint(50, 200)) for _ in range(n)]\n",
    "\n",
    "def clin():\n",
    "    func_r = []\n",
    "    num = 1\n",
    "    for i, ext_res in zip(ids_ct.values,json_resultsct):\n",
    "        func_r.append([f\"{num}. '{i[2]}'\", \n",
    "                       f\" {i[3].lower()}\", \n",
    "                       f\" {' '.join(i[7]).lower()}\",\n",
    "                       {\".\": \" (link)\", \"style\": \"url\", \n",
    "                            \"uri\": f'https://clinicaltrials.gov/study/{i[1]}'}, \n",
    "                      ])\n",
    "        #func_r.append(['- https://clinicaltrials.gov/study/'+i[1]+' '+f\"'{i[2]}'\"])\n",
    "        #func_r.append([ext_res])\n",
    "        for j_n, j in enumerate(ext_res):\n",
    "            func_r_1 = []\n",
    "            func_r_1 = func_r_1+ ['Measure: ', i[-1][j_n]['title'], '\\n',\n",
    "                          {\".s:8;i\": f'Population: {j['population']}'}, '\\n',\n",
    "                          {\".s:8;i\": f'Time: {j['time_frame']}'}, '\\n',\n",
    "                          ]\n",
    "            for out in j['outcomes']:\n",
    "                func_r_1 = func_r_1+ [{\".s:8;i\": out['category_name']},\n",
    "                                ': ',\n",
    "                               {\".s:8;i\": out['outcome']}, '\\n',\n",
    "                              ]\n",
    "            func_r.append(func_r_1)\n",
    "        num+=1\n",
    "    return func_r\n",
    "\n",
    "def papers():\n",
    "    func_r = []\n",
    "    num = 1\n",
    "    for i, ext_res in zip(ids_p.values, extracted_gm):\n",
    "        func_r.append([f\"{num}. '{i[5]}'\", \n",
    "                       {\".\": f\" (link)\", \"style\": \"url\", \n",
    "                            \"uri\": f'https://pubmed.ncbi.nlm.nih.gov/{i[0]}'}, \n",
    "                      ])\n",
    "        if ext_res[0]['source_id']:\n",
    "            func_r.append([f\"    {ext_res[0]['name'].replace('_',' ')}: '{ext_res[0]['value']}'\"+\n",
    "                          \" Based on:\"])\n",
    "            for cb in ext_res[0]['cited_blocks']: \n",
    "                func_r.append([{\".s:8;i\":f\"'{cb}'\"}])\n",
    "            #func_r.append(field['cited_blocks'])\n",
    "        num+=1\n",
    "    return func_r\n",
    "\n",
    "\n",
    "document = {\n",
    "    \"style\": {\n",
    "        \"margin_bottom\": 15, \"text_align\": \"j\",\n",
    "        \"page_size\": \"letter\", \"margin\": [60, 50]\n",
    "    },\n",
    "    \"formats\": {\n",
    "        \"url\": {\"c\": \"blue\", \"u\": 1},\n",
    "        \"title\": {\"b\": 1, \"s\": 13}\n",
    "    },\n",
    "    \"running_sections\": {\n",
    "        \"header\": {\n",
    "            \"x\": \"left\", \"y\": 20, \"height\": \"top\", \"style\": {\"text_align\": \"r\"},\n",
    "            \"content\": [{\".b\": \"This is a header\"}]\n",
    "        },\n",
    "        \"footer\": {\n",
    "            \"x\": \"left\", \"y\": 740, \"height\": \"bottom\", \"style\": {\"text_align\": \"c\"},\n",
    "            \"content\": [{\".\": [\"Page \", {\"var\": \"$page\"}]}]\n",
    "        }\n",
    "    },\n",
    "    \"sections\": [\n",
    "        {\n",
    "            \"style\": {\"page_numbering_style\": \"arabic\"},\n",
    "            \"running_sections\": [\"footer\"],\n",
    "            \"content\": [\n",
    "\n",
    "                {\n",
    "                    \".\": f\"Condition: {fin_condition}\", \"style\": \"title\", \"label\": \"title1\",\n",
    "                },\n",
    "                [{\".b\": f'Treatement 1: {treatements_eng[0]}'}],\n",
    "                [{\".b\": 'Chosen clinical trials:'}],\n",
    "                \n",
    "                *clin(),\n",
    "                \n",
    "                [{\".b\": 'Chosen papers:'}],\n",
    "                [f'Short summary: {answer2}'],\n",
    "                *papers(),\n",
    "                \n",
    "                #{\"image\": \"path/to/some/image.jpg\"},\n",
    "\n",
    "                \n",
    "            ]\n",
    "        }\n",
    "    ]\n",
    "}\n",
    "\n",
    "with open('document.pdf', 'wb') as f:\n",
    "    build_pdf(document, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "80dca6ed-7242-4117-99a0-18957bba47ab",
   "metadata": {},
   "outputs": [],
   "source": [
    "pdf = FPDF()\n",
    "pdf.add_page()\n",
    "\n",
    "pdf.set_font('Arial', '', 14)\n",
    "\n",
    "pdf.cell(40, 10, f'Condition: {fin_condition}')\n",
    "\n",
    "pdf.cell(40, 10, f'Treatement 1: {treatements_eng[0]}')\n",
    "\n",
    "pdf.set_font('Arial', 'B', 12)\n",
    "pdf.cell(40, 10, f'Chosen clinical trials:')\n",
    "\n",
    "pdf.set_font('Arial', '', 12)\n",
    "for i, ext_res in zip(ids_ct.values,resultsct):\n",
    "    pdf.cell(40, 10, '- https://clinicaltrials.gov/study/'+i[1]+' '+f\"'{i[2]}'\")\n",
    "    pdf.cell(40, 10, ext_res)\n",
    "'''    \n",
    "print(f'\\nChosen Papers:')\n",
    "for i, ext_res in zip(ids_p.values, extracted_gm):\n",
    "    print('- https://pubmed.ncbi.nlm.nih.gov/'+i[0]+' '+f\"'{i[5]}'\")\n",
    "    for field in ext_res:\n",
    "        if field['source_id']:\n",
    "            print(f\"    {field['name'].replace('_',' ')}: '{field['value']}'\")\n",
    "            print(field['cited_blocks'])\n",
    "'''            \n",
    "\n",
    "pdf.output(f\"{fin_condition.replace('_',' ')}_{treatements_eng[0]}.pdf\", 'F')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 432,
   "id": "706ab663-428c-4ccc-a3ad-907fa8dc80ef",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy.\\nColorectal cancer (CRC) is presently the third deadliest cancer in the world. This malignant cancer usually precedes the progression of precancerous lesions, and it is challenging to distinguish its nuanced morphological changes. Molecular-based near-infrared-II (NIR-II) fluorescence imaging can effectively recognize lesion targets to improve image contrast and increase early tumor detection compared with traditional wide-light screening endoscopy. c-Met has been determined to be overexpressed in advanced stages of CRC and is considered to be a potent tumor biomarker. Herein, based on the well-targeted inhibitory effect of Crizotinib on c-Met positive tumor cells, the dye IR808 was covalently combined with the drug molecule Crizotinib, resulting in the synthesis of a NIR fluorescent probe Crizotinib-IR808 targeting c-Met positive tumor cells. Then, water-insoluble Crizotinib-IR808 was fabricated by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.'"
      ]
     },
     "execution_count": 432,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers[0][df_papers[0].screen_eval>=3].loc[8].FullText            "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fcc2864f-dc61-4eb8-a720-c4f9040724b5",
   "metadata": {
    "tags": []
   },
   "source": [
    "# d"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "c69ff7c4-4e91-4afc-bdae-ec1fbf094012",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40140597/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40211189/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40526090/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41213063/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41268440/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/38711893/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40369167/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n"
     ]
    }
   ],
   "source": [
    "pmid_list = df_papers[0].PMID.values.tolist()\n",
    "#['41213063',#'26451310',]\n",
    "\n",
    "res = pmid2biocxml(pmid_list, api_key=pubmed_api_key)\n",
    "#print(res)\n",
    "res = [parse_bioc_xml(r) for r in res]\n",
    "# transform the parsed xml into paper content\n",
    "papers0 = []\n",
    "for parsed in res:\n",
    "    paper_content = []\n",
    "    for parsed_ in parsed[\"passage\"]:\n",
    "        paper_content.append(parsed_['content'])\n",
    "    paper_content = \"\\n\".join(paper_content)\n",
    "    papers0.append(paper_content)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8da18fc3-9928-4516-b83c-23f117b51f41",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "a5439e3b-a23a-4460-ae0c-3f07723f3374",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment\\nHeavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression.\\nWIN Consortium International Molecular Tumor Board (MTB), included experts from institutions across 13 countries. Enrollment in suitable clinical trials was explored but limited by availability. Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate VEGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/mÂ² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily. FOLFOXFIRI combined with bevacizumab, or liver-directed therapies for hepatic metastases, or regorafenib with 5FU, or crizotinib (MET inhibitor) combined with regorafenib or dabrafenib, was also suggested.\\nThis case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC. The WIN International MTB aims to provide treatment and biomarker analysis discussion with the ultimate goal of optimizing treatment efficacy by targeting specific molecular alterations, though final treatment decisions remain at the discretion of the treating physician.\\nINTRODUCTION\\nColorectal cancer (CRC) ranks among the most prevalent and lethal cancers globally. The metastatic form of CRC presents significant challenges due to its complexity and the variability in treatment responses. Advances in molecular genetics have markedly improved cancer management, facilitating more personalized treatment strategies based on individual tumor molecular profiles.\\nHere, we present the case of a 62-years-old male patient with metastatic CRC (mCRC) who underwent a comprehensive multimodal treatment regimen. This patientâ\\x80\\x99s tumor genomic analysis revealed aberrations in BRAF, MET, APC, TP53 and NRAS.\\n BRAF V600E mutations in mCRC represent a distinct subset with unique prognostic and therapeutic implications. This mutation is a class I mutation that activates the MAPK pathway, leading to uncontrolled cell proliferation and tumor growth. Specifically, the BRAF V600E mutation is associated with a more aggressive disease course, poorer overall survival, and a higher likelihood of resistance to standard therapies. Multiple studies have also suggested that the BRAF V600E mutation serves as a predictor of reduced efficacy of EGFR monoclonal antibodies, such as cetuximab and panitumumab, either as monotherapy or in combination with chemotherapy. The MET receptor tyrosine kinase, when mutated or amplified, activates the MET signaling pathway, promoting cellular proliferation and metastasis. In mCRC, MET mutations and alterations, though less common than other mutations, can lead to resistance to standard treatments and contribute to more aggressive tumor behavior, significantly impacting disease progression and therapeutic response. APC mutations are highly prevalent in mCRC, occurring in approximately 80% of cases. These mutations are critical drivers of tumor development and progression, primarily through their impact on the WNT signaling pathway. The APC protein normally functions as a negative regulator of the WNT signaling pathway, which controls cell proliferation and differentiation. When APC is mutated, it results in uncontrolled activation of WNT signaling, leading to increased cell growth and tumorigenesis. TP53 is a pivotal tumor suppressor gene frequently mutated in CRC. Mutations in TP53 often result in the loss of its tumor-suppressive functions, leading to increased genomic instability and resistance to apoptosis, which promotes tumor growth and metastasis. The presence of TP53 mutations is generally associated with more aggressive tumor characteristics and may impact the effectiveness of certain therapies. NRAS, a member of the RAS family of oncogenes, plays a crucial role in regulating cell signaling pathways involved in growth and survival. NRAS mutations can lead to continuous activation of the MAPK pathway, which promotes cell proliferation and tumor growth. When mutated, NRAS can drive resistance to anti-EGFR therapies by bypassing the effects of these drugs. While anti-EGFR treatments target the EGFR pathway to inhibit tumor growth, NRAS mutations can activate downstream signaling pathways independently of EGFR, allowing tumor cells to evade EGFR blockade and continue proliferating. \\nThe case presented here was reviewed by an international Molecular Tumor Board (MTB) convened by the WIN consortium, a French-based non-profit association comprising academic oncological centers, industry groups, research organizations, and patients advocates from multiple countries across several continents. The MTB is an international committee of expert physicians and scientists specialized in personalized cancer medicine from 18 centers across 13 countries, as shown in Figure 1. The MTB is unique in bringing together experts from multiple countries which practice in very different healthcare systems with a wide variety of drug access. The purpose of this committee is to improve the knowledge about personalized cancer therapies. As such, discussions that occurred during the MTB are for educational purposes and considered advisory only. The choice of therapy is up to the treating physician and geographic treatment availability. The board of experts evaluated the patientâ\\x80\\x99s medical history and genetic profile, suggesting a variety of treatment options, including customized combination therapies, targeted treatments, standard-of-care approaches and clinical trials. The goal was to discuss treatment strategies tailored to the patientâ\\x80\\x99s unique genetic molecular profile.\\nCASE REPORT DESCRIPTION\\nDiagnosis\\nThe patient, a 62-year-old male, was diagnosed in May 2021 with stage IV CRC presenting with two potentially resectable liver metastases and no evidence of disease elsewhere. His medical history included high blood pressure, hyperuricemia, and kidney stones. Immunohistochemistry (IHC) performed at time of diagnosis showed that the patient was mismatch repair proficient and HER2 negative. Testing for RAS and BRAF mutations, as mandated by local clinical guidelines, identified a BRAF V600E mutation revealed by real-time polymerase chain reaction (RT-PCR) at the time of diagnosis.\\nFirst line of treatment\\nIn May 2021, shortly after his diagnosis, the patient began perioperative chemotherapy with FOLFOX (folinic acid, fluorouracil, and oxaliplatin), which resulted in a partial response. Following this response, the patient underwent surgical resection of the liver metastases. Post-surgery, the patient resumed FOLFOX chemotherapy until the primary colorectal tumor, located in the transverse colon, was also resected. The patient continued with the FOLFOX regimen for an additional two months, completing a total of 12 cycles. A subsequent CT scan confirmed the absence of recurrence. The progression-free survival (PFS) under the first line treatment of FOLFOX lasted for 10 months. However, in June 2022, a potentially resectable recurrence was identified, with two liver metastases and with no evidence of other disease sites.\\nSecond line of treatment\\nIn October 2022, the patient commenced a second line of treatment of FOLFIRI (folinic acid, fluorouracil, and irinotecan hydrochloride). Given the possibility of resectable liver disease recurrence, FOLFIRI was administered without biological agents such as aflibercept or bevacizumab. Unfortunately, this treatment was discontinued after less than two months, in December 2022, due to disease progression which was confirmed by a CT scan revealing a total of 10 liver metastases. The scan also revealed a pulmonary embolism. It is important to note that the primary goal of both the first and second lines of treatment was to facilitate liver disease resection.\\nThird line of treatment\\nIn January 2023 the patient was enrolled in an early phase clinical trial involving an efflux pump inhibitor (EPI) and cancer stem-cell marker ABCG2. It is worth noting that on January 2023, the combination of encorafenib and cetuximab was not a reimbursed treatment in Spain, where the patientâ\\x80\\x99s treatment center is located. Additionally, no clinical trials specifically for BRAFV600-mutated mCRC were available at the center or in nearby institutions. The clinical trialâ\\x80\\x99s treatment was eventually discontinued due to disease progression.\\nAt this time, results from a custom 432-gene hybrid capture-based panel (VHIO-300) of a tissue sample confirmed the presence of a BRAF V600E mutation (Table 1), which had already been identified at the time of diagnosis. Table 1 and Supplementary Table 1 provide a list of additional detected mutations including both pathogenic/likely pathogenic variants and variant of unknown significance (VUS).\\nAdditionally, the tumor mutational burden (TMB) was measured at 11.19 mutations/megabase, which is below the high TMB cutoff of 13 mutations/megabase. This cutoff, defined through cross-validation with FoundationOne, is equivalent to 10 mutations/megabase as used typically in FoundationOne assays. Therefore, the patient did not have a high TMB.\\nFourth line of treatment\\nIn February 2023, the patient began a compassionate use treatment with a combination of dabrafenib and panitumumab, targeting BRAF and EGFR respectively. Initially, the patient showed a partial response. By the time of the documented radiological response, a liquid biopsy was performed by means of the VHIO360 ISO-certified panel using Guardant360Â® technology.\\nctDNA profiling showed a BRAF allele frequency (2.09%) (Table 1 May 2023). However, the disease eventually progressed, accompanied by an increase in BRAF allele frequency (41.58%) (Table 1 August 2023). This line of treatment lasted for five months. ctDNA molecular profiling detected NRAS Q61K at a low allele frequency (0.38%).\\nFifth line of treatment\\nIn August 2023, the patient started treatment with a novel BRAF V600 inhibitor as part of a phase I clinical trial. At the time of screening a CT scan confirmed the presence of liver metastases and, for the first time, identified lung metastases. The patient achieved stable disease as best response in September 2023 with a 13% reduction in the sum of target lesions. However, the disease eventually progressed again after two months. A new VHIO360 test after disease progression showed a BRAF allele frequency of 20.93% and also revealed emerging mutations and amplifications (Table 1 October 2023). Also, the number of copies of MET increased to 10.1, up from 3.2 in the previous test.\\nThroughout his treatment as shown in Figure 2, the patient continued to maintain an ECOG performance status of 0, remaining asymptomatic and physically active. At the time of the MTB, no new treatment had been administered while exploring further therapeutic options after MTB case discussion.\\nDISCUSSION\\nThe case presented here is clinically unique due to the complexity of the tumorâ\\x80\\x99s genetic profile. At disease progression, repeat testing with both circulating tumor DNA (ctDNA) and tissue next-generation sequencing (NGS) proves valuable in identifying new genomic alterations and tracking changes in variant allele frequency (VAF). These tools not only detect emerging resistance mutations but also provide insights into tumor evolution, guiding more informed treatment decisions. While ctDNA offers a non-invasive approach to monitor tumor dynamics in real time, tissue NGS delivers a more comprehensive view of the genomic landscape. When used together, they enhance the detection of actionable targets and support a more personalized approach to cancer therapy.\\nThe multidisciplinary discussion by the experts of the MTB aimed to discuss tailored therapeutic approaches based on the patientâ\\x80\\x99s specific molecular alterations while considering its previous multimodal treatments. The discussion presents a list of therapeutic strategies prioritized by their expected efficacy. While standard-of-care options are considered, they may not appear first if they are not deemed the most suitable match for the patient. Matched therapy, where treatments are tailored to specific molecular alterations in a patientâ\\x80\\x99s tumor, has shown significant benefits in improving clinical outcomes compared to non-matched therapies, especially in heavily pretreated cancer patients. Two landmark studies, I-PREDICT and WINTHER, provide key evidence for this approach. In the prospective I-PREDICT trial, patients received therapies matched to their tumorâ\\x80\\x99s molecular alterations, resulting in improved clinical outcomes, including higher response rates and longer survival. Notably, patients who received a tailored therapy with a higher degree of matching, experienced significantly better progression-free survival than those with fewer matched alterations. The WINTHER trial, which utilized both genomic and transcriptomics data to guide personalized therapies, further demonstrated the feasibility of implementing matched therapy and improving clinical outcomes in patients with advanced cancers.\\nAlso, it is important to mention that as patients with mCRC progress through multiple lines of therapy, the probability of achieving meaningful tumor responses declines significantly. Numerous studies have shown that in heavily pretreated patients - such as the patient described in this case â\\x80\\x93 response rates tend to be low, and OS remains poor. For instance, the pivotal RECOURSE trial, a Phase III study evaluating TAS-102 (trifluridine/tipiracil) in mCRC patients previously treated with at least two chemotherapy regimens, demonstrated a median OS of 7.1 months with TAS-102 versus 5.3 months with placebo. The median progression-free survival (PFS) was 2.0 months vs. 1.7 months, respectively, and the disease control rate reached 44% in the treatment arm. Similarly, the CORRECT trial, a phase III study assessing regorafenib in mCRC patients who had progressed on standard therapies, reported median OS of 6.4 months with regorafenib compared to 5.0 months with placebo, and a median PFS of 1.9 vs. 1.7 months, respectively. More recently, the CAROSELL trial, a phase II study evaluating the combination of zabadinostat and nivolumab in patients with MSS mCRC after at least two prior lines of therapy, showed a median OS of 7 months. Collectively, these findings highlight the critical need for novel, more effective treatment strategies for patients with refractory mCRCâ\\x80\\x94especially in the context of later-line therapies where clinical benefit remains modest.\\nPrior to inclusion in the BRAF inhibitor phase 1 clinical trial, the patient had two MET mutations classified as VUS. The most recent liquid biopsy test at the time of the MTB discussion had identified three MET mutations still classified as VUS. These MET mutations, along with the increase in the number of copies, might have contributed to the resistance mechanism observed in the patient.\\nAdditionally, an NRAS variant was detected at a very low allele fraction, raising the possibility of it being a clonal hematopoiesis of indeterminate potential (CHIP) rather than a true tumor mutation. Since the tests were performed on blood samples (liquid biopsies), without tissue confirmation, the NRAS Q61K mutation could either have represented a minor clone or a CHIP alteration. A tissue biopsy, if feasible, could provide crucial missing information, and particularly confirm whether the NRAS mutation is genuine.\\nThe MTB experts discussed the possibility of enrolling the patient in a clinical trial, but no suitable trials were currently available at the treating cancer center. A clinical study involving an anti-carcinoembryonic antigen (anti-CEA) antibody-drug conjugate (ADC) was considered, but no slots were available at the time. The MTB agreed that an ADC targeting CEA with a topotecan payload could be an interesting approach if the patient is a CEA producer. Although this represents a different direction, it could be highly beneficial if the patient could participate in such a study.\\nAlso, the question arose whether it should be worthwhile to include the patient in a new single-agent BRAF inhibitor trial, given the complex genetic landscape observed in recent tests and the patientâ\\x80\\x99s previous treatments with two BRAF inhibitors, including a novel BRAF inhibitor that was unsuccessful. The consensus was that it might not be prudent to prioritize another BRAF inhibitor trial due to the poor response observed with previous BRAF inhibitors and the patientâ\\x80\\x99s complex genetic profile.\\nDuring the MTB discussion, it was highlighted that prioritizing secondary clinical trials may present challenges, including limited available slots and patient ineligibility. Moreover, if clinical trial opportunities are considered, it is crucial to assess whether the use of local therapies such as hepatic arterial infusion (HAI) or palliative radiotherapy might affect the eligibility of the patient to future clinical trials.\\nExperts in the MTB are favoring a customized combination therapies approach when considering treatment options. This methodology has been in use since 2015 under the I-PREDICT protocol at the University of California, San Diego. This approach involves combining therapies that are often used off-label and may not be accessible in some countries.\\nThe patient presented with significant genetic alterations, including a challenging-to-target APC mutation, a previously targeted BRAF mutation with limited response, an NRAS mutation that could be crucial but might also be a minor clone or CHIP alteration, a notable TP53 mutation, and MET amplifications. Given the patientâ\\x80\\x99s treatment history with BRAF inhibitors, one proposed approach was to consider trametinib, a MEK inhibitor that could target both BRAF and NRAS. Even if the NRAS mutation is a CHIP alteration, trametinib could still be effective against both targets. The EGFR pathway is also of interest, as targeted with the previous combination of panitumumab and dabrafenib (BRAF inhibitor) that was administered to the patient (Line 4 â\\x80\\x93 5 months â\\x80\\x93 PR). Another discussed option was to target the EGFR pathway and the MET alteration, for which amivantamab-vmjw, a bi-specific antibody for MET and EGFR approved in the U.S., was suggested. However, the availability of this drug outside the U.S. is uncertain. The rationale behind this treatment strategy lies in the observation that MET amplification frequently emerges following anti-EGFR therapies, such as the panitumumab, which was used in the patient presented here. While MET amplification confers resistance to anti-EGFR therapies in CRC, this resistance can be overcome by MET kinase inhibitors, which restore sensitivity to EGFR blockade and significantly inhibit tumor growth. Therefore, incorporating a MET inhibitor, such as amivantamab, which targets both EGFR and MET, was considered a potential therapeutic approach.\\nRegorafenib, a VEGF inhibitor, also has potential efficacy, particularly given its ability to down-regulate the WNT pathway activated by APC mutations, and its potential effectiveness in the context of the TP53 alteration, which is associated with an upregulation of the VEGF-VEGFR pathway. Based on these considerations, a customized combination therapy involving amivantamab-vmjw, trametinib, and regorafenib was suggested. While regorafenib is approved in this indication, the other two drugs are not, raising questions about the practicality of this combination. In some regions of the U.S., these drugs may be accessible, but this might not be the case elsewhere. The strategy for administering customized combination therapies involves starting with reduced doses of all drugs, a practice that has been shown to be safe with close monitoring. Indeed, generally, combining multiple anticancer agents often leads to overlapping toxicities, which can be more severe than those observed with single agents. Consequently, it is rare to administer the full recommended doses of each agent in combination therapies to avoid supra-additive toxicities that are frequently observed otherwise. For amivantamab-vmjw, a starting dose of about one-third of the standard dose was suggested due to its challenging tolerability. Trametinib could be started at 1 mg daily, about half of the standard dose, and regorafenib at a starting dose of 40 mg daily for three weeks, followed by one week off. Close monitoring of the patient throughout the treatment would be essential.\\nAnother potential customized combination discussed was trametinib combined with cetuximab and an additional drug such as cabozantinib. Cetuximab was considered for its role in targeting the EGFR feedback loop, while cabozantinib was chosen for its dual inhibition of MET and VEGFR. For this combination, it was suggested to start trametinib at 1 mg daily, cetuximab at half the usual dose (250 mg/m2 intravenously every two weeks in the U.S.), and cabozantinib at an initial lower dose of 40 mg daily, as the approved dose is often too high.\\nA different direction was to explore more standard treatment regimens. Given the patientâ\\x80\\x99s good performance status and the presence of metastases beyond the liver, such treatments could be considered. Since the patient has not previously received antiangiogenic therapy, a regimen like FOLFOXFIRI combined with bevacizumab could be an option, as it is generally well-tolerated. Additionally, depending on the extent of the liver disease, consulting with specialists in liver-directed therapies might be beneficial. If the metastases were confined to the liver, some clinicians might consider hepatic arterial infusion (HAI) pumps or alternating systemic chemotherapy with intrahepatic therapy. Although HAI therapy has become less popular in recent years, it remains effective and could be useful. However, its effectiveness is limited by the need for specialized expertise that may not be available at all treatment centers. Other liver-directed therapies, such as radiofrequency ablation and chemoembolization, could also be considered later, although some practitioners might use these methods earlier in the course of the disease. While these approaches are less relevant for tumors outside the liver, if systemic chemotherapy was being administered and there was a significant TMB in the liver with progression, HAI and other liver-directed therapies could be considered and carefully discussed with liver experts to make sure that such therapy would not be an exclusion criterion for future potential clinical trial options. Indeed, it was highlighted that many clinical trials exclude patients based on the number or type of prior therapies received. This can limit access to potentially beneficial trials for patients who have undergone multiple treatments. Also, certain therapies can impair organ functions, making patients ineligible for enrolling later on trials that require specific organ function benchmarks. In addition, treatments may deteriorate a patientâ\\x80\\x99s performance status, disqualifying them from trials that require better ECOG. These challenges often require adopting strategies to mitigate these hurdles. For example, oncologists should consider potential future trialsâ\\x80\\x99 eligibility when determining full treatment plans for the course of the disease.\\nAnother option discussed was to combine crizotinib, which targets both MET and ALK with other drugs, such as regorafenib or dabrafenib. The question remains whether focusing on targeting MET should be a priority at this stage. Regarding regorafenib, a dose of 40 mg, as previously suggested, may be effective for some patients, but in combination strategies, dose escalation to 80 mg could be explored if tolerated by the patient. The ReDOS study demonstrated that starting with lower doses and escalating if tolerated can be effective.\\nDabrafenib, a BRAF inhibitor could also be considered in combination with trametinib (MEK inhibitor), as the combination has already been used in BRAF-mutated colorectal cancer patients, particularly when these drugs were first introduced.\\nIn general, regorafenib as a monotherapy is not favored due to its limited duration of effectiveness. However, there is experience using regorafenib both as a monotherapy and in combination with 5-fluorouracil (5FU), although this combination has not been fully tested. For patients who progress after regorafenib, adding 5FU has been shown to be an effective regimen. Therefore, regorafenib with 5FU could be also an option.\\nOther potential treatment directions discussed included combining FOLFOX with immunotherapy.\\nIt is important to note that discussions held during the MTB were for educational purposes only. The ultimate decision regarding the patientâ\\x80\\x99s treatment is made exclusively by the treating physician of the patient.\\nWhile the MTB is primarily for educational purposes, there is no obligation/or in some cases ability for the treating physician to follow the treatment options discussed at the MTB. However, specifically for the case presented here, follow up was available. The patient received regorafenib at from December 2023 to February 2024, with the best response being progression in the lungs and liver. Following this progression, the patientâ\\x80\\x99s ECOG performance status deteriorated, and passed away in April 2024.\\nOne limitation was that the trajectory of tumor markers was not included, as the patient received multiple treatments across multiple institutions with varying units and reference ranges, making data availability and consistent interoperations challenging. Another limitation is the lack of ctDNA tumor fraction data at different time points. In the VHIO360 liquid biopsy panel, tumor fraction information is unavailable. However, current guidelines also recommend the use of the mean or maximum VAF of detected somatic mutations at each timepoint to monitor ctDNA kinetics. However, Guardant360 tests do not provide an estimate of tumor fraction. Since the VHIO360 liquid biopsy panel is based on Guardant360 technology, tumor fraction information is similarly unavailable.\\nIn conclusion, the WIN consortiumâ\\x80\\x99s MTB encompassing stakeholders from all over the world discussed several treatment options and emphasized the importance of tailoring treatment strategies and using combinations to limit escape mechanism.'"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers0[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "3ac1dabb-884d-4bd7-9ce3-edd08f6c9e35",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1672, 1652, 27171, 2627, 46819]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[len(i) for i in papers]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "6a9ab051-ac79-4050-93d9-7008b5074ed6",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Case Report: HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: a case study.',\n",
       " 'Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer with poor prognosis, often associated with resistance to treatment. MET amplification has been identified as a potential therapeutic target, but resistance to MET inhibitors, such as crizotinib, remains a significant challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic',\n",
       " 'challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,',\n",
       " 'analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically, a missense mutation in HGF (p.G401A) was observed, which may enhance ligand-receptor binding, while an NF1 mutation (p.M546L) may permit sustained MAPK and PI3K activation despite MET inhibition. These observations are preliminary and require validation in larger patient cohorts. Conclusion: Our',\n",
       " 'a missense mutation in HGF (p.G401A) was observed, which may enhance ligand-receptor binding, while an NF1 mutation (p.M546L) may permit sustained MAPK and PI3K activation despite MET inhibition. These observations are preliminary and require validation in larger patient cohorts. Conclusion: Our findings suggest that acquired resistance to MET inhibitors in MET-amplified HCC may involve clonal evolution and activation of compensatory signaling pathways. These insights highlight the need for dynamic molecular surveillance and the development of strategies targeting multiple pathways to',\n",
       " 'Our findings suggest that acquired resistance to MET inhibitors in MET-amplified HCC may involve clonal evolution and activation of compensatory signaling pathways. These insights highlight the need for dynamic molecular surveillance and the development of strategies targeting multiple pathways to overcome resistance and improve patient outcomes.']"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "splited = split_text_into_chunks(papers[1], chunk_size=600,\n",
    "                                             chunk_overlap=300)\n",
    "splited"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "ac23d300-fc62-407f-8265-409a50f8a216",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib treatment effectiveness',\n",
       "   'value': 'initial tumor regression followed by disease progression',\n",
       "   'source_id': [2],\n",
       "   'cited_blocks': ['challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,']}],\n",
       " [{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'More sensitive to low-risk group',\n",
       "   'source_id': [5],\n",
       "   'cited_blocks': ['performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group.']}],\n",
       " [{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'main_results_crizotinib',\n",
       "   'value': 'no objective responses observed in RASMT advanced CRC patients',\n",
       "   'source_id': [7],\n",
       "   'cited_blocks': ['with low baselineÂ\\xa0KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).']}],\n",
       " [{'name': 'Crizotinib_effectiveness',\n",
       "   'value': 'selectively inhibited the growth of ARID1A-deficient CRC cells',\n",
       "   'source_id': [80, 142],\n",
       "   'cited_blocks': ['validated the synthetic lethal effect of the c-MET inhibitor PHA-665752 (PHA) in two ARID1A knockout (ARID1A-KO) clones, where PHA selectively inhibited the growth of ARID1A-KO HCT116 cells (Fig.Â\\xa01D). Moreover, two FDA-approved c-MET inhibitors, crizotinib, and cabozantinib, also showed synthetic lethality in ARID1A-KO HCT116 clones (Fig.Â\\xa01E, F). These results suggest that c-MET is a potential synthetic lethal target for ARID1A in CRC cells.',\n",
       "    'synthetic lethality in ARID1A-deficient CRC. Notably, FDA-approved c-MET inhibitors, such as crizotinib and cabozantinib, have demonstrated enhanced cytotoxicity in ARID1A-deficient cancers, facilitating the translation of these approved drugs for repurposing in ARID1A-targeted precision cancer medicine.']}]]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=papers,\n",
    "    fields=['Results, string, main results of the study regarding Crizotinib, usually about treatment effectiveness'],#api.DEFAULT_FIELDS,\n",
    "    llm='Qwen/Qwen3-32B',#\"openai-gpt-4o\",\n",
    "    chunk_size=600,\n",
    "    chunk_overlap=300,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "dc85b6da-8fe9-4484-8430-e55e239b2525",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'More sensitive to low-risk group',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group.']}],\n",
       " [{'name': 'Crizotinib treatment effectiveness',\n",
       "   'value': 'initial tumor regression followed by disease progression',\n",
       "   'source_id': [1],\n",
       "   'cited_blocks': ['challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,']}]]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "80601546-e32e-4b65-b837-b5dec0abdfc4",
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_reasoning = ChatOpenAI(\n",
    "    base_url=BASE_URL,\n",
    "    api_key=HUGGINGFACE_HUB_TOKEN,\n",
    "    model=MODEL_NAME_HF,\n",
    "    streaming=True,\n",
    "    temperature=0,\n",
    "    #http_client=httpx_client\n",
    "    http_async_client=httpx.AsyncClient(verify=False)\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "87efd589-f082-4326-bc29-42ab4cd01c9a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "\n",
      "</think>\n",
      "\n",
      "```json\n",
      "[\n",
      "    {\n",
      "        \"name\": \"Crizotinib effectiveness\",\n",
      "        \"value\": \"More sensitive to low-risk group\",\n",
      "        \"source_id\": [3]\n",
      "    }\n",
      "]\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"user\", '/no_think {text}'),\n",
    "    # (\"ai\", \"Good.\")\n",
    "])\n",
    "\n",
    "chain = prompt | llm_reasoning\n",
    "response = await chain.ainvoke({\"text\": ff})\n",
    "\n",
    "#fin_condition = response.content.strip('<think>\\n\\n</think>\\n\\n')\n",
    "print(response.content)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:llms]",
   "language": "python",
   "name": "conda-env-llms-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.14.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
